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SUMMARY 
Carnitine plays an essential role in eukaryotic metabolism by mediating the shuttling of activated 
acyl residues between intracellular compartments. This function of carnitine, referred to as the 
carnitine shuttle, is supported by the activities of carnitine acyltransferases and 
carnitine/acylcarnitine transporters, and is reasonably well studied and understood. While this 
function remains the only metabolically well established role of carnitine, several studies have 
been reporting beneficial effects associated with dietary carnitine supplementation, and some of 
those beneficial impacts appear not to be directly linked to shuttle activity. 
This study makes use of the yeast Saccharomyces cerevisiae as a cellular model system in 
order to study the impact of carnitine and of the carnitine shuttle on cellular physiology, and also 
investigates the eukaryotic carnitine biosynthesis pathway. The carnitine shuttle of S. cerevisiae 
relies on the activity of three carnitine acetyltransferases (CATs), namely Cat2p (located in the 
peroxisome and mitochondria), Yat1p (on the outer mitochondrial membrane) and Yat2p (in the 
cytosol), which catalyze the reversible transfer of activated acetyl units between CoA and 
carnitine. The acetylcarnitine moieties can be transferred across the intracellular membranes of 
the peroxisomes and mitochondria by the activity of the carnitine/acetylcarnitine translocases. 
The activated acetyl groups can be transferred back to free CoA-SH and further metabolised. In 
addition to the carnitine shuttle, yeast can also utilize the glyoxylate cycle for further 
metabolisation of in particular peroxisomally generated acetyl-CoA. This cycle results in the net 
production of succinate from two molecules of acetyl-CoA. This dicarboxylic acid can then enter 
the mitochondria for further metabolism. Partial disruption of the glyoxylate cycle, by deletion of 
the citrate synthase 2 (CIT2) gene, generates a yeast strain that is completely dependent on the 
activity of the carnitine shuttle and, as a consequence, on carnitine supplementation for growth 
on fatty acids and other non-fermentable carbon sources. . 
In this study, we show that all three CATs are required for the function of the carnitine 
shuttle. Furthermore, overexpression of any of the three enzymes is unable to cross-
complement deletion of any one of the remaining two, suggesting a highly specific role for each 
CAT in the function of the shuttle. In addition, a role for carnitine that is independent of the 
carnitine shuttle is described. The data show that carnitine can influence the cellular response 
to oxidative stresses. Interestingly, carnitine supplementation has a protective effect against 
certain ROS generating oxidants, but detrimentally impacts cellular survival when combined with 
thiol modifying agents. Although carnitine is shown to behave like an antioxidant within a cellular 
context, the molecule is unable to scavenge free radicals. The protective and detrimental 
impacts are dependent on the general regulators of the cells protection against oxidative stress 
such as Yap1p and Skn7p. Furthermore, from the results of a microarray based screen, a role 
for the cytochrome c heme lyase (Cyc3p) in both the protective and detrimental effects of 
carnitine is described. The requirement of cytochrome c is suggestive of an involvement in 
apoptotic processes, a hypothesis that is supported by the analysis of the impact of carnitine on 
genome wide transcription levels. 
A separate aim of this project involved the cloning and expression in S. cerevisiae of the 
four genes encoding the enzymes from the eukaryotic carnitine biosynthesis pathway. The 
cloned genes, expressed from the constitutive PGK1 promoter, were sequentially integrated into 
the yeast genome, thereby reconstituting the pathway. The results of a plate based screen for 
carnitine production indicate that the engineered laboratory strains of S. cerevisiae are able to 
convert trimethyllysine to L-carnitine. This work forms the basis for a larger study that aims to 
generate carnitine producing industrial yeast strains, which could be used in commercial 
applications. 
  
OPSOMMING 
Karnitien vervul ‘n noodsaaklike rol in eukariotiese metabolisme deur die pendel van asiel 
residue tussen intersellulêre kompartemente te medieer. Hierdie funksie van karnitien heet “die 
karnitien-pendel“ en word ondersteun deur verskeie karnitien asieltransferases en 
karnitine/asielkarnitien oordragsprotiëne. Die rol van die karnitien-pendel is redelik goed 
gekarakteriseer en is tot op hede die enigste bevestigde rol van karnitien in eukariotiese 
metabolisme. Verskeie onlangse studies dui egter op voordele geasosieer met karnitien 
aanvulling, wat in sommige gevalle blyk om onafhanklik te wees van die pendel aktiwiteit van 
karnitien.  
Hierdie studie maak gebruik van die gis, Saccharomyces cerevisiae, as ‘n sellulêre model 
sisteem om die impak van karnitien op sel fisiologie asook die eukariotiese karnitien biosintese 
pad te bestudeer. Die karnitien-pendel van S. Cerevisiae is afhanklik van die aktiwiteite van drie 
afsonderlike karnitien asetieltransferases (CATs), naamlik Cat2p (gelokaliseer in die 
peroksisoom en die mitochondria), Yat1p (op die buitenste membraan van die mitochondria) en 
Yat2p (in die sitosol). Die drie ensieme kataliseer die omkeerbare oordrag van asetielgroepe 
tussen CoA en karnitien. Die terugwaartse reaksie stel CoA-SH vry om sodoende verbruik te 
word in verdere metaboliese reaksies. Gis is in staat om, afsonderlik van die karnitien-pendel, 
gebruik te maak van die glioksilaat siklus vir verdere metabolisme van asetiel-CoA wat gevorm 
word in die peroksisoom. Gedeeltelike onderbreking van hierdie siklus deur uitwissing van die 
sitraat sintase (CIT2) geen, genereer ’n gisras wat afhanklik is van die funksie van die karnitien-
pendel en ook van karnitien aanvulling vir groei op vetsure en nie-fermenteerbare 
koolstofbronne. 
Hierdie studie dui daarop dat al drie CATs noodsaaklik is vir die funksionering van die 
karnitien-pendel. Ooruitdrukking van enige van die drie ensieme lei slegs tot self-
komplementasie en nie tot kruis-komplementasie van die ander twee CATs nie. Hieruit word ’n 
hoogs spesifieke rol vir elk van die drie ensieme afgelei. ’n Pendel-onafhanklike rol vir karnitien 
word ook in hierdie werk uitgewys in die bevordering van weerstand teen oksidatiewe stres. Dit 
is noemenswaardig dat karnitien ’n beskermende effek het in kombinasie met oksidante wat 
ROS genereer en ’n nadelige effek in kombinasie met sulfhidriel modifiserende agente. Dit word 
aangedui dat karnitien antioksidant funksie naboots in die konteks van ’n gis sel terwyl die 
molekuul nie in staat is om vry radikale te deaktiveer nie. Beide die beskermende asook die 
nadelige inwerking van karnitien is afhanklik van Yap1p en Skn7p, wat reguleerders is in die 
algemene beskerming teen oksidatiewe stres. Die resultate van ’n “microarray“ gebaseerde 
studie dui op ’n rol vir die sitokroom c heem liase (Cyc3p) in beide die beskermende en 
nadelige gevolge van karnitien aanvulling. Die vereiste vir sitochroom c dui op ’n moontlike rol 
vir apoptotiese prosesse. Hierdie hipotese word verder versterk deur ‘n analise van die impak 
van karnitien op genoomwye transkripsievlakke. 
’n Afsonderlike doelwit van hierdie studie was toegespits op die klonering en uitdrukking van 
die vier ensieme betrokke in eukariotiese karnitien biosintese in S. cerevisiae. Die gekloneerde 
gene, uitgedruk vanaf die konstitutiewe PGK1 promotor, was geïntigreer in die gisgenoom om 
die pad op te bou. Die resultate van ’n plaat gebaseerde karnitien produksie toets dui aan dat 
die geneties gemanipuleerde gisrasse wel in staat is om trimetiellisien oor te skakel in L-
karnitien. Hierdie werk vorm die hoeksteen van ’n studie wat die ontwikkeling van karnitien 
produserende kommersiële gisrasse as doelwit stel.  
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1.1. INTRODUCTION 
 
Intracellular compartmentalization by biological membranes has contributed greatly to 
the evolutionary diversification of eukaryotes. It does, however, also create hurdles to 
the distribution and flux of many important metabolic pathways, since many 
intermediates of metabolism can not easily cross compartmental membranes. In the 
case of energy metabolism, such membranes are impermeable to CoA-activated acyl 
residues, the primary source of energy production in respiratory conditions. In yeast 
grown on non-fermentable carbon sources, the transfer of such residues is an essential 
requirement for energy production, since the generation and the further use of these 
metabolites take place in different compartments (Van Roermund et al, 1995). This 
obstacle is effectively circumvented by the reversible transfer of acyl residues from CoA 
to L-carnitine, catalysed by the activity of carnitine acyl transferases. Acylcarnitine can 
then be transported across the membranes of organelles by carnitine/acylcarnitine 
translocases. This system is conserved in function throughout the eukaryotic kingdom 
and is referred to as the carnitine shuttle. 
In the yeast, Saccharomyces cerevisiae, the carnitine shuttle closely resembles that 
of higher eukaryotes with minor, but notable differences in composition. These 
differences can mostly be accounted for by distinctions in carbohydrate and fatty acid 
metabolism between yeast and higher eukaryotic organisms. Firstly, in yeast, -
oxidation of fatty acids occurs exclusively in the peroxisome, compared to peroxisomal 
and mitochondrial -oxidation in mammals (Schmalix and Bandlow 1993; Stemple et al. 
1998). Yeast also has access to a separate pathway, in the form of the partially 
peroxisomal glyoxylate cycle, producing succinate from acetyl-CoA, which can enter the 
mitochondrial tricarboxylic acid cycle for further metabolism. Consequently, yeast only 
displays carnitine acetyltransferase activity, whereas higher eukaryotes utilize several 
carnitine acyltransferases with variable affinities for acyl esters of varying chain lengths. 
The acetyl transferase activity in yeast is catalysed by three carnitine acetyltransferases 
(CATs), namely Cat2p (localized in both mitochondria and peroxisomes), Yat1p 
(localized on the outer-mitochondrial membrane) and Yat2p (residing in the cytosol) 
(Figure 1.1 A; Kispal et al. 1993; Schmalix and Bandlow 1993; Swiegers et al, 2001; 
Franken et al, 2008). In mammalian systems, a single carnitine acetyltransferase is 
present and active in both the peroxisomal and mitochondrial lumens. All three yeast 
CATs are required for a functional carnitine shuttle, but the specific roles of these 
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enzymes within the context of the shuttle and metabolism in general remain elusive 
(Swiegers et al, 2001). Obstructing the glyoxylate cycle by deletion of the citrate 
synthase 2 (CIT2) gene, which catalyzes the first reaction of this pathway, renders the 
yeast strain entirely dependent on the carnitine shuttle and also on carnitine 
supplementation for growth on fatty acids and non-fermentable carbon sources (Van 
Roermund et al, 1995; Swiegers et al, 2001). This also signifies that, unlike higher 
eukaryotes, which utilize four enzymatic steps to convert the precursor trimethyllysine to 
L-carnitine (Figure 1.1 B), S. cerevisiae is unable to neo-synthesize its own carnitine 
(Swiegers et al, 2002). 
A B 
 
Figure 1.1. (A). Diagrammatic representation of the carnitine shuttle and glyoxylate cycle of the 
yeast, Saccharomyces cerevisiae. Indicated are the locations of the three yeast carnitine 
acetyltransferases namely Cat2p in the peroxisome and mitochondria, Yat1p on the outer 
mitochondrial membrane and Yat2p in the cytosol. The location of the carnitine/acetylcarnitine 
translocase in the mitochondrial membrane is also indicated. (B) Illustration of the carnitine 
biosynthesis pathway present in higher eukaryotes. The four central enzymes to this pathway, 
namely trimethyllysine hydroxylase (TMLH), hydroxytrimethyllysine aldolase (HTMLA), 
trimethylaminobutyraldehyde dehydrogenase (TMABA-DH) and -butyrobetaïne hydroxylase (BBH), 
catalyzes the conversion of trimethyllysine to L-carnitine. In mammals trimethyllysine originates as a 
product of protein degradation, whereas the fungus N. crassa is able to enzymatically convert free 
Lysine to L-carnitine (Vaz and Wanders, 2002). 
The enzymes and activities of the carnitine shuttle in mammalian systems have 
been intensively studied and largely characterized throughout the second half of the 
previous century. The majority of current carnitine related research concentrates on the 
effect of systemic carnitine deficiencies and also the therapeutic applications of carnitine 
supplementation. Research has shown that carnitine supplementation is generally 
associated with beneficial effects in humans, and dietary supplementation of carnitine or 
acylcarnitines is proposed as either potential treatment or as supplemental treatment for 
a range of diseases (Ramsay et al, 2004; Calabrese et al, 2006; Petersen et al, 2005). 
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Among these, carnitine has been indicated to be of benefit to patients affected by 
cardiac ischemia, hepatic steatosis, type 2 diabetes, Alzheimer’s disease and also as a 
supplemental treatment to counter the damaging effects of anti-retroviral administration 
and chemotherapies. The therapeutic effects of carnitine is mostly attributed to it’s 
stimulatory function on mitochondrial metabolism and also on the balancing effect of the 
carnitine shuttle on the limited and compartmentalized pools of CoA and acyl-CoA’s 
(Ramsay et al, 2004). Recent reports are, however, indicating possible roles for 
carnitine that would fall outside its metabolic function in the shuttling of the 
intermediaries of energy metabolism. Carnitine and acylcarnitines have been suggested 
to function as potentiators of the cells natural defenses against stress, as possible 
antioxidants and have also been indicated to have an effect on the regulation of 
programmed cell death (apoptosis) (Mutomba et al, 2000; Calabrese et al, 2006; Zhu et 
al, 2008; Wenzel et al, 2005; Ferrara et al, 2005). The precise mechanisms behind 
these effects are currently unclear and also hampered by difficulties of studying 
mammalian systems leading to contradictory reports, which may in part arise from 
differences between the systemic concentrations of carnitine achieved in separate 
studies. An overview of carnitine related metabolism and the impact thereof on 
eukaryotic cellular physiology comparing yeast and higher eukaryotes is presented in 
Chapter 2. 
The use of yeast as a model system in the study of carnitine-related metabolism has 
aided in the initial description of the fates of cellular pools of acetyl-CoA and also in the 
description of shuttle components (Van Roermund et al, 1995; Kispal et al, 1993). 
However, with the shift of focus to more clinical application, the use of yeast in carnitine 
related research has diminished. Current knowledge of the shuttle’s components and 
their function in yeast is lagging behind that of higher eukaryotic systems. Insights 
gained from using the well established genetic model system available in yeast cell 
biology may however contribute significantly to the understanding of the carnitine 
shuttle’s function and also it’s greater impact on cellular physiology. Therefore, a central 
aim of this work was to study the fundamental role and effects of the separate shuttle 
components, namely carnitine, acetylcarnitine and also the three CATs, in S. cerevisiae. 
As a means to achieve this, a phenotypic analyses of single, double and triple deletion 
mutants of the three yeast CATs and also the effect of carnitine supplementation in 
different stress conditions was undertaken. The results of this work are described in 
Chapter 3. An outcome of this study pointed towards a role for carnitine in the protection 
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against cellular stress induced by hydrogen peroxide and also certain organic acids. 
Since the impact of oxidative stress induced by various redox stressors have been 
extensively described in yeast, a follow-up study was pursued aiming to elucidate the 
mechanisms by which carnitine supplementation is able to protect against oxidative 
stresses. During the course of this work it became increasingly clear that the effect of 
carnitine under oxidative stress conditions could be mediated on a genetic level. On 
account of this, whole genome expression analysis, using cDNA microarrays were 
performed in order to screen for possible genetic links. A role for the cytochrome heme 
lyase (Cyc3p) in the mediation of the effect of carnitine in redox stress conditions was 
established in an initial analysis of these results. The results of this work are described 
in Chapter 4. Chapter 5 provides a more detailed description of the effects of carnitine 
on differential gene expression. The results indicate that the effect of carnitine 
supplementation is expected to have a direct impact on various aspects of cellular 
growth, iron homeostasis and possibly the regulation of programmed cell death. 
A second part of this study involved the cloning of the four enzymes required for 
carnitine biosynthesis from the fungus, Neurospora crassa, and the reconstitution of this 
pathway in S. cerevisiae. N. crassa was chosen as a donor organism for the cloning of 
the carnitine biosynthesis genes, since it has also been indicated to have an enzymatic 
activity capable of converting free lysine to trimethyllysine, which serves as the 
precursor for this pathway (Borum and Broquist, 1977; Figure 1.1 B). This work forms 
part of a larger study, being conducted by SunBio at the University of Stellenbosch, of 
which the eventual aim would be to create an industrial strain of S. cerevisiae that would 
be able to biosynthesize carnitine. This work was done in collaboration with Dr. Anita 
Burger, from SunBio, and describes the establishment of this pathway in a laboratory 
yeast strain, forming part of the initial proof of concept for the project. The results of this 
work are discussed in Chapter 6. 
1.2. PROJECT AIMS 
 
The following aims were set for this project: 
 
1. To investigate the function of L-carnitine and the carnitine shuttle using the yeast, S. 
cerevisiae as a genetic model system: 
 (i)  Investigate the role of the components of the carnitine shuttle in S. cerevisiae 
using a genetic approach. . 
 (ii)  Investigate the protective function of carnitine in oxidative stress. 
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 (iii)  Establish S. cerevisiae as a model system for the elucidation of the metabolic 
and physiological functions of carnitine and the carnitine shuttle and specifically 
its effects on cellular stress. 
 
2. Cloning and expression of genes involved in carnitine biosynthesis from the fungus, 
N. crassa, in S. cerevisiae: 
 (i)  Cloning of the four genes involved in carnitine biosynthesis from N. crassa. 
 (ii)  Reconstitution of the pathway in the yeast, S. cerevisiae. 
 (iii)  Establish if the recombinant strains of S. cerevisiae are able to neo-synthesize 
L-carnitine. 
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2.1. INTRODUCTION 
 
L-carnitine (3-hydroxy-4-N-trimethylaminobutanoate) is a quaternary amine derived from 
the amino acids lysine and methionine. The molecule owes its name to its initial 
discovery in extracts from meat at the beginning of the previous century. The central 
role played by carnitine in eukaryotic energy metabolism was, however, only recognized 
a half century later. Carnitine has, since then, been discovered in various 
microorganisms, fungi, plants and mammals (Bremer, 1983). Since most eukaryotes are 
able to catalyze the endogenous synthesis of L-carnitine, it has been classified as a 
conditionally essential nutrient. 
The core metabolic function of carnitine is the transfer of acyl residues between the 
limited and compartmentalized pools of coenzyme A (CoA). The trafficking function of 
carnitine is assisted by various carnitine-acyltransferases, which catalyze the reversible 
trans-esterification of acyl groups to carnitine, and also integral membrane 
carnitine/acylcarnitine translocases (reviewed in Zammit, 1999 and Ramsey et al, 
2004). This system of cooperative intra-organellar transport is referred to as the 
carnitine shuttle and has been extensively characterized in higher eukaryotes. A similar 
system has been elucidated and shown to function in a similar capacity in the yeast 
Saccharomyces cerevisiae. Several carnitine deficiencies, which can have severe 
metabolic effects, have been described and attributed to mutations of enzymes involved 
in the carnitine shuttle. Considering the central role of carnitine in energy metabolism 
and the modulation of free pools of CoA, several therapeutic avenues are currently 
being considered for diseases such as insulin independent (type 2) diabetes, obesity, 
steatoepatitis and lipotoxic heart damage (reviewed in Foster, 2004). 
Several beneficial effects associated with carnitine supplementation have also been 
reported that can not be directly attributed to functions of carnitine within the context of 
the shuttle. These include reports indicating a role for carnitine in the defence against 
cellular stresses related to the build-up of reactive oxygen species, age associated 
mitochondrial decay and also apoptosis (Gulcin, 2006; Silva-Adaya et al, 2008; Hagen 
et al, 1998). In addition carnitine has recently been indicated to protect against oxidative 
and organic acid stress in S. cerevisiae (Franken et al. 2008). This review discusses the 
metabolic role of carnitine by in particular comparing yeast and higher eukaryotic 
systems and aims to identify focal areas where yeast research can contribute to the 
understanding of carnitine related impacts on cellular physiology. 
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2.2. SOURCES AND UPTAKE OF CARNITINE 
2.2.1. CARNITINE DERIVED FROM THE EXRACELLULAR ENVIRONMENT 
 
In humans, 75% of total carnitine is derived through dietary uptake of carnitine (Lennon 
et al, 1986; Stanley, 2004). The status of dietary carnitine intake in healthy humans 
correlates with carnitine plasma concentrations, which is exceptional for nutrients that 
are under tight metabolic regulation. The primary sources of dietary carnitine are animal 
products, especially red meats, which contains between 300 and 600 μmol of carnitine 
per 100 g. Smaller quantities are found in grain products (5 – 50 μmol/100g), fruits (5 – 
20 μmol/100g), vegetables (5 – 20 μmol/100g), legumes (~ 0.5 μmol/100g) and dairy 
products (20 – 200 μmol/100g) (Rudman et al, 1977; Panter and Mudd, 1969). Although 
a small but statistically significant difference in carnitine plasma concentrations has 
been observed between people with an omnivorous diet compared to a cereal based 
diet or vegan diet, there is no evidence of clinical significance or pathophysiological 
consequences (Lombard et al, 1989; Cederblad and Lindsted, 1972; Cederblad 1987; 
Khan Siddiqui and Bamji, 1980). Dietary carnitine intake in higher eukaryotes is 
considered important but not essential, since endogenous biosynthesis is capable of 
compensating for deficiencies. Endogenous synthesis is observed in most, if not all, 
higher eukaryotes, and also in most fungi. However, the yeast S. cerevisiae is unable to 
neo-synthesize its own carnitine and is entirely dependent on extracellular sources 
(Swiegers et al, 2002). Furthermore, no information regarding carnitine concentrations 
within yeast are available. 
2.2.2. CARNITINE BIOSYNTHESIS 
2.2.2.1 Carnitine biosynthesis in higher eukaryotes 
 
The carnitine requirement of higher eukaryotes can be met by endogenous synthesis. L-
carnitine is synthesized via a four step enzymatic process, utilizing various hydroxylases 
and dehydrogenases, from the precursor trimethyllysine (for review see Vaz and 
Wanders, 2002). The pathway for carnitine biosynthesis was initially described and 
biochemically characterized in the fungus, Neurospora crassa, which utilizes the same 
central carnitine biosynthesis pathway conserved in higher eukaryotes (Fraenkel, 1954; 
Figure 2.1). A key difference between carnitine synthesis in N. crassa and mammalian 
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systems, however, is in the source of the precursor trimethyllysine. N. crassa possesses 
an enzymatic activity that sequentially methylates free lysine to form trimethyllysine 
(Borum and Broquist, 1977), whereas mammalian lysine is methylated only when part of 
a peptide. The mammalian system is therefore dependent on the liberation of the 
precursor after protein degradation (La Badie et al, 1976; Dunn et al, 1984). 
Figure 2.1. Diagrammatic representation of the eukaryotic carnitine biosynthesis pathway. The 
precursor, trimethyllysine (TML), originates either from protein degradation in mammals or via the 
enzymatic methylation of free lysine, as is the case in the fungus, N. crassa. TML is subsequently 
converted to L-carnitine by the enzymatic activities of trimethyllysine hydroxylase (TMLH), 
hydroxytrimethyllysine aldolase (HTMLA), trimethylaminobutyraldehyde dehydrogenase (TMABA-
DH) and -butyrobetaïne hydroxylase (BBH). The intermediates of the pathway are indicated as 
follows, HTML = hydroxytrimethyllysine and TMABA = trimethylaminobutyraldehyde (Adapted from 
Vaz and Wanders, 2002) 
 
The enzyme trimethyllysine hydroxylase (TMLH) catalyzes the first step of carnitine 
biosynthesis by the addition of a hydroxyl group to the third carbon of trimethyllysine, 
leading to the formation of 3-hydroxy-N6-trimethyllysine (Hulse et al, 1978; Sachan and 
Broquist, 1980; Sachan and Hoppel, 1980). In mammalian systems the enzyme is 
localized in the mitochondria, compared to a cytosolic localization in N. crassa, and the 
conversion takes place in the liver, kidney, heart and brain. The enzyme requires 2-
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oxoglutarate, Fe2+, molecular oxygen and ascorbate as cofactors. In both N. crassa and 
mammals the pathway and enzymes downstream of the first reaction is located in the 
cytosol. The aldolytic cleavage of 3-hydroxy-N6-trimethyllysine to form 3-hydroxy-N6-
trimethylaminobuteraldehyde is catalyzed by the enzyme hydroxytrimethyllysine 
aldolase (HTMLA), requiring pyridoxal 5’-phosphate as cofactor, to form 4-N-
trimethylaminobutyraldehyde. The enzyme is active in most tissues, however, the 
greatest activity was found to be in hepatic cells (Hulse et al, 1978). The enzyme was 
purified from rat liver and found to be a serine hydroxymethyltransferase, which 
catalyzes a range of overlapping aldolytic reactions within the cell (Henderson et al, 
1982; Stein and Englard, 1981). 4-N-trimethyllaminobutyraldehyde dehydrogenase 
(TMABA-DH) catalyzes the formation of -butyrobetaïne using niacin in the form of NAD 
as a cofactor (Vaz et al, 2000; Kikonyogo and Pietruszko, 1996; Lin et al, 1996; Kurys et 
al, 1993; Chern and Pietruszko, 1995). -Butyrobetaïne enters the circulatory system 
and is actively taken up, primarily by the liver and kidneys, where it is hydroxylated on 
the third carbon by the activity of -butyrobetaïne hydroxylase (BBH) in order to form L-
carnitine (Vaz et al, 1998). Molecular oxygen and Fe2+ are required for BBH activity. 
The synthesized L-carnitine is transported by the circulatory system to be taken up by 
other tissue cells. 
Unlike mammals, S. cerevisiae is unable to neo-synthesize its own carnitine and 
none of the carnitine biosynthesis genes are encoded by the yeast’s genome (Swiegers 
et al, 2001). Conversely, all four genes from the carnitine biosynthesis pathway have 
recently been identified and characterized in the yeast Candida albicans (Strijbis et al, 
2009). 
2.2.2.2. Heterologous expression of carnitine biosynthesis genes in S. cerevisiae 
 
Recently, the N. crassa gene encoding TMLH has been cloned and functionally 
expressed in S. cerevisiae (Swiegers et al, 2002). In chapter 5, the cloning and 
expression in S. cerevisiae of the genes encoding the enzymes downstream of TMLH 
from N. crassa is described. In this study, the entire carnitine biosynthesis pathway was 
reconstituted in yeast and found to successfully catalyze the conversion of 
trimethyllysine to L-carnitine. In addition, the free lysine methyltransferase encoding 
gene was also cloned from the same organism and expressed in yeast. The assay 
system that was established to assess whether carnitine is produced, however, is not 
sensitive enough to indicate if this enzyme is functional and will require more detailed 
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analysis to establish if it is indeed functional. The same enzyme has previously been 
expressed in a bacterial system and found to catalyze the step-wise conversion of 
lysine to trimethyllysine (patent application No. WO 2007/007987 A1). Considering that 
carnitine is currently being marketed as a health supplement with an array of beneficial 
applications, yeast based, single cell or fermented products with enhanced carnitine 
levels could create substantial commercial interest. 
2.2.3. CARNITINE UPTAKE 
2.2.3.1. The mammalian organic cation transporters 
 
The mammalian organic cation transporters belong to the major facilitator superfamily 
and are characterized by the presence of 12 transmembrane domains, as well as a 
large extracellular hydrophilic loop between the first and second predicted 
transmembrane domains which contains two to five glycosylation sites (reviewed by 
Lahjouji et al, 2001). A subfamily has been described which has the ability to transport 
carnitine and some of its esters. The members of the carnitine/organic cation 
transporter family, namely OCTN1, OCTN2 and OCTN3 have variable characteristics in 
their tissue specific expression profiles and also their affinities for carnitine. 
OCTN1 was originally cloned from human fetal kidney cells and is expressed 
throughout a diverse range of tissues. It has been characterized as a multispecific, 
bidirectional, pH-dependent organic cation transporter (Tamai et al, 1997). The rat 
OCTN1 has a very low affinity for carnitine. Furthermore, carnitine transport is facilitated 
in a Na+-independent manner by OCTN1 (Wu et al, 2000). Intriguingly, the mouse 
OCTN1 does exhibit Na+-dependent carnitine transport, indicating an apparent specie-
specific difference for the same transporter (Tamai et al, 2000). A second carnitine 
transporter, OCTN3 has been cloned from mice and was found to be expressed 
primarily in the testis and also kidney. OCTN3 mediates carnitine transport in a Na+-
dependent manner. 
OCTN2 is considered to be the major transporter responsible for carnitine and also 
-butyrobetaïne (the direct precursor of carnitine in the biosynthesis pathway) uptake. 
OCTN2 functions as a Na+-dependent carnitine transporter as well as facilitating Na+-
independent transport of other organic cations (Tamai et al, 1998). Na+-dependent 
carnitine transport takes place at a high affinity (Km = 4.3). In addition to carnitine, 
various organic cations and short chain acylcarnitine esters are also transported by 
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OCTN2. Furthermore, various clinically important drugs are transported by OCTN2, 
such as pyrilamine, quinidine, verapamil, and valproate (Wu et al, 1999). It has also 
been indicated that various xenobiotics, such as quinine and S-methylmethionine 
sulfonium significantly inhibit carnitine uptake by OCTN2. Carnitine uptake by OCTN2 
was additionally shown to be inhibited by various ß-lactam containing antibiotics, 
namely cephaloridine, cefoselis, cefepime, and cefluprenam. Since OCTN2 is widely 
expressed in the heart, skeletal muscles, placenta, small intestines and the brain, 
absorption and dispersal of these drugs are likely to be effected by OCTN2. 
A lack of functional OCTN2 carnitine transporters results in an autosomal recessive 
disease referred to as primary carnitine deficiency. Primary carnitine deficiency occurs 
at a frequency of between 1:40 000 – 1:100 000 (Koizumi et al, 1999; Wilcken et al, 
2001). Several missense and nonsense OCTN2 mutations leading to residual carnitine 
transport activity have been identified (Lahjouji et al, 2001). The disease is 
characterized by a loss of 90-95% of systemic carnitine and has predominantly a 
metabolic, in the form of hypoglycemia or hyperammonemia, or cardiac presentation 
(Scaglia et al, 1998). In affected children, signs of metabolic disturbances usually 
manifest before the age of two and can result in coma and death if not treated in time 
with intravenous glucose. Cardiac presentation is more common in older patients in the 
form of cadriomyopathy. In some cases, children are only diagnosed due to the birth of 
an affected sibling and show only mild developmental augmentation (Wang et al, 2001). 
If primary carnitine deficiency is diagnosed before irreversible organ damage occurs, 
patients respond positively to dietary carnitine supplementation (100 – 400 mg/kg/day). 
The disease is diagnosed by the measurement of plasma carnitine levels and should be 
differentiated from other causes of carnitine deficiency, such as defects of fatty acid 
oxidation and the carnitine shuttle (Scaglia and Longo, 1999). 
2.2.3.2. Additional transporters involved in mammalian carnitine uptake 
 
In addition to the organic cation transporter family, CT2 and ATB0,+ have also been 
shown to be involved in the uptake of carnitine (Enomoto et al, 2002; Nakanishi et al, 
2001). CT2 was found to present in the epididymal epithelium of testis and not to be 
expressed in the brain or other tissues. ATB0,+, which belongs to the Na+, Ca2- - 
dependent family of amino acid transporters, was also indicated to transport carnitine in 
an Na+, Ca- - dependent manner. ATB0,+ was reported to be expressed in the intestinal 
tract, trachea, lungs, mammary glands and hippocampus (Sloan and Mager, 1999). 
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ATB0,+, in combination with OCTN2 is considered to regulate carnitine uptake through 
the blood brain barrier (Ganapathy et al, 2000) 
2.2.3.3. Carnitine uptake in S. cerevisiae. 
 
The S. cerevisiae general amino acid transporter, Agp2p, was identified in a screen for 
mutants defective the carnitine-dependent transport of activated acetyl residues 
between the peroxisome and mitochondria (Van Roermund et al, 1995, 1999). AGP2, 
encodes for a protein of 596 amino acids wit 12 potential transmembrane domains and 
belongs to a family of assumed plasma membrane proton symporters (André et al, 
1995). It was subsequently shown that Agp2p is required for the transport of carnitine 
into yeast cells. The data furthermore indicated that the transport of carnitine is Na+-
independent but H+- dependent. The uptake of carnitine was also found to be induced in 
media containing oleate as carbon source, which could possibly be linked to a putative 
oleate response element (ORE) in the gene promoter and suggests carnitine uptake in 
yeast to be functionally coordinated with fatty acid metabolism. In a separate study, it 
was shown that carnitine uptake by Agp2p was shut down during conditions of osmotic 
stress (Lee et al, 2002). This effect was suggested to be due to the transcriptional 
repression of AGP2 by elements of the Hog1 MAP kinase pathway. Yeast have been 
shown to import acetylcarnitine from the growth medium, however this uptake has not 
yet been linked to Agp2p mediated import (Franken et al, 2008). It would also be of 
interest to investigate the potential of the mammalian transporters to complement 
deletion of AGP2 since this could provide a straightforward system in which to 
characterize various human, disease causing mutations. 
2.3. THE CARNITINE SHUTTLE 
2.3.1. THE CARNITINE SHUTTLE OF HIGHER EUKARYOTES 
 
In mammals, -oxidation of fatty acids takes place in both the peroxisome and 
mitochondria. Very long chain fatty acids are shortened or debranched in the 
peroxisome, resulting in only partial -oxidation of fatty acids to acetyl-CoA or propionyl-
CoA (from -branched fatty acids) (Wanders et al, 1995; Leenders et al, 1996; Schulz 
1991). For the complete oxidation of fatty acids to CO2 the activated acyl groups from 
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the peroxisome need to enter the mitochondria (Bieber 1988; Reddy and Mannaerts 
1994). The critical role of carnitine in the metabolism of fatty acids is due to the fact that  
acyl-CoA esters are impermeable to membranes of organelles and no transporter for 
these intermediates exists (for review see Zammit 1999). Trafficking between 
compartments is achieved by the transfer of acyl groups from CoA to carnitine by a 
diverse group of carnitine acyltransferases and transport across organellar membranes 
by the carnitine/acylcarnitine translocase (Figure 2.2). Aside from the inter-organellar 
transfer of activated acyl groups the carnitine shuttle has an additional role in the 
balancing of the cells compartmentalized and limited pools of coenzyme A. Various 
carnitine acyltransferases have been described, including the carnitine 
acetyltransferase (CAT, located in both the peroxisome and mitochondria), carnitine 
octanoyltransferase (COT, residing in the peroxisome), and the carnitine 
palmitoyltransferases (CPTI on the outer mitochondrial membrane and CPTII on the 
mitochondrial inner membrane). The carnitine/acylcarnitine translocase, CACT, is 
located in the inner membrane of the mitochondria. The activities of these enzymes and 
their function in the carnitine shuttle will be discussed separately in the following 
sections. 
2.3.1.1. The carnitine acetyl (CAT) and octanoyl (COT) transferases 
 
Carnitine acetyl transferases (CAT), using carnitine, acetylcarnitine, CoA-SH and acetyl-
CoA as substrates, catalyze the freely reversible conversion between carnitine and 
acetylcarnitine. In addition the enzyme has also been shown to use other short chain 
acyl-CoA’s, such as propionyl-CoA, as substrate. From studies in rat cellular systems, 
the subcellular distribution of the enzyme was shown to be both the in the peroxisome 
(30%), the lumen of the mitochondria (50%), and also in the lumen of the endoplasmic 
reticulum (ER) (20%) (Kahonen et al, 1979; Markwell et al, 1973). CAT is encoded by a 
single gene, with differential localization of the encoded proteins achieved by alternate 
mRNA splicing which leads to two transcripts, one of which contains a mitochondrial 
targeting sequence. Both peptides contain a putative peroxisomal targeting signal 
(AKL), suggesting that the presence of the mitochondrial targeting signal overrides the 
effect of the peroxisomal signal. It has been suggested that the “KVEL” sequence 
present in CAT could be responsible for ER targeting (Corti et al, 1994). CAT is an 
abundant protein that has been extensively studied. The chemical, kinetic and structural 
properties of the enzyme are well established and gene sequences have been identified 
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from many species, including yeast, human, mouse and rat (for review see Ramsey and 
Naismith, 2003). 
Figure 2.2. Localization of the different mammalian carnitine acyltransferases, carnitine acetyl 
transferase (CAT in the mitochondria and peroxisome), carnitine octanoyltransferase (COT in the 
peroxisome) and the two carnitine palmitoyltransferases (CPTI on the outer mitochondrial membrane 
and CPTII on the mitochondrial inner membrane).The carnitine/carnitine-acyl transporter CACT is 
located in both the mitochondrial and peroxisomal membranes. The diagram gives a simplified 
representation of the composition of the mammalian carnitine shuttle and its effect on the balancing 
of compartmentalized pools of CoA and acyl-CoA pools. 
 
The function of peroxisomal CAT is the transfer of acetyl and propionyl moieties, 
generated by partial -oxidation of fatty acids from CoA to carnitine, which is followed by 
transport out of the peroxisomes, allowing -oxidation to proceed through regeneration 
of free CoA-SH. The acylcarnitine can than be transported to the mitochondria, enabling 
further metabolism. In the mitochondria CAT plays a central role in the regulation of 
acetyl-CoA metabolism, which lies at a metabolic crossroads between the catabolic 
TCA cycle, synthesis of molecules to be exported from the mitochondria for various 
cellular functions and the synthesis of ketone bodies in mammalian liver cells. The ratio 
between free CoA and acetyl-CoA plays a key role in the regulation of the switch 
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between glycolysis and gluconeogenesis and also the metabolism of fatty acids (for 
review see Zammit, 1994). The interconversion between carnitine and acetylcarnitine 
catalyzed by the activity of CAT is considered to have a major impact on the regulation 
of this decisive point in carbon metabolism. Furthermore, acetyl groups bound to 
carnitine provide a reservoir of activated acetyl groups that can be transferred to CoA 
and utilized as energy source through the citric-acid cycle in times of metabolic demand. 
The carnitine octanoyl transferase (COT) enzyme is located in the peroxisomal 
matrix and catalyzes the transfer of medium to long chain acyl residues between CoA 
and carnitine. The enzyme’s activity has a broad range of chain-length specificity, which 
would be a logical necessity since it is the only long chain acyl transferase present in 
the peroxisome and its activity would be required for the export of a wide range of acyl 
moieties (Ramsay, 1999). 
2.3.1.2. The carnitine palmitoyltransferase system 
 
Fatty acids in the cytosol are activated by the activity of the long-chain acyl-CoA 
synthase (LCAS), which is located on the outer mitochondrial membrane. The ATP 
released and stored after the -oxidation of these residues represents a major energy 
source for most cells and tissues (Eaton et al, 1996; Kunau et al, 1995; Bartlett and 
Eaton, 2004). The activated acyl residues in the cytosol and peroxisomes utilize the 
carnitine palmitoyl system to enter the mitochondria for further metabolism (reviewed in 
Ramsay et al, 2001; Figure 2.3). This system consists of several proteins, including (i) 
the outer mitochondrial carnitine palmitoyltransferase I (CPTI) which converts acyl-
CoA’s to their representative acylcarnitine esters, (ii) the carnitine/acylcarnitine 
translocase (CACT) that  translocates the produced acylcarnitines into the matrix of the 
mitochondria and (iii) the carnitine palmitoyl transferase II (CPTII), an enzyme 
associated with the inner leaflet of the mitochondrial membrane that converts the 
acylcarnitine esters to their respective acyl-CoA’s. The carnitine palmitoyl transferase 
system plays a key regulatory role in controlling the flux through -oxidation. As a 
consequence, mutations of either the carnitine palmitoyltransferases or the translocase 
result in potentially severe metabolic diseases. The carnitine palmitoyltransferases are 
also currently being considered as drug targets for the control of type 2 diabetes 
mellitus. The following section will discuss the function and regulation of this system and 
its components. 
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Figure 2.3. Diagrammatic representation of the carnitine palmitoyltransferase system, its effect on 
the regulation of the intramitochondrial acyl-CoA/CoA ratio and the locations of it’s constituents 
within the mitochondria. Carnitine palmitoyltransferase I (CPTI), present on the outer membrane of 
the mitochondria, catalyzes the conversion of long-chain acyl-CoA’s to long-chain acylcarnitines. 
The converted acylcarnitines are transported into the mitochondria by the activity of the 
carnitine/acylcarnitine translocase (CACT), to be reconverted to their represented acyl-CoAs by the 
activity of CPTII on the inner-mitochondrial leaflet. After -oxidation, the resulting acetyl-CoA is 
converted to acetylcarnitine (by the activity of CAT) to be utilized in further metabolic processes 
(Adapted from Vaz and Wanders, 2002). 
CPT I exists in three organ specific isoforms, namely the liver (L-CPTI), muscle (M-
CPTI) and brain type (B-CPTI) carnitine palmitoyl transferases (McGarry and Brown, 
1997; Price et al, 2002). The muscle and liver specific isoforms of CPTI differ 
significantly in their kinetic and regulatory properties. L-CPTI displays a higher affinity 
for carnitine and lower affinity for its physiological inhibitor malonyl-CoA compared to 
the muscle isoform. The two proteins are encoded by two separate genes, located on 
different chromosomes and also have distinct tissue distributions (McGarry and Brown, 
1997; Kerner and Hoppel, 1998; Van der Leij et al, 2000). In contrast to CPTII, CPTI 
cannot be extracted in a catalytically active form and needs to be reconstituted in 
liposomes in order to recover activity when expressed in Pichia pastoris (McGarry and 
Brown, 2000). Mitoplast preparations from S. cerevisiae expressing CPTI provide an 
enzyme that has similar properties and membrane topology than the native form (Brown 
et al, 1994; Prip-Buus et al, 1998). Expression in yeast has considerable advantages, 
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since there is no CPT activity present in yeast, which would enable the study of isolated 
mutant forms of CPTI. The intrinsic dependence of CPTI activity on mitochondrial 
membrane fluidity has, nonetheless, provided difficulty in the characterization of CPTI’s 
activity and the sensitivity to inhibitors (Zammit, 2008). The brain type CPTI, was initially 
considered to be inactive, since no activity could be detected from yeast extracts that 
heterologously expressed B-CPTI (Price et al, 2002). It has, however, been indicated 
that B-CPTI knock-out mice have reduced food intake and body weight, but do have an 
increased predisposition to obesity compared to wild type mice on a high-fat diet 
(Roomets et al, 2008). It was only recently indicated that B-CPTI does in fact have 
catalytic activity and that the protein is located in the endoplasmic reticulum (Sierra et 
al, 2008). In contrast, the mitochondrial matrix associated CPT II is present only as a 
single isoform and is ubiquitously expressed (Kopec and Fritz, 1973; West et al, 1971; 
Brown et al, 1993). 
Acylcarnitines that are imported into the mitochondria by the carnitine/acylcarnitine 
translocase CACT do not equilibrate with acylcarnitine in the mitochondrial lumen 
(Murthy and Pande, 1985). Based on this finding it has been postulated that CPTII could 
be localized on the inner mitochondrial membrane in direct contact with CACT in such a 
manner that channeling would occur from the transporter into the receiving CPTII (Rufer 
et al, 2009). This would create a microenvironment from which the carnitine that is 
liberated, after transesterification to CoA, would be transported back to the cytosol by 
CACT. This creates in interesting possibility regarding the biochemical interaction 
between CACT and mitochondrial CAT. It has been observed that most hepatic CAT 
activity resides in the mitochondrial lumen, where it functions to buffer pools of activated 
acetyl-CoA by equilibration with acetylcarnitine (Ramsay and Naismith, 2003). In 
addition, excess acetyl-CoA generated by -oxidation can be transported into the 
cytosol by CACT. This function is dependent on the transfer of acetyl groups from CoA 
to carnitine by CAT. If CPTII is involved in this process, as proposed by Rufer et al. 
(2009) the interaction between CPTII and CACT needs to be established in such a 
manner that bidirectional transport of acetyl-CoA to and from CPTII is possible. This 
proposed simultaneous processing, however, still needs to be experimentally 
supported. Such confirmatory findings would contribute to the understanding of the 
stimulation of gluconeogenesis by acetyl-CoA. 
Malonyl-CoA was assumed to be mainly sourced from glycolysis, until studies using 
isotope labeled substrates established that peroxisomal -oxidation is the major supplier 
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of acetyl-CoA for the synthesis of malonyl-CoA in heart cells (Poirier et al, 2002; Reszko 
et al, 2004). The inhibition of CPTI activity by malonyl-CoA, presents an interesting 
aspect of the regulation of fatty acid degradation. Detailed studies have identified the 
first 18 bp on the amino-terminal of CPTI to be required for malonyl-CoA inhibition (Shi 
et al, 1998; Shi et al, 1999). Moreover, an increase in membrane fluidity of the 
mitochondrial outer membrane disrupts the interaction between the N- and C-terminal 
domains, suggesting a degree of flexibility and complex mutual interactions between the 
two domains. In addition to malonyl-CoA sensitivity, phosphorylation based regulation of 
CPTI activity has also been suggested (Kerner et al, 2004; Kerner et al, 2005). 
Phosphorylation of CPTI on two sites, Ser741 and Ser 747, situated in the carboxy-
terminal catalytic domain, has been associated with increased activity and modulation of 
malonyl-CoA sensitivity (Distler et al, 2007). Aside from phoshorylation it has been 
indicated that both the liver and muscle isoforms of CPTI is also nitrated (Fukumoto et 
al, 2002; Fukumoto et al, 2004). The addition of nitrate residues occurs on the 
C-terminal amino acids Tyr589 and Tyr282, which are speculated to have an impact on 
substrate binding. Acetylation of the N-terminal Ala2 has also been recently reported 
(Eaton et al, 2003). These modifications are likely to contribute to the alosteric 
regulation of CPTI activity. 
CPTI, based on its key role in the maintenance of fatty acid -oxidation and the 
connected effect on glucose homeostasis, has emerged as an attractive target in the 
treatment various metabolic diseases, such as type 2 diabetes, cardiac reperfusion 
injury and psoriasis. The modulation of CPTI activity by substances such as L-
aminocarnitine, tetradecyl glycidic acid, etomoxir and phenylalkyl oxirane carboxylates 
received considerable research interest over the past five years. The discussion of this 
research area, however, falls outside the boundaries of this review (for recent reviews 
see Rufer et al, 2009) 
2.3.2. THE CARNITINE SHUTTLE OF S. CEREVISIAE 
 
The function of the carnitine shuttle is conserved between S. cerevisiae and mammals. 
There are, however, differences in the composition of the two systems that can be 
largely related to the variation in metabolic make-up when comparing yeast to higher  
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Figure 2.4. Cross-species sequence alignment of carnitine acyl-transferases. Shaded sequences 
indicate regions identical to a consensus sequence derived from the alignment of 15 carnitine 
acyltransferases. The Roman numbered bars indicates the two CPTI transmembrane domains. 
Carnitine acyltransferase domains are indicated using + and x symbols (Prosite PS00439 and 
PS0040). N-terminal mitochondrial and C-terminal peroxisomal targeting sequences are indicated in 
boxes. Start methionines of the peroxisomal forms of CAT are underscored. The circled and 
numbered residues indicate CPTI point mutations which result in loss of either malonyl-CoA 
sensitivity or enzyme activity (Ramsey et al, 2001). 
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eukaryotes. Firstly, -oxidation in yeast takes place solely in the peroxisome, compared 
to mitochondrial and peroxisomal oxidation of fatty acids in mammals (Kunau et al.  
1995). In addition, the generation of acetyl-CoA in the cytosol due to the metabolism of 
non-fermentable carbon sources does not occur in mammalian systems (Schmalix and 
Bandlow 1993; Stemple et al. 1998). Finally, an additional metabolic pathway that is 
absent in mammals, the glyoxylate cycle, impacts significantly on the metabolic 
importance of carnitine. This pathway allows the further metabolisation of peroxisomally 
generated acetyl-CoA without any requirement of the carnitine shuttle (Van Roermund 
et al. 1995). This metabolic “bypass” combines two molecules of acetyl-CoA to form 
succinate, which can then be transported by the membrane bound carrier Acr1p to the 
mitochondria (Palmieri et al. 1999). Deletion of the yeast citrate synthase (CIT2) gene, 
which is responsible for the first reaction of the glyoxylate cycle, effectively blocks this 
pathway and creates a yeast strain that is entirely dependent on the carnitine shuttle 
and carnitine supplementation for growth on non-fermentable carbon sources and fatty 
acids (Van Roermund et al. 1995; Swiegers et al, 2001). This finding has been 
efficiently used as a genetic tool for the isolation and characterization of the 
components of the carnitine shuttle in S. cerevisiae. Another significant difference 
between the two systems is the apparent absence of long chain carnitine acyl 
transferase activity in S. cerevisiae (Kispal et al. 1993). Indeed, to date, only carnitine 
acetyl-transferase activity has been described. However, this activity is catalyzed by 
three separate CATs in yeast. CAT2 is considered to be the dominant enzyme of the 
three, responsible for 95% of total carnitine acetyl-transferase activity (Kispal et al. 
1993). This enzyme, similar to the mammalian CAT (Figure 2.4), localizes to both the 
peroxisome and the mitochondria. The regulation of CAT2 localization is achieved by 
the presence of two ATG codons in the gene’s open reading frame and two separate 
transcripts, one of which encodes an N-terminal mitochondrial targeting signal. There is 
a peroxisomal targeting sequence (AKL) present at the C-terminal of both peptides and 
it appears that, similar to the mammalian CAT, the presence of the mitochondrial signal 
overrides the peroxisomal sequence (Corti et al, 1994). In addition to Cat2p, two 
additional CATs (Yat1p and Yat2p) which share a high degree of similarity have been 
identified (Schmalix and Bandlow 1993; Swiegers et al, 2001; Figure 2.5). Yat1p is 
associated with the outer mitochondrial membrane and Yat2p has been shown to be 
cytosolic (Franken et al, 2008). Interestingly, all three yeast CATs are required for a 
functional carnitine shuttle. Deletion of any one of the CATs in combination with CIT2 
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indeed results in complete loss of growth on non-fermentable carbon sources. 
Furthermore, over-expression of each CAT only results in self-complementation and not  
 
Figure 2.5. Diagrammatic representation of the carnitine shuttle and the glyoxylate cycle in S. 
cerevisiae. The three yeast carnitine acetyl transferases, Cat2p in the mitochondria and peroxisome, 
Yat1p on the outer-mitochondrial membrane and Yat2p in the cytosol are indicated along with the 
carnitine/acetylcarnitine translocase Crc1p. Cit2p combines two units of peroxisomally generated 
acetyl-CoA, the fist step of the glyoxylate cycle, forming succinate. 
 
cross-complementation of any of the other two enzymes. This clearly indicates a very 
specific function for each of the three enzymes. It is currently not clear what the specific 
requirement of three separate CATs, all catalyzing the same reaction would potentailly 
be. 
Apart from the three CATs, Crc1p, an orthologue of the human 
carnitine/acylcarnitine translocase CACT has also been identified. Transport of 
acetylcarnitine to the mitochondria is mediated by the activity of Crc1p (Palmieri et al. 
1997; Van Roermund et al. 1995). It is, however, not clear if Crc1p is located in both the 
mitochondrial and peroxisomal membranes and if the transporter would be involved in 
the export of acylcarnitine residues from peroxisomes. 
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2.3.3. THE CARNITINE SHUTTLE OF CANDIDA ALBICANS 
 
In the yeast C. albicans, phagocytosis leads to transcriptional profiles similar to that 
observed in cells growing on non-fermentable carbon sources (Lorenz et al, 2004). This 
finding has created a surge of interest in the processes involved in the regulatory 
mechanisms associated with carbon limitation in this pathogenic yeast. Among the 
group of genes significantly upregulated under these conditions are the carnitine acetyl-
transferases (Prigneau et al, 2004). The genome of C. albicans encodes for three 
carnitine acetyl transferases, namely CTN1, CTN2 and CTN3, which have been named 
according to their homology to the three S. cerevisiae CATs (CTN1 is similar toYAT1, 
CTN3 is similar to YAT2 and CTN2 is similar to CAT2). Similar to the S. cerevisiae 
CAT2 gene, CTN2 also has two separate start codons and conserved mitochondrial and 
peroxisomal targeting signals (Elgersma et al, 1995). Interestingly, C. albicans only 
possesses a mitochondrial and not a peroxisomal citrate synthase activity and is 
dependent on the carnitine shuttle for growth on fatty acids and non-fermentable carbon 
sources and also the transport of acetyl units from the peroxisome (Strijbis et al, 2008). 
Similar to CAT2, CTN2 contributes the majority of CAT activity. The lack of a separate 
pathway for the channeling of peroxisomally generated acetyl-CoA would also explain 
that, in contrast to deletion of S. cerevisiae CATs, mutants of the C. albicans carnitine 
acetyl-transferases have distinct phenotypes when grown on different carbon sources 
(Zou and Lorenz, 2008). Both CTN1 and CTN2 are unable to grow on ethanol, acetate 
and citrate, whereas only CTN2 is unable to grow on oleic acid as carbon source. CTN3 
has no distinguishable growth variances on separate carbon sources when compared to 
wild type (Prigneau et al, 2004; Zhou and Lorenz, 2008). Complementation of the S. 
cerevisiae CAT mutants results in intriguing differences and similarities between the two 
species. CTN2 was found not to be functional in S. cerevisiae, whereas, CTN3 was able 
to complement deletion of YAT2 in combination with CIT2. On the other hand, CTN1 
was able to restore growth in both a Δcit2Δyat1 and also a Δcit2Δyat2 strain (Zhou and 
Lorenz, 2008). 
2.4. PLEIOTROPIC CONSEQUENCES ASSOCIATED WITH CARNITINE-
RELATED METABOLIC AVTIVITIES  
 
In healthy humans, 80% of carnitine is present in its free form and the average ratio of 
acylcarnitine:carnitine is 0.25. A ratio of 0.4 is considered to be abnormal and indicative 
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of carnitine deficiency (Deufel, 1990). The ratio between serum acylcarnitine and free 
carnitine is highly sensitive to intramitochondrial metabolic alterations. A reduced pool of 
carnitine can either be a result primary carnitine deficiency (OCTN2 mutation) or has 
been attributed to a wide variety of diseases (Table 2.1). These clinical observations are 
in agreement with the view that a normal endogenous pool of carnitines is essential for 
normal cellular function and has provided the rational for the use of carnitine as a 
therapeutic supplement for the treatment of a wide variety of diseased or stressed 
states. 
Table 2.1. Causes of carnitine deficiency. 
Primary carnitine deficiency (OCTN2). 
 
Secondary carnitine deficiency: 
 Genetically mediated metabolic errors (fatty acid oxidation or branched chain amino acid 
metabolism disorders) 
 
Acquired conditions: 
 Decreased synthesis (liver cirrhosis) 
 Decreased intake (malnutrition; malabsorption) 
 Decreased body stores/increased requirement (sepsis; burns; trauma) 
 Increased loss (heart failure; hypertension; diabetes) 
 Mitochondrial dysfunction (HIV infection; inflammatory myopathies; chronic fatigue syndrome) 
 Drugs (pivaloyl-antibiotics; valproate; antiretroviral nucleoside analogues) 
 
As a consequence, substantial clinical evidence has accumulated over the past 
decade that supports a role for carnitine and its acyl esters as molecules with 
considerable therapeutic potential in a diverse group of diseases, such as Alzheimer’s 
disease, heart ischemia, organic acidurias, and diabetes. The beneficial effects 
associated with carnitine supplementation can mostly be attributed to its function in the 
equilibration of the acylation state of the limited pool of CoA through the large cellular 
pools of carnitine. However, recent studies are indicating carnitine to have additional 
functions, unrelated to its metabolic role in the carnitine shuttle. In particular, links to the 
cells defense against stresses and also in the process of programmed cell death have 
been suggested (apoptosis) (Moretti et al, 1998; Mutomba et al, 2000; Pastorino et al, 
1993). The metabolic and physiological effects associated with carnitine and 
acylcarnitine supplementation will be discussed in this section. 
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2.4.1. REMOVAL OF HARMFUL/EXCESS ORGANIC ACIDS 
 
Acylcarnitine is exported along a concentration gradient from 0.5 - 1 mM inside the 
cytosol to 50 μM of total carnitine in the plasma (Sandor et al, 1985). The accumulation 
of excess intracellular acyl groups is reflected in the acylation state of the total plasma 
carnitine, which is clearly illustrated in the diagnostic acylcarnitine profiles of ß-oxidation 
impaired patients (Fingerhut et al, 2001; Sim et al, 2001; Gempel et al 2002). Diabetic 
patients excrete more long-chain acylcarnitine esters than control patients and this 
characteristic has been proposed to be used as a diagnostic tool in monitoring the 
therapy of diabetes mellitus (Moder et al, 2003). Carnitine and its short chain esters are 
effectively reabsorbed in the kidney while long chain variants are excreted (Evans and 
Fornasini, 2003). Therefore, sufficient carnitine levels are required in the plasma in 
order to excrete excess acyl moieties. Longer chain acylcarnitine esters can be 
excreted up to a total of one gram per day. In such cases, continuous carnitine 
supplementation is required to maintain the excretion of excess acids. 
Deficiency of 2-methylacetoacetyl-CoA thiolase results in increased total and ester 
bound carnitine concentrations and also an enhanced acylcarnitine/free carnitine ratio. 
Supplementation of L-carnitine in these patients leads to an increase in the excretion of 
short and branched chain acylcarnitines (Fontaine et al, 1996). A similar effect is 
observed in the build-up of excess long-chain acyl groups is found in patients exhibiting 
a deficiency of the very long chain acyl-CoA dehydrogenase (VLCAD). Mice bearing 
knock-out mutations of VLCAD, unsupplemented with carnitine, displayed an increase 
in plasma acylcarnitines (C14-C18) and decrease in free carnitine. Exposing the fasted, 
VLCAD deficient mice to cold stress resulted in a further five-fold increase in the 
concentration of long chain acylcarnitines and resulted in a 33% mortality rate, 
indicating an increase in acylation of cellular CoA pools and the importance of 
maintaining the integrity thereof in cellular/organ function (Spiekerkoetter et al, 2004). 
Certain drug treatments result in the production of excess organic acids, and the 
removal of these acids from cells appears dependent on the function of carnitine (for 
review see Arrigoni-Martelli and Caso, 2001). For instance, treatment of epilepsy with 
valproate leads to overacylation of the mitochondrial CoA pool and can result in the 
development of Reyes disease. Use of pivaloyl antibiotics also results in the excretion of 
excess acylated carnitine, with plasma free carnitine levels decreasing to almost 10% of 
the normal levels (Brass, 1994). Secondary carnitine deficiency arising from drug 
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treatment or from the dilution of plasma carnitine concentration observed in dialyses 
patients, results in high levels of ketone production, high blood acylcarnitine/free 
carnitine ratios and high lipid levels detectable in the liver and plasma (Steiber et al, 
2004). These effects are effectively reversed by co-supplementation with carnitine. 
2.4.2. MODULATION OF CARBON METABOLISM THROUGH THE CoA/ACYL-CoA 
RATIO 
 
Cardiac ischemia is characterized by a relative deficit in the availability of myocardial 
oxygen. One of the strategies followed in the treatment of this disease is to optimize the 
function of the heart in relation to oxygen availability by improving the balance between 
fatty acid and pyruvate (from glycolysis) metabolism in the mitochondria (Lopaschuk, 
2004). Increased rates of fatty acid oxidation are associated with lower rates of glucose 
oxidation and higher rates of glycolysis, which is considered to play a key role in 
myocardial ischemic injury (Stanley et al, 2005). When glucose is processed through 
glycolysis, pyruvate oxidation is inhibited, which results in an increase in lactate 
production and a decrease in intracellular pH that alters the movement of Ca2+ and Na+ 
across the cell membrane and increases the ATP demand at a time when ATP 
formation is diminished (Dennis et al, 1991; Liu et al, 2002). As fatty acid oxidation 
recovers quicker during ischemia, glycolytic formation of lactate is increased, resulting 
in a decline in cardiac efficiency. 
A common factor shared by pharmacological agents used in the treatment of 
ischemia and heart failure is the ability to drive energy metabolism in the direction of 
glucose oxidation by directly or indirectly activating pyruvate dehydrogenase (PDH) 
(Lopaschuk et al, 2002; Stanley et al, 2005). Using carnitine supplemented to the 
perfusion medium to obtain a two fold increase of carnitine in the myocardium resulted 
in an increased flux through PDH and subsequently also glucose consumption 
(Broderick et al, 1992). The effect of carnitine supplementation on PDH is mediated by 
the activity of the mitochondrial CAT. An increase in the intracellular carnitine 
concentration drives the forward reaction catalyzed by CAT toward the production of 
acetylcarnitine. As a consequence this is suggested to result in a decrease in 
mitochondrial acetyl-CoA, a potent activator of pyruvate dehydrogenase kinase, which 
keeps PDH in a more active state (Broderick et al, 1992; Figure 2.6 A). An unexpected 
outcome of carnitine supplementation in these conditions is a decreased rate of fatty 
acid oxidation. This counterintuitive action of carnitine seemingly results from the fact 
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that the lowered mitochondrial matrix concentration of acetyl-CoA overcomes the mass-
action effect of an increased carnitine concentration on CPTI activity (Saddik et al, 
1993). This would result in an increased flux through the electron transport chain, 
associated with a higher rate of pyruvate oxidation. The beneficial effect of an increased 
rate of glucose oxidation relative to fatty acid oxidation on cardiac function has  
Figure 2.6. Possible effects of supplementation of high levels of carnitine. Direction of flux is 
indicated by solid arrows and broken arrows indicate regulatory effects (A) Increased carnitine 
concentration affects the use of carbon fuel sources in cardiac muscle. The mass-action effect 
caused by high levels of carnitine on CPTI is overcome by the effect of carnitine that shifts the 
equilibrium of the mitochondrial CAT away from acetyl-CoA synthesis. The resulting de-inhibition of 
pyruvate dehydrogenase kinase (PDHK) results in enhanced oxidation of glycolytic pyruvate. (B) 
Insulin sensitivity is affected by fatty acid oxidation rate. The major contribution towards systemic 
insulin-sensitive glucose metabolism resides in the skeletal muscles. Derepressed fatty acid 
oxidation, increasing the supply of long-chain acyl-CoA for diacylglycerol (DAG) and ceramide 
synthesis, and also incomplete fatty acid oxidation, resulting in carnitine esters of -oxidation 
intermediates, have been suggested to influence insulin resistance. (C) Hepatic steatosis is highly 
related to insulin resistance. Carnitine supplementation potentially increases fatty acid oxidation, 
diverting metabolism away from triacylglyceride (TG) synthesis, through a mass-action effect on the 
reaction catalyzed by CPTI. Intermediates of TG synthesis are known to result in increased insulin 
resistance in the liver and also other tissues. High levels of carnitine shifts the CAT catalyzed 
reaction away from acetyl-CoA synthesis, resulting in lower levels of activated pyruvate carboxylase 
(PC) and PDH kinase, which leads to derepressed gluconeogenesis. (Adapted from Arduini et al, 
2008). 
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been well established (Broderick et al, 1992). Propionyl-carnitine has also been 
indicated to have the same beneficial effects, with the added benefit of ATP generation 
from the metabolism of the propionyl moiety (Wiseman and Brogden, 1998; Zammit et 
al, 1998; Schonekess et al, 1995; Loster et al, 1999; Felix et al, 2001). As can be 
expected, acetylcarnitine did not show the same beneficial outcome on cardiac function, 
since it would not have a similar effect on the mitochondrial pools of acetylcarnitine and 
acetyl-CoA. 
Carnitine supplementation has also been indicated as a possible effective treatment 
of the metabolic inflexibility and insulin insensitivity associated with type 2 diabetes 
(Gunal et al, 1999; Biolo et al, 2008). Skeletal muscle is a major site of glucose 
deposition in response to insulin and as a result a major site of insulin resistance in type 
2 diabetes. A major contributing factor of insulin resistance in skeletal muscle appears 
to be a decreased ability of insulin to induce the switch from lipid to carbohydrate 
oxidation (Kelley and Mandarino, 2000). Interestingly, a 15 % increase of skeletal 
muscle carnitine was shown to result in a significant decrease in PDH activity (30%) 
(Stephens et al, 2006). The carnitine treatment additionally resulted in a 30 % increase 
of glycogen and a 40 % decrease of muscle lactate content. These observations 
suggest that an increase in muscle carnitine concentration reduces glycolytic flux and 
carbohydrate oxidation at the level of PDH, by diverting muscle glucose uptake towards 
glycogen storage, resulting from an increase in non-oxidative glucose disposal 
(Stephens et al, 2007). As can be expected from the reciprocal relationship between 
fatty acid oxidation and glucose oxidation, carnitine administration leads to an increase 
in the oxidation of fat, an effect which has been observed in healthy and overweight 
patients (Müller et al, 2002; Wutzke and Lorenz, 2004). Comparing the effect carnitine 
supplementation in cardiac to skeletal muscle illustrates a biphasic function, which 
would depend on whether the mass-action effect on CPTI or the changes in 
intramitochondrial acetyl-CoA concentrations, resulting from mass-action effect on the 
mitochondrial CAT, would predominate. Alternatively, it is also possible that increased 
levels of carnitine initiate distinct actions depending on the relative importance of the 
equilibriums catalyzed by the two carnitine acyltransferases in cardiac compared to 
skeletal muscle cells. 
Administration of carnitine may also result in the alleviation of the impairment of the 
insulin signaling cascade, associated with type 2 diabetes patients, that functions in 
skeletal muscle cells. It is well known that an increased lipid supply to skeletal muscle 
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leads to an accumulation of long chain acyl-CoA esters, diacylglycerols and ceramides, 
which are potent inhibitors of insulin signaling (Kelley and Mandarino, 2000; Schmitz-
Pfeifer, 2000; Summers, 2006). The stimulatory mass-action effect of increased levels 
of carnitine on the activity of CPTI may lower long chain acyl-CoA levels, thereby 
improving insulin signaling (Ramsay and Arduini, 1993; Zammit, 1999; Figure 2.6 B). 
When considering diseases such as insulin resistance, type 2 diabetes, dyslipidemia 
and end-stage renal disease, which are affected by alterations in lipid and glucose 
homeostasis, the liver is known to play a central role in the progression of such 
metabolic disorders. The plasma lipid profiles of patients suffering from such diseases 
are often characterized by high levels of triglycerides and low levels of high density 
lipoprotein (HDL) cholesterol (Prichard, 2003; Liu and Rosner; 2006; Kwan et al, 2007). 
Carnitine supplementation in this context should either result in a decrease in de novo 
fatty acid synthesis in the liver by diverting acetyl moieties to the formation of 
acylcarnitine, which would subsequently be secreted, or by reducing the availability of 
long chain acyl-CoAs, which serve as a substrate for triglyceride synthesis (Colemen 
and Lee, 2004; Figure 2.6 C). This action would be mediated by the mass-action effect 
of high levels of carnitine on the carnitine acyl-transferases, CPTI and the mitochondrial 
CAT. Consequently, high levels of supplemented carnitine would be predicted to result 
in a lower secretion rate of very low density lipoprotein (VLDL) triglyceride and 
associated cholesterol, translating in a reduction of plasma lipids (Coleman and Lee, 
2004). Lowered secretion of VLDL would in turn lead to an increase in plasma HDL, 
since reducing the amount of triglyceride present in HDL decreases its catabolism in the 
liver (Marsh et al, 2000). Moreover, it has also been suggested that carnitine may be 
required for the transfer of long-chain acyl groups to the endoplasmic reticulum for the 
esterification of diacylglycerol to form triacylglycerol destined for excretion within VLDL 
(Zammit, 1999). It is also considered likely that the increase of fatty acid oxidation by 
supplemented carnitine would antagonize the development of hepatic steatosis, which 
contributes greatly to the susceptibility of insulin resistance on a systemic level 
(Petersen et al 2005, Arduini et al, 2008). 
While these hypotheses have been substantiated in some studies (Power et al, 
2007; Rajasekar and Anuradha, 2007; Rodrigues et al, 1988), other studies showed no 
significant effect of carnitine supplementation in animal models of insulin resistance and 
dyslipidemia (Brady et al, 1986; Dai et al, 2004). The discrepancies in the datasets can 
probably be explained by variations in the concentration of supplemented carnitine and 
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the resulting concentrations that were achieved in plasma and target organs. The 
pharmacological actions exerted by carnitine are at carnitine concentrations (low 
millimolar range) higher than the low micromolar to low millimolar range systemic and 
cellular levels that are normally present (Rebuoche and Engel, 1984; Evans, 2003; 
Evans and Fornasisni, 2003; Tein, 2003). The maintenance of high carnitine plasma 
and target organ levels that are required to illicit such desired pharmacological 
responses remain difficult to achieve. Achieving such levels would be required to obtain 
more conclusive data to resolve these questions. At this stage, the most effective 
means of delivering and maintaining high systemic levels of carnitine currently seems to 
be through peritoneal or hemodialysis (Vacha et al, 1983; Vacha et al, 1989; Veselá et 
al, 2001; Brass et al, 2001). 
Since the maintenance of specific carnitine concentrations may be less of a hurdle in 
yeast biology, a better understanding of the specific functions of the three yeast CATs 
and their influence on the regulation of carbon metabolism through modulating the 
concentrations of compartmentalized pools of CoA would surely contribute to the 
understanding of the cellular role of the carnitine shuttle. It would specifically be of 
interest to establish the impact of the two “minor” CATs, Yat1p and Yat2p in this regard. 
2.4.3. MODULATION OF THE CELLULAR STRESS RESPONSE 
 
Several studies are proposing a role for acetylcarnitine in the prevention of the 
deterioration of brain function associated with aging and neurodegenerative disorders. 
Acetylcarnitine is more prevalently used in the study of neurodegeneration since it is 
readily able to cross the blood-brain barrier (Parnetti et al, 1992). The beneficial effect of 
acetylcarnitine supplementation in neurodegeneration is mainly due to its stimulation of 
mitochondrial respiration, allowing the neuronal ATP production required for 
maintenance of membrane potential (McDaniel et al, 2003). Acetylcarnitine has, 
however, been indicated to be neuroprotective by a variety of other effects such as by 
stimulating an increase in protein kinase C (PKC) activity. Supplementation of 
acetylcarnitine has also been shown to counteract the loss of NMDA receptors and 
increasing the production of neurotrophins, effects that are exclusively related to 
synaptic plasticity (McDaniel et al, 2003). 
In recent studies, it has been demonstrated that acetylcarnitine, by transcriptional 
induction of heme-oxygenase-1 (HO-1) and Hsp70, is able to reduce A toxicity in 
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primary cortical neuronal cultures (Abdul et al, 2006). Studies in rats have shown an 
improvement of life-span and cognitive behavior and also long-term memory (McDaniel 
et al, 2003). Moreover, long-term acetylcarnitine administration prevents the age related 
decay of mitochondrial respiration and decreases oxidative stress markers by the up-
regulation of HO-1, Hsp70 and superoxide dismutase-2 (SOD2) in ageing rats 
(Calabrese et al, 2006b). Acetylcarnitine has been shown to induce HO-1 expression in 
a time and dosage dependent manner. This effect is associated with the upregulation of 
other heat shock proteins and also the redox sensitive transcription factor Nrf2. It has 
been proposed by the authors of this work that the upregulation of HO-1 and Hsp’s 
might involve the acetylcarnitine dependent acetylation of DNA binding transcription 
factors, such as Nrf2, resulting in the induction of target genes (Calabrese et al, 2005; 
Calabrese et al, 2006a) (Figure 2.7). This hypothesis, however, still needs to be 
substantiated. It could, nevertheless, suggest a role for acetylcarnitine as a potentiator 
of the cells natural defense response and would present promising therapeutic 
possibilities in pathophysiological conditions where the activity of HO-1 pathway is 
required. 
 
Figure 2.7. The proposed role of acetylcarnitine in the regulation of the cellular stress response. 
Depletion of heat shock proteins resulting from various proteotoxic and genotoxic events leads to the 
induction of stress kinase, and pro-inflammatory and apoptotic signaling cascades. Stress induced 
apoptosis is prevented by Hsp70, which interferes with SAPK/JNK signaling and blocks the caspase 
proteolytic cascade. By activating the transcription factor, Nrf2, acetylcarnitine induces the 
upregulation of heme oxygenase-1 (HO-1) and Hsp60 and could counteract nitrosative stress and 
NO-mediated toxicity. HO-1 may also directly decrease NO synthase protein levels by degrading 
heme, which serves as a co-factor. (PLA2: phospholipase; IL: interleukin; SAPK: stress-activated 
protein kinase; JNK: c-Jun N-terminal kinase; GSNO S-nitrosoglutathione; adapted from Calabrese 
et al, 2006) 
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2.4.4. MODULATION OF PROGRAMMED CELL DEATH 
 
Signal transduction via the cell surface glycoprotein Fas, also referred to as CD95, is 
considered central in the regulation of programmed cell death (apoptosis). L-carnitine 
was shown to inhibit apoptosis by interaction with Fas-ligand and the Fas receptor 
systems (Moretti et al, 1998). Fas receptor mediated signal transduction activates acid 
sphingomeylinase in lysosomes and consequently the breakdown of sphingomyelin and 
the release of ceramide occur. The addition of carnitine results in an immediate 
inhibition of acid sphingomeylinase under in vivo and in vitro conditions (Di Marzio et al, 
1997). In addition carnitine was shown to inhibit caspase 3, 7 and 8 and also the 
mitochondrial permeability transition (Mutomba et al, 2000; Pastorino et al, 1993). In T 
lymphocytes a separate mechanism was described for the inhibition of apoptosis by 
carnitine, where the reduction of ceramide release resulting from carnitine addition 
stimulated levels of insulin-like growth factor-1 (Di Marzio et al, 1999). Insulin growth 
factor-1 inhibits the dimerization of the apoptosis regulating proteins BCL-2-BAX in the 
mitochondrial membrane and also inhibits transcription from the BCL-2 promoter (Wang 
et al, 1998; Pugazenthi et al, 1999). Carnitine supplemented in combination with lipoic 
acid has also been indicated to prevent mitochondrial loss of cytochrome c, and thereby 
activation of caspase-3, in skeletal muscle of aging rats. This effect is speculated to be 
resulting from the protection of mitochondrial membrane integrity (Tamilselvan et al, 
2007). Supplementation of acetylcarnitine in thioredoxin deficient cells prevents the 
induction of signaling events leading to apoptosis by suppressing oxidative stress in and 
around mitochondria (Zhu et al, 2007). 
Recently, interesting claims have been made which describe a dual role for carnitine 
in regulating the onset of apoptosis. A number of studies report the addition of carnitine 
to have different effects on the regulation of apoptosis in cancer cells compared to 
normal cells. Observations in cancer cells such as HT-29 and U937 leukemic cells have 
suggested that apoptosis is increased by the addition of carnitine and carnitine 
derivatives (Wenzel et al, 2005; Ferrara et al, 2005). A recent study has indicated 
carnitine to induce apoptosis in mouse cancer cells, by inducing both the mitochondrial 
and Fas regulated signaling cascades (Fan et al, 2009). It is currently not clear by what 
mode of action carnitine addition would result in the divergent regulation in cancer cells 
compared to normal cell systems. 
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2.4.5. OXIDATIVE STRESS PROTECTION IN S. CEREVISIAE 
 
Carnitine supplementation has recently been shown to have a stress protective effect in 
S. cerevisiae (Franken et al, 2008). This was shown to be specific for stress conditions 
induced by hydrogen peroxide and certain organic acids and independent of the 
carnitine shuttle. No protection by supplemented carnitine was observed for osmotic 
and thermal stresses. Interestingly, a role for CAT2, independent of carnitine seems 
evident in the protection against oxidative stress.  
The work done in Chapter 5 points towards carnitine’s effect against oxidative stress 
being specific and not due to an enhancement of the general response against oxidative 
stress. Intriguingly, while carnitine protects against certain ROS generating oxidants, an 
inverse and detrimental effect is observed in combination with thiol modifying agents. It 
is tempting to speculate a similar function involved in this context to be responsible for 
the diverse effects observed in the regulation of programmed cell death. Of further 
interest is the requirement of the cytochrome c heme lyase, Cyc3p, both carnitine 
related protection and toxicity. CYC3 was also shown to be upregulated by the 
presence of carnitine during oxidative stress. This suggests that carnitine is not only 
able to maintain mitochondrial integrity by the action of the shuttle but possibly also by 
upregulation of cytochrome c content. This could possibly have an impact on both 
oxidative phosphorylation function as well as one of the main events associated with 
apoptosis induction, the release of cytochrome from the mitochondria. 
2.5. CONCLUSION 
 
Due to the central and role that carnitine and the carnitine shuttle play in eukaryotic 
energy metabolism, the composition and function of this system has been a topic of 
intensive research interest for the past 60 years. Understanding of the proteins and 
enzymes involved in this area of metabolism has greatly advanced knowledge of the far 
reaching impact that the carnitine shuttle has on the regulation of metabolism. As a 
consequence of this regulatory function, specifically on the concentrations of and ratios 
between compartmentalized pools of free CoA and acylated CoA, carnitine and its 
esters have a considerable potential as therapeutic agents or supplements in a diverse 
range of metabolic diseases. The modes of action of these molecules, mediated by the 
action of the shuttle enzymes are slowly emerging. In addition, it is becoming clear that 
not all phenotypic effects of carnitine administration can be attributed to its role in the 
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shuttling of intermediaries. The broadening of this knowledge base is comparatively 
slow, since most studies in this field are either clinical or diagnostic in nature and do not 
contribute to the understanding of the mechanisms underlying the effects of carnitine. In 
addition, carnitine and acylcarnitines appear to have distinct, but overlapping functions 
depending on the context of the cell or tissue system that is being studied, making it 
difficult to draw conclusions between systems. 
In the yeast, S. cerevisiae, the carnitine shuttle shares its central metabolic function 
with that of higher eukaryotes. The carnitine acetyl-transferases and 
carnitine/acetylcarnitine transporter involved have been identified and localized within 
the cell. The functional and metabolic impact of these enzymes is, however, not as 
clearly understood as that of mammalian systems. Nevertheless, S. cerevisiae does 
present an ideal model system for the studies of carnitine and carnitine shuttle related 
phenotypes, since blockage of the glyoxylate bypass creates a system in which the 
shuttle and its effects can be studied using the wide array of genetic tools available in S. 
cerevisiae. Such studies benefit from the relative simplicity of the yeast metabolism, 
which is not under the same multidimensional control effective in a multicelullar system. 
Furthermore, S. cerevisiae is unable to synthesize its own carnitine, enabling precise 
control of the concentrations of carnitine in experimental conditions. Yeast is currently 
being advocated as an effective model for the study of the molecular effects associated 
with various metabolic and neurodegenerative diseases. The use of this system could 
therefore add greatly to our understanding of the function of carnitine within the context 
of the eukaryotic cell. 
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ABSTRACT 
 
To date, the only reported metabolic and physiological roles for carnitine in 
Saccharomyces cerevisiae are related to the activity of the carnitine shuttle. In yeast, 
the shuttle transfers peroxisomal activated acetyl-residues to the mitochondria. 
However, acetyl-CoA can also be metabolised by the glyoxylate cycle to form succinate. 
The two pathways therefore provide a metabolic bypass for each other, and carnitine-
dependent phenotypes have only been described in strains with non-functional 
peroxisomal citrate synthase, Cit2p. Here we present evidence for a role of carnitine in 
stress protection that is independent of CIT2 and of the carnitine shuttle. The data show 
that carnitine improves growth during oxidative stress and in the presence of weak 
organic acids in WT and in CAT deletion strains. Our data also show that strains with 
single, double and triple deletions of the three CAT genes generally present identical 
phenotypes, but that the deletion of CAT2 decreases survival during oxidative stress in 
a carnitine-independent manner. Overexpression of single CAT genes does not lead to 
cross-complementation, suggesting a highly specific metabolic role for each enzyme. 
The data suggest that carnitine protects cells from oxidative and organic acid stress, 
while CAT2 contributes to the response to oxidative stress.  
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3.1. INTRODUCTION 
The -oxidation of fatty acids in mammalian cells takes place in both mitochondria and 
peroxisomes. Medium and long-chain fatty acids are catabolised primarily in 
mitochondria whereas very long-chain fatty acids and certain branched-chain fatty acids 
are broken down primarily by peroxisomes (Wanders et al. 1995; Leenders et al. 1996; 
Schulz 1991). It is generally accepted that mammalian fatty acid -oxidation in 
peroxisomes is incomplete and only involves chain shortening of fatty acids to produce 
acetyl-CoA and/or propionyl-CoA plus medium-chain acyl-CoAs. These are then 
transported as carnitine esters to the mitochondria, where they are further oxidised to 
CO2 and H2O (Bieber 1988; Reddy and Mannaerts 1994). The importance of 
peroxisomal -oxidation is emphasised by the existence of inherited diseases in man 
that are caused by an impairment in peroxisomal -oxidation (Wanders et al. 1995).  
In contrast, the degradation of fatty acids in yeast takes place exclusively in 
peroxisomes (Kunau et al. 1995). The acetyl-CoA produced in the peroxisome has to be 
transported to the mitochondria for complete oxidation to CO2 and H2O. Two pathways 
(Figure. 3.1) for further utilisation of peroxisomal acetyl-CoA have been identified (Van 
Roermund et al. 1995). In the first, acetyl-CoA enters the peroxisomal glyoxylate cycle, 
a net producer of succinate, which is subsequently transported to the mitochondria, 
probably via a putative dicarboxylate carrier, Acr1p (Palmieri et al. 1997). The second 
pathway involves the intraperoxisomal transfer of the activated acetyl from CoA to 
carnitine, which is catalysed by carnitine acetyltransferase (CAT). Acetylcarnitine is 
subsequently transported to the mitochondria through the carnitine acetylcarnitine 
translocase Crc1p (Palmieri et al. 1997; Van Roermund et al. 1995). Mitochondrial CAT 
catalyses the reverse reaction to form carnitine and acetyl-CoA to enter the tricarboxylic 
acid cycle (TCA) for energy production. This process is referred to as the carnitine 
shuttle. In addition, this shuttle also plays a role when yeast cells are grown on other 
non-fermentable carbon sources, such as acetate and ethanol. The metabolism of these 
compounds results in the production of acetyl-CoA in the cytoplasm, which needs to be 
transported to the mitochondria for energy production (Schmalix and Bandlow 1993; 
Stemple et al. 1998). 
The existence of two pathways for the utilisation of peroxisomal acetyl-CoA was 
suggested on the basis of results showing that disruption of either the CIT2 gene, 
encoding the peroxisomal glyoxylate cycle enzyme citrate synthase, or the CAT2 gene, 
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encoding the peroxisomal and mitochondrial carnitine acetyltransferase, did not affect 
the growth of yeast on oleate, whereas a mutant with both genes disrupted (cit2cat2) 
failed to grow on this carbon source, due to an inability to oxidise this fatty acid (Van 
Roermund et al. 1995). 
Agp2p
Carnitine
Fatty acids
Ethanol/
Acetate
ß-oxidation
Acetyl-CoA     +     Carnitine
CoA-SH     +     Acetylcarnitine Acetylcarnitine + CoA-SH
Cat2p Cat2p
Yat2p
Carnitine
+
Acetyl Co-A
TCASuccinate
Ethanol/
AcetateAcetyl-CoA
Carnitine
Yat1p Crc1p
Peroxisome Mitochondrium
Cit2p
Acr1p
Figure 3.1. Schematic representation of the glyoxylate pathway and the carnitine shuttle in 
Saccharomyces cerevisiae. The three yeast carnitine acetyl transferases, Cat2p in the mitochondria 
and peroxisome, Yat1p on the outer-mitochondrial membrane and Yat2p in the cytosol are indicated 
along with the carnitine/acetylcarnitine translocase Crc1p. Cit2p combines two units of peroxisomaly 
generated acetyl-CoA, the fist step of the glyoxylate cycle, forming succinate.  
 
Besides Cat2p, two additional CATs have been identified in S. cerevisiae. Cat2p is 
responsible for >95% of the total CAT activity in oleate-grown yeast cells (Kispal et al. 
1993). A second gene, YAT1, codes for a CAT that presumably is associated with the 
outer surface of the mitochondria and contributes an estimated 5% of total CAT activity 
in acetate- and ethanol-grown cells (Schmalix and Bandlow 1993). A third gene, YAT2, 
codes for a CAT that has been suggested to be cytosolic and that shows a high 
contribution to CAT activity in ethanol-grown cells (Swiegers et al. 2001). The sequence 
homologies among the three CAT-encoding genes are extensive. Swiegers et al. (2001) 
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showed that, in a strain with a disrupted peroxisomal citrate synthase, all three carnitine 
acetyltransferases are essential for growth on all non-fermentable carbon sources. 
This rather surprising set of data raises the question about the specific function of 
each of the three CAT enzymes in S. cerevisiae, since our current understanding of the 
carnitine shuttle does not require the existence of three independent carnitine 
acetyltransferases to ensure survival on non-fermentable carbon sources.  
The role of carnitine in the metabolism of S. cerevisiae has not been investigated 
beyond the shuttling of acetyl residues. However, data in mammalian systems suggests 
that carnitine does have broader functions, such as its role in the maintenance of 
nutritional redox balance, the regulation of various gene subsets possibly involved in 
longevity and also regulation of the cells stress response (for review see Calabrese et 
al. 2006).  
In this paper, we further explore specific roles of CAT enzymes and of carnitine. The 
data show that the three CAT enzymes play highly specific roles, since no cross 
complementation occurs even when individual CAT genes are overexpressed. 
Nevertheless, double and triple deletion mutants show phenotypes identical to the three 
single CAT gene deletion strains. The intracellular localisation of Cat2p and Yat1p 
confirms previous data, while we localise Yat2p to the cytoplasm by C-terminal GFP 
tagging. Our results also indicate that both carnitine and acetylcarnitine promote growth 
in a cit2 strain, and that this effect is dependent on the presence of all three CATs. 
Furthermore, the constitutive expression of the Schizosaccharomyces pombe malate 
permease (MAE1) gene can compensate for the growth defect of a Δcit2 strain when 
cells are grown on non-fermentable media supplemented with L-malic acid.  
Since a role for carnitine as a stress protectant has been described in mammalian 
and bacterial systems (Kunau et al. 1995; Calabrese et al. 2006), the possibility of a 
similar function in yeast was investigated. Our data clearly show that the presence of 
carnitine improves growth in the presence of H2O2 and of weak organic acids such as 
lactate. Surprisingly, this effect appears to be independent of the activity of the carnitine 
shuttle. The data also indicate that deletion of CAT2 leads to a significant reduction in 
the survival of cells grown in respiratory conditions after exposure to oxidative stresses. 
This is the first report of carnitine protecting against certain stresses in S. cerevisiae. 
Similar impacts in mammalian systems have been reported, but no information 
regarding the underlying mechanisms has been published. S. cerevisiae may be a 
useful model for elucidating the molecular nature of this protective activity.  
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3.2. MATERIALS AND METHODS 
3.2.1. YEAST STRAINS AND MEDIA 
 
All yeast strains used in this study are derived from strain S288c genetic background 
and are listed in Table 3.1. Yeast were grown either on rich YPD (1% yeast extract, 2% 
peptone, 2% glucose) or on minimal YND media, containing 0.67% (w/v) yeast nitrogen 
base (YNB) without amino acids (DIFCO) and 2% (w/v) glucose supplemented with 
amino acids according to the specific requirements of the respective strains. Amino 
acids were added to concentrations specified by Ausubel et al. (1994). To study the 
phenotypical effect of overexpression of each carnitine acetyltransferase, two different  
 
Table 3.1. Yeast strains used in this study. 
Yeast strains Relevant genotype Sources and references 
FY23 MATa leu2 trp1 ura3 Winston et al. 1995 
FY23yat1 MATa trp1 ura3 yat1::LEU2 Swiegers et al. 2001 
FY23yat2 MATa trp1 ura3 yat2::LEU2 Swiegers et al. 2001 
FY23cat2 MATa trp1 ura3 cat2::LEU2 Swiegers et al. 2001 
FY23yat2yat1 MATa ura3 yat2::LEU2 yat1::TRP1 This study 
FY23yat1cat2 MATa trp1 yat1::LEU2 cat2::URA3 This study 
FY23yat2cat2 MATa trp1 yat2::LEU2 cat2::URA3 This study 
FY23yat2cat2yat1 MATa yat2::LEU2 cat2::URA3 yat1::TRP1 This study 
FY23cit2yat1 MATa ura3 cit2::TRP1 yat1::LEU2  Swiegers et al. 2001 
FY23cit2yat2 MATa ura3 cit2::TRP1 yat2::LEU2 Swiegers et al. 2001 
FY23cit2cat2 MATa ura3 cit2::TRP1 cat2::LEU2 Swiegers et al. 2001 
BY4747 MAT his3 leu2 lys2 ura3 Euroscarf deletion library 
BY47472Δyap1 MAT his3 leu2 lys2 ura3 yap1::KanMX4 Euroscarf deletion library 
BY47472Δyat1 MAT his3 leu2 lys2 ura3 yat1::KanMX4 Euroscarf deletion library 
BY47472Δyat2 MAT his3 leu2 lys2 ura3 yat2::KanMX4 Euroscarf deletion library 
BY47472Δcat2 MAT his3 leu2 lys2 ura3 cat2::KanMX4 Euroscarf deletion library 
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media with non-fermentable carbon sources were used. Both media contained 0.67% 
(w/v) YNB without amino acids (DIFCO), 2% of agar and either 2% (v/v) ethanol (YNE) 
or 2% (w/v) glycerol (YNG) as sole carbon source, supplemented with 10 mg/L of L-
carnitine (+C).  
For the localisation studies, yeast was grown in test tubes containing 5 ml of either 
YNE [0.67% (w/v) YNB without amino acids (DIFCO) and 2 % (v/v) ethanol] or YNO 
[0.67% (w/v) YNB without amino acids (DIFCO) and 0.1 % oleic acid] media. To 
investigate the effect of the Schizosaccharomyces pombe malate permease (MAE1) 
gene, strains were spotted on YNEM media, containing 0.67% (w/v) YNB without amino 
acids (DIFCO), 2% (v/v) ethanol, 1% (w/v) L-malic acid and 0.5% agarose, the pH of the 
media was set to 3.5 with 1M KOH.  The effect of organic acid stress was monitored on 
YND media with various concentrations of acetate and lactate added, the pH was 
buffered at 3.5 with phosphate buffer to ensure that any differences observed would be 
due to the presence of the mentioned organic acids and not variation in pH. For the 
stress tolerance experiments, cells were either grown in YND or YNG media with 
addition of the required stress agent and carnitine where indicated. YNG was preferably 
used for all stress experiments, since growth on non-fermentable carbon sources 
utilises the carnitine shuttle, with the only exception being oxidative stress under 
growing conditions which was performed on YND plates containing H2O2, since YNG 
does not support growth in these conditions. 
3.2.2. DNA MANIPULATION 
 
All plasmids used in this study are listed in Table 3.2 and the primers are listed in Table 
3.3. Standard DNA techniques were carried out as described by Sambrook et al. (1989). 
Standard procedures for the isolation and manipulation of DNA were used throughout 
the study (Ausubel et al. 1994). Restriction enzymes, T4 DNA-ligase and Expand Hi-
Fidelity polymerase used in the enzymatic manipulation of DNA were obtained from 
Roche Diagnostics (Randburg, South Africa) and used according to the specifications of 
the supplier. Escherichia coli DH5 (GIBCO-BRL/Life Technologies) was used as host 
for the construction and propagation of all plasmids. Sequencing of all plasmids was 
carried out on an ABI PRISMTM automated sequencer. 
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Table 3.2. Clones and constructs. 
Plasmids Relevant genotype Sources and references 
YCplac33 CEN4 URA3 Gietz and Sugino 1988 
YEplac112 2 TRP1 Gietz and Sugino 1988 
YEplac181 2 LEU2 Gietz and Sugino 1988 
Ydp-W TRP1 Berben et al. 1991 
Ydp-U URA3 Berben et al. 1991 
pGEM-T-easy-YAT1  Swiegers et al. 2001 
pGEM-T-easy-YAT2  Swiegers et al. 2001 
pGEM-T-easy-CAT2  Swiegers et al. 2001 
pcat2 cat2::URA3 This study 
pyat1 yat1::LEU2 Swiegers et al. 2001 
pyat1 yat1::TRP1 This study 
YEplac112-T-GFP2-B-BGL 2 TRP1 Our laboratory 
pYES2-mtBFP 2 URA3 Westermann and Neubert 2000 
YCplac33-YAT1-GFP CEN4 URA3 YAT1 This study 
YCplac33-YAT2-GFP CEN4 URA3 YAT2 This study 
YCplac33-CAT2-GFP CEN4 URA3 CAT2 This study 
pGEM-T-easy-Cat2p  This study 
YEplac 112-mtBFP 2 TRP1 This study 
YEplac181-BFP-P 2 LEU2  This study 
YCplac33-PGKpt CEN4 URA3 PGKP PGKT Our laboratory 
YCplac33-PGKp-YAT1-PGKt CEN4 URA3 YAT1 This study 
YCplac33-PGKp-YAT2-PGKt CEN4 URA3 YAT2 This study 
YCplac33-PGKp-CAT2-PGKt CEN4 URA3 CAT2 This study 
pHV3 2 LEU2 PGKP MAE1 PGKT Volschenk et al. 1997 
YCplac33-PGKp-MAE1-PGKt CEN4 URA3 MAE1 This study 
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Table 3.3. Primers used in this study. Introduced primer sequences are underlined. 
Primer Sequence 
CAT2F1 5’-GACACTGTTCGCCAAATTTCG-3’ 
CAT2R1 5’-ATAAGCAAGGCACAATATCC-3’ 
YAT1F1 5’-ATCAGCATCAGCATCAGC-3’ 
YAT1R1 5’-AGAGGTAATCCAAACGACG-3’ 
YAT1-GFP-F *5’-GATCGAATTCGTGGAAATCATCGCGCGCAAGCCA-3’ 
YAT1-GFP-R *5’-GATCGGTACCACCGGACACGCTCACGTCGAAGTA-3’ 
YAT2-GFP-R *5’-GATCGGTACCTTGATCTAAGGTCGCCACCTTTCT-3’ 
YAT2-GFP-F *5’-GATCGAATTCGAGGCAGCCCGTGTTGCGTCACAA-3’ 
CAT2-GFP-F *5’-GATCGAATTCTTTCTTGGAAATTCTGTCAAATCT-3’ 
CAT2-GFP-R *5’-GATCGGTACCTAACTTTGCTTTTCGTTTATTCTC-3’ 
Cat2p  5’-GATCCTGCAGTCGCGAGAGTGCTTTCTTTTTAG-3’ 
BFP-P(R) *5’-GATCAAGCTTTTATAACTTTGCTTTGTATAGTTCATCCATGCCAT-3’ 
BFP-P(F) *5’-GATCTCGCGAATGAGTAAAGGAGAAGAACTTTTCAC-3’ 
mtBFP-F *5’-GATCTCGCGAATGGCCTCCACTCGT-3’ 
mtBFP-R *5’-GATCAAGCTTTTATTTGTATAGTTCATCCATGCCATGT-3’ 
CAT2ov-F *5’-GATCGAATTCATGAGGATCTGTCATTCGA-3’ 
CAT2ov-R *5’-GATCCTCGAGTCATAACTTTGCTTTTCG-3’ 
YAT1ov-F *5’-GATCGAATTCATGCCAAACTTAAAGAGACT-3’ 
YAT1ov-R *5’-GATCCTCGAGTCAACCGGACACGCTCA-3’ 
YAT2ov-F *5’-GATCGAATTCATGTCAAGCGGCAGTA-3’ 
YAT2ov-R *5’-GATCGTCGACTTATTGATCTAAGGTCGCC-3’ 
5’-mae1 *5’-GATCGAATTCATGGGTGAACTCAAGGAAATC-3’ 
3’-mae1 *5’-GATCAGATCTTTAAACGCTTTCATGTTCACT-3’ 
 
3.2.3. CONSTRUCTION OF MULTIPLE CAT MUTANTS 
 
To create the double mutants FY23yat1cat2 and FY23yat2cat2, the CAT2 gene 
was disrupted in either the FY23yat1 or FY23yat2 strain (Swiegers et al. 2001). For 
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this purpose, a 595 bp BamHI/BglII fragment internal to the CAT2 gene of the plasmid 
pGEM-T-easy-CAT2 was replaced by a 1.1 kb URA3 gene from plasmid YDp-U. The 
resulting construct, pcat2::URA3, was used to isolate a 2.9 kb disruption cassette 
containing the URA3 gene plus CAT2 flanking regions, and this was transformed into 
FY23yat1 and FY23yat2. Transformants were isolated on selective media and the 
disruption was verified by polymerase chain reaction (PCR) using the primers CAT2F1 
and CATR1 (Table 3). To create the FY23yat1yat2 double mutant, a yat1 disruption 
construct was created by using the plasmid pyat1::LEU2 and removing the LEU2 gene 
as a 1.6 kb BamHI fragment and replacing it with a 0.8 kb TRP1 fragment from plasmid 
YDp-W. The resulting disruption construct, pyat1::TRP1, was used to isolate a 1.9 kb 
fragment containing the TRP1 gene and YAT1 flanking regions. This was transformed 
into strain FY23yat2 and the disruption was verified using primers YAT1F1 and 
YAT1R1. To create a yeast strain without any known CAT-encoding genes, the same 
fragment was transformed into strain FY23yat2cat2. The disruptions were verified 
using primers YAT1F1 and YAT1R1. 
3.2.4. CONSTRUCTION OF CAT-GFP AND BFP PLASMIDS 
 
The 759 bp GFP open reading frame contains a KpnI site nine nucleotides after the 
start codon. The YAT2 gene was amplified from the pGEM-T-easy-YAT2 plasmid using 
the primers YAT2-GFP-F and YAT2-GFP-R. In the reverse primer, the stop codon was 
replaced with a KpnI restriction site (Table 3). The resulting 3.1 kb fragment was 
inserted as a EcoRI/KpnI fragment into the YEplac112-T-GFP2-B-BGL plasmid. From 
this construct, a 4.0 kb XbaI/NarI fragment was subcloned into the YCplac33 vector. 
The YAT1 and CAT2 genes and their respective promoter regions were amplified from 
the pGEM-T-easy-YAT1 or pGEM-T-easy-CAT2 plasmid, using either the YAT1-GFP-F 
and YAT1-GFP-R or the CAT2-GFP-F and CAT2-GFP-R primers. The resulting 
EcoRI/KpnI fragments of 3.1 kb were subsequently ligated in the YCplac33-YAT2-GFP 
plasmid digested with EcoRI and KpnI containing the GFP open reading frame. 
For co-localisation studies, the blue fluorescent protein (BFP) encoding gene, with 
either a mitochondrial or a peroxisomal signal sequence, was used and expressed 
under the promoter of CAT2. The promoter was amplified from the YCplac33-CAT2-
GFP plasmid by using the primers CAT2-GFP-F and Cat2p. The resulting 1.2 kb 
fragment was blunt-ligated into the pGEM-T-easy vector and digested with EcoRI and 
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PstI, purified and subcloned into YEplac181 and YEplac121. To fuse the mitochondrial-
targeted blue fluorescent protein to the promoter, the BFP and the mitochondrial pre-
sequence were amplified by PCR, using the mtBFP-F and mtBFP-R primers and the 
pYES2-mtBFP plasmid as template. The resulting 960 base pair fragment was cloned 
into the plasmids as a NruI/HindIII digest. To construct the peroxisomal-targeted BFP, a 
primer was designed containing the peroxisomal targeting signal type 1 (PTS-1) at the 
C-terminus of the open reading frame (Table 3). Using the primers BFP-P(R) and BFP-
P(F), a 630 base pair fragment was obtained by PCR, using the pYES2-mtBFP plasmid 
as template, and cloned as a NruI/HindIII fragment into the YEplac181 and YEplac121 
vectors containing the CAT2 promoter.  
3.2.5. CONSTRUCTION OF THE OVEREXPRESSION PLASMIDS 
 
The CAT2 gene was amplified from the YCplac33-CAT2-GFP plasmid template by 
PCR, using primers CAT2ov-F and CAT2ov-R (Table 3). The resulting 2.0 kb fragment 
was blunt-ligated into the pGEM-T-easy vector. The YAT1 gene was amplified from the 
YCplac33-YAT1-GFP plasmid template by PCR, using the YAT1ov-F and YAT1ov-R 
primers. A 2.1 kb fragment was ligated into the pGEM-T-easy vector. The remaining 
carnitine acetyltransferase gene, YAT2, was amplified from the YCplac33-YAT2-GFP 
plasmid template by PCR using the YAT2ov-F and YAT2ov-R primers. A 2.7 kb 
fragment was ligated into the pGEM-T-easy vector. The pGEM-T-easy-CAT2 and 
pGEM-T-easy-YAT1 plasmids were digested with EcoRI and XhoI, resulting in 
fragments of 2037 and 2104 base pairs respectively. The pGEM-T-easy-YAT2 plasmid 
was digested with EcoRI and SalI and resulted in a fragment of 2796 base pairs. These 
fragments were ligated into the EcoRI/XhoI site of the YCplac33-PGKpt plasmid. The 
resulting three plasmids, YCplac33-PGKpt-CAT2, YCplac33-PGKpt-YAT1 and 
YCplac33-PGKpt-YAT2, contained the CAT2, YAT1 or YAT2 gene under control of the 
phosphoglycerate kinase I (PGK) promoter.  
3.2.6. CONSTRUCTION OF THE MAE1 EXPRESSION PLASMID 
 
The Schizosaccharomyces pombe malate permease gene, MAE1, was amplified from 
genomic DNA by PCR, using primers 5’-mae1 and 3’-mae1 (Table 3) and blunt-ligated 
into the pGEM-T-easy vector. This plasmid was subsequently digested with EcoRI and 
 Chapter3: Research Results I       59 
 
BglII and the resulting fragment of 1323 base pairs, corresponding to the open reading 
frame of the MAE1 gene, was then ligated into the EcoRI/BglII site of the YCplac33-
PGKpt plasmid. 
3.2.7. FLUORESCENT MICROSCOPY 
 
In order to determine the intracellular location of the three proteins Yat1p, Yat2p and 
Cat2p in vivo, each was C-terminally tagged with GFP. Centromeric shuttle vectors 
carrying in-frame fusions of GFP to the 3’ end of YAT1, YAT2 and CAT2 under 
transcriptional control of their respective native promoters were introduced into the 
haploid yeast FY23. For direct fluorescent visualisation of the yeast peroxisomes and 
mitochondria, both organelles were targeted with a BFPp controlled by the promoter of 
CAT2 on a multi-copy plasmid. A Nikon E400 microscope with UV source and 
appropriate filter sets was used to visualise fluorescence. Images were taken with a 
Nikon COOLPIX 990 digital camera. Scion Image for Windows was used to capture 
video images, and Microsoft Photo Editor 3.0 was used for editing the images. 
3.2.8. STRESS TOLERANCE EXPERIMENTS 
 
The osmotic stress experiments were performed by spotting serial dilutions (1:10) of 
cultures of the wild type strains BY4742 and FY23 and also the various single double 
and triple mutants of the CATs on YND media with various concentrations of sodium 
chloride up to 2 M and also on the same series of media with carnitine added to 10 mgL-
1. In order to confirm the results quantitatively, growth curves were performed in liquid 
media with the same strains under similar NaCl concentrations. 
For the evaluation of oxidative stress tolerance, pre-cultures of cells were grown 
overnight to be inoculated into fresh YND media. The cultures were grown to an optical 
density (O.D.), measured at 600 nm, of ~ 1 and diluted to a concentration of 
approximately 3 X 106 cells per ml. Five subsequent 10:1 dilutions were spotted in 
10 μL droplets onto YND media containing 0.5, 1, 1.5 and 2 mM of hydrogen peroxide 
with and without addition of L-carnitine (1, 10, 100 and 1000 mgL-1). The plates were 
incubated at 30°C for three days after which growth was monitored. 
To perform oxidative and thermal stress experiments under non-growing conditions 
cells from overnight cultures were inoculated into YNG media with and without carnitine 
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added (1, 10, 100 and 1000 mgL-1) and grown to mid-log phase (O.D.600 of ~ 1). 
Cultures were washed once in 0.9% NaCl, diluted to a concentration of ~ 2 X 106 cells 
per ml in 0.9% NaCl containing 0.1% of Triton-X100 and 3 mM of hydrogen peroxide for 
the induction of oxidative stress. At measured time intervals 100 μL of cells were 
removed and appropriate dilutions were plated onto YPD an incubated at 30°C for two 
days after which the plated colonies were counted. 
Cultures used for thermal stress experiments were treated similarly. Cells were 
harvested, washed once and resuspended in sterile water at a concentration of 
approximately 3 X 107 cells per ml. Aliquots of 100 μl were dispensed into 0.6 ml PCR 
tubes and incubated at 45°C for 45 min in a thermocylcer. For the induction of 
thermotolerance, cells were pre-incubated at 40°C for 30 min and subsequently treated 
at 50°C for 45 min. At different time intervals cells were removed, placed on ice for one 
minute to be plated onto YPD in appropriate dilutions. The plates were incubated for two 
days. The percentage of survival was determined against untreated cells. Differences 
between assay values were calculated at a p < 0.05 level using the student paired t-
test. 
Similarly, strains to be used in the organic acid tolerance experiments were grown in 
YND to an O.D.600 of ~ 1, washed once with sterile water and diluted to a concentration 
of approximately 3 X 106 cells per ml. Aliquots of 10 μl of the resuspended cells and 
also four subsequent 1:10 dilutions were spotted on YND plates containing 2.1, 4.2, or 
5.1 % v/v of lactate or 0.2, 0.3, 0.4 % v/v of acetate, with and without the addition of 
carnitine to a final concentration of 10 mgL-1. Plates were monitored for growth after 72 
hours incubation at 30°C. 
3.3. RESULTS 
3.3.1. EFFECT OF CAT GENE DELETION ON CELLULAR GROWTH 
 
To monitor if single CAT gene deletions or combination of deletions in double and in the 
triple disrupted strains have an effect on yeast growth, growth curves were obtained 
from cultures grown in fermentable (YND) and non-fermentable (YNE) media 
supplemented with L-carnitine. As shown in Figure 3.2, no significant difference in 
growth characteristics could be observed. Duration of lag phase, mean generation time 
in the exponential growth phase and the final biomass production were similar. It also is 
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clear, that in strains with a functional peroxisomal citrate synthase, the inability to shuttle 
acetyl-CoA via the carnitine system does not affect the growth speed, since the mean 
generation time of the strains in YNE media with and without supplementation of L-
carnitine showed no significant differences. Growth in other non-fermentable carbon 
sources and also oleate followed the same pattern (data not shown). 
 
Figure 3.2. Growth curves of single, double and triple CAT gene deletions grown in (A) YND media, 
(B) YNE media and (C) YNE media supplemented with L-carnitine. 
3.3.2. SUB-CELLULAR LOCALISATION OF THE THREE CARNITINE ACETYL-
TRANSFERASES 
 
In order to determine the exact intracellular localisation of each CAT protein (Yat1p, 
Yat2p and Cat2p) in vivo, each was C-terminally tagged with GFP. Wild type strain 
FY23 was transformed with the centromeric plasmid YCplac33, carrying in-frame 
fusions of GFP to the 3’ end of YAT1, YAT2 and CAT2 under transcriptional control of 
their respective native promoters. To differentiate between cellular organelles, e.g. 
mitochondria and peroxisomes, strains were co-transformed with one of the shuttle 
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vectors YEplac112 and YEplac181, carrying the BFP with either a mitochondrial or a 
peroxisomal signal sequence under the transcriptional control of the CAT2 promoter. 
Figure 3.3 shows the blue fluorescent protein that was used as a control to 
distinguish between the mitochondria and the peroxisome and also the three GFP 
tagged CATs. In all co-transformed strains, similar fluorescent signals could be 
observed for the targeted BFP.  
A: BFP B: Yat1
C: Yat2 D: Cat2
Mitochondrial Peroxisomal
 
Figure 3.3. Localization of the three yeast CATS. (A) BFP tagged with either a peroxisomal or 
mitochondrial signaling sequence which was used as a control and co-expressed with GFP tagged 
versions of (B) CAT2, (C) YAT2 or (D) YAT1.  Signals generated by the GFP chimeras concur with 
co-expressed BFP localized to either the mitochondria for Yat1p and the mitochondria and 
peroxisome in the case of Cat2p. Yat2p-GFP is visualised throughout the cytosol. 
 
Yat1p is linked to the mitochondria, which confirms existing data. However, the 
fluorescent signal is much weaker than for Cat2p. Cat2p is associated with the 
mitochondria and what is presumably the peroxisome. Yat2p, on the other hand, 
appears to be distributed throughout the cell, suggesting cytoplasmic localisation.  
3.3.3. COMPLEMENTATION OF THE GROWTH DEFECT OF THE Δcit2 MUTANT 
THROUGH THE CARNITINE SHUTTLE 
 
Previous studies have indicated that deletion of CIT2 creates a strain that is completely 
dependent on the presence of carnitine for growth on non-fermentable carbon sources 
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and fatty acids. In these conditions the activities of all three CATs are required and 
deletion of any one leads to a loss of growth even in the presence of carnitine (Swiegers 
et al. 2001). Supplementation of media with either carnitine or acetylcarnitine was able 
to rescue the Δcit2 growth defect (Figure 3.4), while deletion of any one of the CATs in 
addition to CIT2 results in loss of growth. 
 
Figure 3.4. Growth of Δcit2 and Δcit2Δcat mutant strains in (A) YNG, (B) YNG + carnitine and (C) 
YNG +acetylcarnitine, both supplemented to 100 mgL-1. 
 
To assess if the overexpression of one of the three CAT genes under the constitutive 
PGK promoter could overcome the growth defect on non-fermentable carbon sources in 
the cit2 background, the double mutants (FY23cit2yat1; FY23cit2yat2 and 
FY23cit2cat2) were transformed with the YCplac33-PKGpt plasmid carrying, either 
the YAT1, YAT2 or CAT2 gene. Transformants were streaked out on YNE or YNG agar 
plates, supplemented with L-carnitine. The plates were incubated at 30°C for 14 days. 
In the cit2 background, the overexpression of the deleted CAT gene could rescue 
 Chapter3: Research Results I       64 
 
growth (Figure 3.5 A-C), indicating the functionality of the genes on the plasmid. 
However, in none of the cases cross-complementation could be observed, indicating a 
specific and unique metabolic function for each of the three CAT genes. 
?cit2?cat2
?cit2?yat1
?cit2?yat2
A CAT2 B YAT1
C YAT2
cit2cat2
cit2yat2 cit2yat1
 
Figure 3.5. Overexpression of the CAT genes under the PGK1 promoter. Strain layout as indicated. 
(A) overexpression of CAT2, (B) overexpression of YAT1 and (C) overexpression of YAT2. 
Overexpression of each of the CAT genes was able compliment its own deletion, but unable to 
cross-complement deletion of any of the other two CATs. 
3.3.4. EXPRESSION OF S. pombe MAE1 COMPENSATES FOR THE Δcit2 
GROWTH DEFECT ON NON-FERMENTABLE CARBON SOURCES 
 
Peroxisomally produced acetyl-CoA can be utilised in two ways, either through shuttling 
via the carnitine system, or by forming C4 compounds, in particular succinate by the 
glyoxylate cycle. To assess whether efficient uptake of extracellular C4 compounds, 
which is not present in S. cerevisiae, could compensate for the glyoxylate cycle and 
possibly induce phenotypical differences between the three CAT mutants, we generated 
a strain that has an efficient uptake of C4 dicarboxylic acid by expressing the S. pombe 
malate permease gene (MAE1). For this purpose, the various Δcit2 mutant strains were 
transformed with YCplac33-PKGpt plasmid carrying the MAE1 gene or the YCplac33-
PKGpt plasmid as control. Strains were grown in YND media to an optical density 
(OD600) of ~ 1.0 and then spotted in five 10:1 serial dilutions on YNEM media with and 
without carnitine. The plates were incubated at 30°C for 7 days. As shown in Figure 3.6, 
the expression of the S. pombe malate permease (MAE1) gene complemented the 
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carnitine dependency of a cit2 deletion strain. Furthermore, expression of MAE1 
complements deletion of CIT2 in combination with any of the three CATs, while no 
difference is observed between the three cit2cat double mutants. 
Addition of carnitine however did not only results in the complementation of Δcit2, 
but also led to significantly enhanced growth of the wild type strain FY23 on YNEM. This 
is the first carnitine-dependent phenotype observed in a WT genetic background. The 
enhancement of growth by carnitine is especially clear in strains expressing the MAE1 
gene, even when CAT genes are deleted.  
 
cit2yat1
cit2yat2
cit2cat2
wt
cit2
cit2yat1
cit2yat2
cit2cat2
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Figure 3.6. Serial dilutions of the wild type strain, the cit2 background and the cit2cat double 
mutants expressing the Schizosaccharomyces pombe malate permease gene (MAE1). The growth 
medium used was YNEM and also YNEM containing carnitine. Similar to the addition of carnitine, 
overexpression of MAE1 rescues the growth defect of a Δcit2 strain in these conditions. Carnitine 
addition further enhances growth of the wild type, FY23, and also the mutant strains on YNEM 
plates, especially in strains expressing MAE1. 
3.3.5. CARNITINE ENHANCES GROWTH DURING ORGANIC ACID STRESS 
INDUCED BY THE PRESENCE OF LACTATE 
 
These results led us to investigate a possible role of carnitine in alleviating organic acid 
toxicity in yeast. For this purpose, growth was monitored on plates containing harmful 
concentrations of lactic and acetic acid, as previously described (Kawahata et al. 2006).  
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Carnitine addition to YND plates containing lactate results in an increase in growth 
compared to the plates without carnitine (Figure 3.7). This effect was very clear on 
plates containing 5.1% lactate. This enhancement is similar to what is observed on the 
malate containing YNEM plates (Figure 3.6). Furthermore, the effect of carnitine was 
independent of the presence of the three CATs and therefore also of the carnitine 
shuttle. A similar phenotype could, however, not be seen in the case of acetate 
containing plates (data not shown). 
 
Figure 3.7. Serial dilutions of the wild type strain FY23 and the triple CAT mutant 
FY23Δyat1Δyat2Δcat2 (indicated as Δcat) spotted on YND plates containing 5.1% lactate with and 
without the addition of carnitine. Carnitine enhances growth under conditions of organic stress 
induced by the presence of lactate, independent of the carnitine shuttle. 
3.3.6. CARNITINE PROMOTES GROWTH IN THE PRESENCE OF HYDROGEN 
PEROXIDE 
 
To further investigate the possible role of carnitine in stress protection, we assessed 
various other stress conditions. Studies in bacterial systems have established that 
carnitine can act in a protective capacity as a compatible solute in osmotic stress 
conditions in prokaryotes (Kunau et al. 1995). In humans the emerging role of carnitine 
and acetylcarnitine as therapeutic agents for neurodegenerative disorders and anti-
oxidant modulator has recently been speculated to involve the redox dependent 
activation of vitagenes through induction of the heat shock response. Induction of the 
heat shock response has also been suggested in protection against various diseases, 
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such as cancer aging and also various states of neurodegeneration (for review see 
Calabrese et al. 2006). 
In order to investigate a possible role for carnitine in protection against conditions of 
cellular stress in yeast, cells were subjected to osmotic (NaCl), thermal and oxidative 
(H2O2) stresses. In the case of osmotic, thermal and oxidative shock in non-growing 
conditions no difference in survival was observed between cells grown in the presence 
or absence of carnitine (Figure 3.8, A-D), which was added at concentrations ranging 
from 1 to 1000 mgL-1  (only data for 100 mgL-1 carnitine are shown). Carnitine does, 
however, clearly enhance growth of the wild type strain BY4742 in the presence of 
hydrogen peroxide (Figure 3.8 E). Growth enhancement was independent of carnitine 
concentrations (1, 10, 100 and 1000 mgL-1). This finding was also confirmed in the 
FY23 genetic background. Furthermore, addition of carnitine does not change the 
requirement for the transcriptional activator Yap1p (Figure 3.8, E) which was used as 
control. 
 
Figure 3.8. Stress tolerance experiments performed on the wild type BY4742 strain. (A)  Growth 
curve of strains in YND compared to YND with 1.6 M NaCl and carnitine addition. (B) Serial 1:10 
dilutions spotted onto plates containing 1.5 M NaCl. (C) Percentage survival after exposure to 45°C, 
strains was harvested from YNG cultures with and without carnitine addition. (D) Percentage survival 
after exposure to 3 mM H2O2, strains was harvested from YNG cultures with and without carnitine 
addition. (E) Serial dilutions of BY4742 and BY4742Δyap1 spotted onto plates containing 2 mM 
H2O2. All experiments were done in triplicate. 
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3.3.7. CAT2 IS REQUIRED FOR PROTECTION AGAINST OXIDATIVE SHOCK IN 
CELLS GROWN UNDER RESPIRATORY CONDITIONS 
 
To further investigate whether the carnitine shuttle or the three yeast CATs are involved 
in or have an impact on the yeast’s ability to tolerate various cellular stresses, strains of 
the BY4742 genetic background with deletions of each CAT gene were exposed to 
thermal, oxidative and osmotic stress conditions. In the case of thermal stress, we also 
assessed resistance after a period of pre-adaptation by heating the cells to 40°C for 30 
min before a thermal shock was executed at 50°C. In the case of oxidative stress on 
YND plates (performed as described for the wild type strains) no difference could be 
observed between the mutant strains (data not shown). There was also no difference in 
the survival of the strains exposed to thermal and osmotic shock (data not shown). 
However, the survival percentage after exposure to oxidative stress and also thermal 
stress with pre-adaptation (Figure 3.9, A and B), was reduced by 10% to 20% in the 
Δcat2 mutant strain when compared to the wild type. This reduced survival was 
independent of the presence of carnitine in the culture growth medium. No difference 
could be observed between the Δyat1 and Δyat2 mutant strains and the wild-type. 
Figure 3.9. Survival percentages of BY4742 and strains bearing single mutations of each CAT after 
exposure to (A) heat shock at 50°C with a 30 min period of pre-adaptation at 40°C and (B) Oxidative 
shock in 3 mM H2O2. Strains were grown in YNG media with and without carnitine addition prior to 
induction of stresses. All experiments were done in triplicate. 
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3.4. DISCUSSION 
 
The aim of this study was to investigate the specific roles of the three CAT genes 
encoded by the yeast genome and to identify possible physiological roles of L-carnitine. 
Our genetic analysis of CAT and CIT2 deletion mutants in all combinations clearly 
demonstrate that the shuttle system has no effect on growth in strains with a functional 
glyoxylate cycle.  
The data also confirm previous information regarding the localization of Cat2p and 
Yat1p, and localise Yat2p to the cytosol. The overexpression of any of the three CAT 
genes can not cross-complement the deletion of another CAT gene, indicating that each 
of the genes fulfils a unique and very specific function in the shuttling and regulation of 
acetyl-CoA and CoA pools inside the various cellular compartments. It is unlikely that 
the specificity is only due to the difference in localisation. Indeed, in such a case, some 
cross complementation in overexpressing strains would be likely. In addition, it is 
unclear why three enzymes would be required to maintain a “minimum “shuttling activity 
if such activity was limited to the transfer of activated acetyl residues between 
cytoplasm, mitochondria and peroxisomes.  
Furthermore, addition of either carnitine or acetylcarnitine to the growth medium 
reinstates growth in the carnitine dependent Δcit2 mutant strain, indicating that yeast 
cells are able to take up acetylcarnitine from the growth medium. 
The provision of C4 compounds through the expression of the 
Schizosaccharomyces pombe malate permease gene (MAE1) was able to compensate 
for the growth defect of the Δcit2 deletion strains on non-fermentable carbon sources, 
but no phenotypic differences between the different CAT mutants could be observed, 
indicating that the effect is a compensation for the peroxisomal citrate synthase and 
does not improve growth in CAT-gene specific manners. This set of data suggests that 
the main role of the glyoxylate cycle is indeed the synthesis of C4 intermediates. The 
enhanced growth of the Δcit2 single mutant compared to the Δcit2Δcat double mutants 
in the presence of carnitine furthermore indicates that complementation through a 
functional carnitine shuttle is more effective than supplying the cell with C4 
intermediates. 
Our data strongly suggest that carnitine plays other, previously unrecognised roles in 
S. cerevisiae. The compound has a clear growth enhancing impact on wild type strains 
growing on malate and ethanol containing medium, as well as on plates containing 
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inhibiting concentrations of lactate. The impact of carnitine in these conditions appears 
entirely independent of the three CAT enzymes and the carnitine shuttle, since the 
enhancement is observed in the Δcit2Δcat double mutants that express the malate 
transporter MAE1 and in the triple CAT deletion strain when grown in the presence of 
inhibitory concentrations of lactate. These data strongly suggest a role for carnitine in 
alleviating the toxic effects of certain organic acids. 
 Acetic acid toxicity appeared not to be affected by carnitine. This may be explained 
by the finding that lactate and acetate inhibit yeast growth in different manners, with 
acetate leading to an increase in cellular ATP demand required for maintenance, while 
lactate appears to affect cells in a different and unknown manner (Maiorella et al. 1983; 
Narendranath et al. 2001). The underlying mechanisms of this phenotype need further 
investigation and will be the focus of future studies. 
The investigation of other stress conditions did not reveal any impact of carnitine on 
NaCl induced osmotic stress tolerance. This observation can be linked to reports that 
carnitine uptake via the membrane transporter Agp2 is shut down by the Hog1p MAP 
kinase pathway when exposed to high concentrations of sodium chloride (Lee et al. 
2002).  
The data also show that the compound appears not to increase cellular survival 
during heat or oxidative shocks. No effect was observed when growing cells in the 
presence or absence of carnitine before administration of such shock. However, the 
presence of carnitine clearly enhances growth when cells are grown in stressful 
conditions. Indeed, carnitine that was added to YND plates containing H202 clearly 
enhanced the yeast’s ability to grow under these conditions. This effect was dependent 
on the transcriptional activator Yap1p, which regulates several enzymes which protects 
against oxidants (Grey and Brendel 1994; Hussain and Lenard 1991; Schnell et al. 
1992), suggesting some direct molecular role for carnitine in the process. 
Further studies are required to evaluate the effect of carnitine addition in cells grown 
under oxidative stress conditions on cellular oxidation levels. It will also be of interest to 
establish if the protection offered by carnitine against hydrogen peroxide is related to 
that observed for the organic acids, malate and lactate, since it is known that the 
presence of organic acids can result in oxidative stress (for review see Piper et al. 
2001). 
The results indicate that deletion of CAT2 significantly decreases survival of the 
mutant strain when exposed to either oxidative stress or pre-adaptive thermal stress 
 Chapter3: Research Results I       71 
 
(FY23Δcat2 survival vs other strains, p < 0.05). Since the cultures used for the 
experiments were grown in media containing a non-fermentable carbon source (YNG), 
to ensure that the enzymes involved in the carnitine shuttle are actively expressed, 
resistance to such stresses are intrinsically higher due to the activities associated with 
respiratory growth (Jamieson 1992; Barros et al. 2004). A decrease in survival does 
therefore not necessarily indicate a decrease in the efficiency of the yeasts defence 
systems, but possibly an indirect effect on peroxisomal or mitochondrial function caused 
by the deletion of CAT2. The inability of the Δcat2 mutant strains to respond to pre-
adaptation could be a result of the associated build-up of reactive oxygen species in 
these conditions. It is intriguing that this effect is independent of carnitine and therefore 
also of the carnitine acetyl transferase activity of Cat2p. This CAT2 effect was also not 
apparent when the strains were tested for growth in the presence of H2O2, where CAT2 
gene deletion did not lead to any significant change in phenotype (results not shown). 
However, these experiments can only be carried out on fermentable carbon sources, 
and it is therefore possible that the CAT enzymes are either not expressed or not 
functional in these conditions. No significant effect on survival was observed for the 
other two CATs, Yat1p and Yat2p. It will, however, be necessary to investigate the 
effect of CAT deletion and overexpression on cellular oxidation status to gain a clearer 
insight into the effects of these enzymes on oxidative stress.  
Several lines of evidence indicate that carnitine and the shuttle have pleiotropic and 
beneficial effects in higher eukaryotic cells (Steiber et al. 2004). Furthermore, mutations 
in higher eukaryotic acyltransferases can give rise to severe metabolic disorders (for 
review see Ramsay and Zammit 2004). Many of these impacts have been attributed to 
the role of the shuttle in energy metabolism, the balancing effect on compartmentalised 
pools of CoA in the cell and the removal of harmful organic acids through transfer to 
carnitine. However, carnitine has recently been implicated in enhancing stress 
resistance by up-regulating certain elements of the mammalian heat shock response, 
thereby creating a proposed cytoprotective state (Calabrese et al. 2006). These 
findings, together with carnitine’s potential as an anti-oxidant and the increasing 
research focus on a role for carnitine as a therapeutic agent with several possible 
applications, highlight the potential importance of the phenotypes described in this 
paper. Indeed, the investigation of the molecular nature of carnitine-dependent but 
shuttle-independent phenotypes will be easier in an accessible model system such as 
S. cerevisiae.  
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ABSTRACT 
 
L-Carnitine plays a well documented role in eukaryotic energy homeostasis by acting as 
a shuttling molecule for activated acyl residues across intracellular membranes. This 
activity is supported by carnitine acyl-transferases and transporters, and is referred to 
as the carnitine shuttle. However, several pleiotropic and often beneficial effects of 
carnitine in humans have been reported that appear to be unrelated to the shuttling 
activity, but little conclusive evidence regarding the molecular networks that would be 
affected by carnitine exist. We have recently demonstrated a protective role of carnitine 
in cellular stress in yeast that is independent of the carnitine shuttle. Here we show that 
carnitine specifically protects against oxidative stress caused by hydrogen peroxide and 
the superoxide generating agent menadione. The data also indicate that carnitine has a 
detrimental effect on cellular survival when combined with thiol-modifying agents. A 
genetic analysis indicates that central elements of the oxidative stress response, in 
particular the transcription factors Yap1p and Skn7p, are required for carnitine to exert 
its protective effect, but that several downstream effectors of the response are 
dispensable. A DNA microarray-based global gene expression analysis identified 
Cyc3p, a cytochrome c heme lyase, as being important for carnitine's protective impact 
in oxidative stress conditions. These findings establish a direct genetic link to a 
carnitine-related phenotype that is independent of the shuttle system. The data suggest 
that the yeast Saccharomyces cerevisiae should provide a useful model for further 
elucidation of carnitine's physiological roles. 
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4.1. INTRODUCTION 
 
The role of L-carnitine in the carnitine shuttle has been well characterized for its function 
in the transfer of the activated products of energy metabolism between intra-cellular 
compartments (Bieber, 1988; Reddy and Manaerts 1994). Activated acyl residues are 
transferred to carnitine by the activities of various carnitine acyl transferases and 
transported by carnitine/acylcarnitine carriers across the membranes of the 
mitochondria and peroxisomes. Collectively, this molecular network is referred to as the 
carnitine shuttle. The carnitine shuttle of Saccharomyces cerevisiae closely resembles 
that of higher eukaryotes in function, with minor differences in composition. Most 
notably, yeast appears to only posses carnitine acetyl-transferase activity, in contrast to 
the long chain acyl-transferase activities present in higher eukaryotes (Kispal et al, 
1993). In yeast, this activity is ascribed to three carnitine acetyl-transferases (CATs), 
Yat1p, Yat2p and Cat2p, compared to a single mitochondrial CAT in mammalian 
systems (Schmalix an Bandlow, 1993; Swiegers et al, 2001). Furthermore, in yeast the 
glyoxylate cycle provides an alternative route by which activated acetyl-residues can 
gain access to the mitochondrial tricarboxilic acid cycle (Plamieri et al, 1997; Van 
Roermund et al, 1995). A final difference between yeast and mammals is that in yeast 
acetyl coenzyme A is generated both in cytosol and peroxisomes, compared to the 
exclusive peroxisomal acetyl-CoA generation in higher eukaryotes (Kunau et al, 1995). 
Carnitine supplementation results in various beneficial effects in human subjects or 
cell lines. Most notably supplementation of carnitine and of various acylcarnitines has 
been associated with protecting against neurodegeneration and mitochondrial decay 
resulting from ageing and against the onset of apoptosis in various cell lines (Calabrese 
et al, 2005, Calabrese et al, 2006, Rani and Panneerselvam, 2001), also suggesting a 
link to oxidative stress protection. Several hypotheses have been generated to explain 
these effects. These include the upregulation of the mammalian stress responsive gene 
HO-1, encoding a heme oxygenase (Calabrese et al, 2006; Calo et al, 2006). 
Furthermore, carnitine has also been postulated to have a possible intrinsic antioxidant 
capacity which has been proposed to be involved in some of the observed effects in 
neuronal apoptosis protection (Gulcin, 2006; Silva-Adaya et al, 2008). Carnitine, 
through its involvement in energy metabolism, has been reported to have a stimulatory 
effect on mitochondrial metabolism, which has been linked to the benefits of carnitine 
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and acetylcarnitine supplementation. In particular, feeding carnitine to rats was shown 
to reverse the age dependent decline in mitochondrial membrane potential and decline 
in cardiolipin levels (Hagen et al, 1998). In thioredoxin deficient DT 40 cells 
acetylcarnitine was shown to specifically protect against oxidative stress in and around 
mitochondria, including the release of cytochrome c and SOD1 (Zhu et al, 2008). 
However, it is unclear if these changes are influenced directly or indirectly by the 
presence of carnitine and acylcarnitines. Moreover, no direct mechanisms have thus far 
been proposed to explain the different, generally beneficial effects of dietary carnitine 
supplementation. 
Recently we have demonstrated a role for carnitine in the protection against weak 
organic acid stress induced by for example acetate and oxidative stress induced by 
hydrogen peroxide in the eukaryotic model organism, Saccharomyces cerevisiae 
(Franken et al, 2008). This effect was found to be independent of all yeast CATs and 
therefore also of the carnitine shuttle. Here we present an analysis of the protective 
effect of carnitine against oxidative stress in yeast. The data indicate that carnitine 
specifically protects against the effects of the ROS generating agents H2O2 and 
menadione. Intriguingly, carnitine has an opposite and detrimental effect when 
combined with the thiol modifying agents diamide and DTT. This observation is the first 
report of a damaging effect associated with carnitine supplementation. The data indicate 
that carnitine has no free radical scavenging activity. A genetic analysis reveals that 
carnitine requires genetic mediation, in particular the general regulators of the oxidative 
stress response, encoded by YAP1 and SKN7, to exert its effect. A global gene 
expression analysis by DNA microarray comparing stressed and unstressed yeast 
grown in the presence and absence of carnitine led to the identification of the 
cytochrome c heme lysase Cyc3p as being important for carnitine-mediated stress 
protection. This finding links carnitine to mitochondrial functions, and suggests several 
possible pathways through which carnitine may exert its molecular effects. 
4.2. EXPERIMENTAL PROCEDURES 
4.2.1. YEAST STRAINS AND MEDIA 
 
The wild type strain BY4742 and all single gene knock-outs used in this study were 
obtained from Euroscarf (Frankfurt, Germany). The strains in which Yap1p and Msn2p 
have been replaced with GFP tagged versions of the same proteins were purchased  
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from Invitrogen. All strains are derived from the S288c genetic background and were 
grown either on YPD or minimal YND media containing 0.67% (w/v) yeast nitrogen base 
(YNB) without amino acids (DIFCO) and 2% (w/v) glucose supplemented with amino 
acids according to the specific requirements of the respective strains. 
4.2.2. MULTI-COPY EXPRESSION OF CYC3 AND CREATION OF THE 
ΔCYC1ΔCYC7 DOUBLE MUTANT 
 
The plasmids and constructs used in this study are listed in Table 4.1 and the primers 
for the amplification of CYC3 and also the CYC1 integration cassette are listed in Table 
4.2. Standard DNA techniques were used for the isolation and manipulation of DNA 
throughout the study (Sambrook et al, 1989; Ausubel et al, 1994). Restriction enzymes, 
T4 DNA-ligase and Expand Hi-Fidelity polymerase used in the enzymatic manipulation 
of DNA were obtained from Roche Diagnostics (Randburg, South Africa) and used 
according to the specifications of the supplier. Escherichia coli DH5 (GIBCO-BRL/Life 
Technologies) was used as host for the construction and propagation of all plasmids. 
Sequencing of all plasmids was carried out on an ABI PRISMTM automated sequencer. 
TABLE 4.1. Plasmids and constructs used in this study 
Plasmids Relevant genotype Sources and references 
pGEM-T-easy  Promega 
pGEM-T-easy-CYC3  This study 
YEplac195 2 URA3 Gietz and Sugino, 1988 
YEplac195-CYC3 2 URA3 CYC3 This study 
YDp-U 2 URA3 Berben et al, 1991 
 
 
For the cloning of CYC3, the primer pair CYC3-F and CYC3-R was used, which 
amplifies a 1551 bp fragment containing the CYC3 promoter, open reading frame (ORF) 
and terminator. The amplified fragment was ligated into the cloning vector pGEM-T-
easy (Promega). The CYC3 gene cassette was excised using the EcoRI site from the 
pGEM-Teasy vector and a SalI site upstream of the CYC3 STOP codon. The excised 
fragment was ligated into the plasmid YEpLac195 (Gietz and Sugino, 1988) using 
EcoRI and SalI restriction sites. 
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For the amplification of the CYC1 disruption cassette the primer pair CYC1-URA3int-
Fp and CYC1-URA3int-Rp was used, which amplifies the URA3 cassette from the 
plasmid YDp-U and incorporates 5’ and 3’ flanking regions homologues to regions 
outside the CYC1 ORF. The amplified disruption cassette was transformed into the 
BY4742Δcyc7 strain to create the Δcyc1Δcyc7 double mutant. Integration was verified 
by PCR using the primers CYC1-F and CYC7-R. 
Table 4.2. Primers used in this study. Sequences with homolgy to the URA3 region of the 
plasmid YDp-U are underlined 
Primer Sequence 
CYC3-F 5-‘GGAGCAAGTTGTGGTTTACAACACC  -3’ 
CYC3-R 5’-CGAGACGAATGGCGACATTTG-3’ 
CYC1-
URA3int-Fp 
5’-
ATGTGTGCGACGACACATGATCATATGGCATGCATGTGCTCTGTGCTGCAGGTC 
GACGGATCCG-3’ 
CYC1-
URA3int-Rp 
5’-
GTGGGAGGAGGGCGTGAATGTAAGCGTGACATAACTAATTACATGGGTGATTG 
ATTGAGCAAGCTGG-3’ 
CYC1-F 5’-GCAAGATCAAGATGTTTTCACCG-3’ 
CYC1-R 5’-ATAATGTTACATGCGTACACGCG-3’ 
4.2.3. ABTS ANTIOXIDANT ASSAY 
 
To determine the antioxidant capacity of carnitine the ABTS [2,2’-azinobis-(-3-ethyl-
benzothiazolin-6-sulfonic acid)] radical cation decolouration assay was used as  
previously described (Re et al, 1999; De Beer et al, 2003). The assay can be effectively 
used for lipophilic and hydrophilic antioxidants and is based on the preformation of the 
blue/green ABTS•+ chromophore by oxidation with potassium persulfate, which is then 
reduced in the presence of hydrogen donating antioxidants. The resulting decolouration 
can subsequently be measured spectrophotometrically. The ABTS•+ radical monocation 
was formed by addition of 88 μl of a 140 mM potassium persulfate solution to 5 ml of 7 
mM ABTS, which was protected from light and incubated overnight at room 
temperature. The ABTS solution was diluted to and O.D. 0.7 at 734 nm for use in the 
assay. Dilution series of 50, 100, 150, 200, 300 and 400 mM were set up for Trolox, 
ascorbic acid, -butyrobetaïne and L-carnitine. The reaction mixture consisted of 200 μl 
of the diluted ABTS solution to which 10 μl of each of the samples from the mentioned 
dilution series was added. ABTS decolouration was measured after 4 min at O.D. of 
734nm. Assays were done in triplicate. 
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4.2.4. PREPERATION OF PLATES CONTAINING REDOX STRESS INDUCING 
AGENTS 
 
The plates used for the assessment of the effect of various oxidants (H2O2, menadione, 
linoleic acid hydroperoxide (LoaOOH), cumene hydroperoxide (CHP) and diamide) and 
also the thiol reducing agent DTT in combination with carnitine were prepared on the 
day before cultures were spotted. SCD agar medium was left to cool to 50°C before the 
addition of the oxidants (0.5 and 1.5 mM H2O2; 0.1 and 0.2 mM menadione; 1.0 and 1.5 
mM LoaOOH; 0.1 and 0.25 CHP; 0.8 and 1.2 mM Diamide; 8.0 and 16 mM DTT) and 
also L-carnitine (added in a concentration range between 50 and 1500 mgL-1). Plates 
were stored overnight at 4°C in the dark. Linoleic acid hydroperoxide was prepared as 
described by Evans and co-workers (Evans et al, 1998). 
4.2.5. DETERMINATION OF INTRACELLULAR ROS 
 
The oxidant sensitive probe 2’,7’-dichlorofluoresciein diacetate (DCFH-DA, Sigma) was 
used for the detection of intracellular ROS. The dye is cell permeable and widely used 
for the rapid quantification of ROS in eukaryotic cells (Jakubowski and Bartosz, 1997). 
The DCFH-DA probe is nonfluorescent until acetate groups are removed by intracellular 
esterases and can then be oxidized by intracellular ROS to the fluorescent compound 
2’,7’-dichlorofluorescein (DCF), which can be detected as a indirect measure of 
intracellular ROS. Cultures of BY4742 were grown overnight to inoculate fresh SCD and 
media and also SCD containing carnitine (1000 mgL-1) to an O.D.600 of 0.1. A duplicate 
set was also inoculated, which was to be treated with 0.6 mM H2O2 for 30 and 90 min 
respectively, when the cultures reached mid-log phase. After treatment the cultures 
were harvested, washed once and resuspended in phosphate buffered saline (PBS). 
Cells were diluted to ~ 106 per ml; DCFH-DH was added to a concentration of 100 μM 
and incubated for 30 min at 28 °C. Data were acquired using the BD FACSAria cell 
sorter, equipped with 407 nm, 488 nm and 633 nm lasers and the BD FACSDiva 6.1 
software. The samples were acquired with an event rate of 600 per second using a 70 
μm nozzle. Intensity histogram overlays were generated using FlowJo 2.1.1. The 
experiment was done in triplicate. 
4.2.6. MICROARRAY ANALYSIS 
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Cultures of the wild type strain BY4742 was grown overnight in SCD containing tubes to 
serve as pre-cultures. Two flasks containing 50ml of freshly prepared SCD media and 
also two containing SCD with carnitine (1000 mgL-1) was inoculated to an O.D.600 ~ 0.1 
and grown to mid-log phase (O.D.600 0.4 -.0.5). A duplicate set was also inoculated and 
exposed to 0.4 mM H2O2 for 30 min before harvesting and isolation of total RNA. RNA 
was isolated as previously described (Schmitt et al, 1990). Probe preparation and 
hybridization to Affymetrix Genechip® microarrays were performed according to 
Affymetrix instructions, starting with 6 μg of total RNA. Results for each condition were 
derived from 2 independent culture replicates. The quality of total RNA, cDNA, cRNA 
and fragmented cRNA were confirmed using the Agilent Bioanalyzer 2100.  
4.2.7. TRANSCRIPTOMICS DATA ACQUISITION AND STATISTICAL ANALYSIS 
 
Acquisition and quantification of array images and data filtering were performed using 
Affymetrix GeneChip® Operating Software (GCOS) version 1.4. All arrays were scaled 
to a target value of 500 using the average signal from all gene features using GCOS. 
Genes with expression values below 12 were set to 12+ the expression value as 
previously described (Boer et al, 2003) in order to eliminate insignificant variations. 
Determination of differential gene expression between experimental parameters was 
conducted using SAM (Significance Analysis of Microarray) version 2. The two-class, 
unpaired setting was used and genes with a Q value of 0.5 (p < 0,005) were considered 
differentially expressed. Only genes with a fold change greater than 1.8 (positive or 
negative) were taken into consideration. 
4.3. RESULTS 
4.3.1. RELATIONSHIP OF L-CARNITINE TO KNOWN REDOX STRESSORS 
 
It has previously been established that carnitine supplementation enhances growth of 
yeast strains in conditions of organic acid stress and also oxidative stress induced by 
hydrogen peroxide (Franken et al, 2008). Since a range of oxidative stress inducing 
agents have been identified and their effects on the physiology of yeast cultures have 
been reasonably well characterized (Thorpe et al, 2004; Gasch et al, 2000), it was of 
interest to investigate the effect of carnitine supplementation of cultures exposed to 
these compounds. The compounds that were chosen for this study include the ROS 
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generating oxidants hydrogen peroxide, the superoxide generating agent menadione, 
linoleic acid hydroperoxide (LoaOOH, a byproduct of lipid peroxidation), cumene 
hydroperoxide (CHP, an aromatic hydroperoxide) and also the thiol oxidizing agent 
diamide. 
With regards to ROS generating oxidants, carnitine visibly enhances growth of 
exposed cultures in all cases except for exposure to CHP (Figure 4.1 A). Although there 
is a growth enhancing effect in the case of linoleic acid hydroperoxide, it is not as clear 
as in the case of H2O2 and menadione. 
Figure 4.1. Carnitine supplementation (100 and 1000 mgL-1) in combination with redox stress inducing 
agents. (A) ROS inducing stressors: H2O2 (1.5 mM), Menadione (0.1 mM), LoaOOH (1.0 mM) and CHP 
(0.8 mM). (B) Thiol modifying agents: the thiol oxidizing agent diamide and the thiol reducing agent DTT 
was used at final concentrations of 1.2 mM and 8 mM respectively. 
 
Interestingly carnitine addition in combination with the thiol oxidant diamide leads to 
a significant decrease in growth compared to cultures that are only exposed to the 
oxidant (Figure 4.1 B). Similar results are observed in combination with the thiol 
reducing agent dithiothrietol (DTT). The effect of carnitine is concentration dependent, 
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with effects on plates being visible from below 100 mgL-1 upwards. This effect was 
observed in the case of protection against  H2O2 and menadione and also for the 
damaging effects of diamide and DTT (Figure 4.1). Furthermore, when liquid (SCD) 
cultures were grown to mid-log phase in the presence of carnitine, harvested, washed 
and spotted on peroxide plates (without carnitine supplementation), carnitine was found 
to excert a protective effect at concentrations of 1 mgL-1 in the liquid medium (data not 
shown). 
 
Figure 4.2. Assessment of carnitine’s possible role as an antioxidant. (A) Flow-cytometer profiles of ROS 
accumulation in strains treated with 0.6 mM H2O2 for 30 and 90 min with and without carnitine 
supplementation detected by the fluorescent probe DCFH-DA. (B) Carnitine does not exhibit the ability to 
scavenge free radicals using the ABTS decoloration assay, ascorbate and Trolox was used as controls. 
(C), Carnitine supplementation rescues the synthetic methione auxotrophy of a Δsod2 strain under 
aerobic growth conditions in a concentration dependent manner. 
4.3.2. CARNITINE DOES NOT SCAVENGE FREE RADICALS, BUT BEHAVES LIKE 
AN ANTIOXIDANT IN A BIOLOGICAL CONTEXT 
 
A role for carnitine and some of its esters have been clearly indicated in protecting 
against the onset of apoptosis, ageing and other states associated with the build-up of 
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oxidative stress (Rani and Panneerselvam, 2001). As indicated, carnitine addition to 
yeast cultures exposed to 0.6 mM H2O2 was, similar to observations in higher 
organisms, able to dramatically decrease the amount of intracellular ROS in yeast, as 
detected by the fluorescent probe DCFH-DA (Figure 4.2 A). One line of argumentation 
suggests that this could be due the antioxidant effect of carnitine itself (Gulcin, 2006). 
To investigate if L-carnitine is indeed able to scavenge free radicals, the molecule was 
used in an ABTS free radical scavenging assay. As is clear in Figure 4.2 B, carnitine is 
unable to scavenge free radicals and would, therefore, be unable to function as a 
molecular antioxidant. 
Using carnitine in a yeast based biological antioxidant screen proposed by Žyracka 
and co-workers (Žyracka et al, 2005; Figure 4.2 C) illustrates that carnitine addition to 
cultures of a Δsod1 strain abolishes the synthetic methionine auxotrophy of the strain 
under aerobic conditions. The effect of carnitine is concentration dependent and 
comparable to the effects reported for antioxidants such as ascorbate, glutathione, 
cystein and N-acetylcystein (Žyracka et al, 2005). -Butyrobetaïne, the direct precursor 
of carnitine in the eukaryotic carnitine biosynthesis pathway and differing only by a 
hydroxyl group on the third carbon from carnitine, did not show any free redical 
scavenging activity and was unable to complement the auxotrophy of Δsod1.  
4.3.3. THE PROTECTIVE EFFECT OF CARNITINE REQUIRES THE MAJOR 
PATHWAYS INVOLVED IN OXIDATIVE STRESS PROTECTION 
 
In yeast, the main responses to oxidative stress are regulated by the transcription 
factors Yap1p, Msn2p and also Skn7p (Jamieson, 1998). These responses include the 
upregulation of antioxidant enzymes, such as the superoxide dismutases, SOD1 and 
SOD2, and enzymes involved in glutathione metabolism, such as GLR1. To assess if 
the action of carnitine requires these pathways, strains bearing deletions of genes 
involved in these pathways were assessed for their oxidative stress response in the 
presence or absence of carnitine. The genes assessed included YAP1 and genes 
encoding regulators of its activity, including the Yap1p binding protein Ybp1 (Veal et al, 
2003) and the thiol peroxidase Hyr1p (Delaunay et al, 2002), which transduces a redox 
signal to Yap1p, as well as the transcription factor Skn7p and the downstream 
antioxidant enzymes Sod2p (superoxide dismutase, Saffi et al, 2006), Tsa1p (a 
thioredoxin peroxidase, Chae et al, 1994), Trx2p (a thioredoxin, Pedrajas et al, 1999), 
Glr1p (a glutathione oxidureductase, Grant, 2001) and Gsh1p (catalyzes the first step in 
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glutathione biosynthesis, Ohtaki and Yabuuchi, 1991). The strains were spotted on 
plates containing H2O2 (0.5 and 1.0 mM) with and without the addition of carnitine to a 
final concentration of 1000 mgL-1. From the results (Figure 4.3) it is clear that carnitine 
supplementation leads to enhanced survival in the case of Δsod2, Δtsa1 and Δtrx2 
strains. In the case of gene deletion of YAP1, SKN7 and the genes required for 
glutathione metabolism, carnitine was unable to compensate for the deletion of the 
respective genes. 
It has been indicated that certain molecules, such as green tea polyphenols, are 
able to induce the activation of Yap1p and also Msn2p, localized in the cytosol under 
non-stress conditions, which leads to the nuclear localization of the two transcription 
factors in order to activate target gene sets (Maeta et al, 2007). Considering that 
carnitine has been proposed to act through the mammalian regulator of stress induced 
genes, namely Nrf2 (Calabrese et al, 2005), the effect of carnitine on the localization of 
Yap1p and Msn2p using GFP-fusions of the two transcription factors was investigated. 
Cultures exposed to carnitine did, however, not lead to a change in localization of either 
Yap1p or Msn2p (data not shown). 
 
Figure 4.3. The effect of carnitine supplementation on strains with deletions of genes required for the 
cells defense against oxidative stress. The transcription factors Yap1p and Skn7p and genes involved in 
glutathione metabolism (GSH1 and GLR1) are required for carnitine’s protective effect, whereas carnitine 
supplementation results in enhanced growth of strains with deletions of the antioxidant enzymes SOD2, 
TRX2 and TSA1. 
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4.3.4. SCREENING FOR POSSIBLE GENETIC LINKS TO THE PROTECTION 
AGAINST OXIDATIVE STRESS BY CARNITINE 
 
To screen for possible genetic mediators of the protective effect of carnitine, microarray 
analysis was performed, comparing the wild type strain BY4742 grown in SCD with and 
without carnitine supplementation. In addition global expression analysis of cultures 
grown to mid-log (with and without carnitine addition) and then exposed to H2O2 was 
also performed. The data discussed in this publication have been deposited in NCBI's 
Gene Expression Omnibus (Edgar et al, 2002) and are accessible through GEO Series 
accession number GSE16346  (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= 
GSE16346). 
Table 4.3. Genes upregulated by carnitine and genes of overrepresented transcription factors 
screened on H2O2 and H2O2 with carnitine (1000 mgL-1). Only deletion of CYC3, showed 
decreased responsiveness to carnitine. Two strains, highlighted in shaded blocks, were 
included because the genes showed significant up-regulation in the microarrays comparing 
yeast cells in the presence or absence of carnitine without H2O2. 
Deletion strains with WT-level H2O2 
sensitivity (expression fold change: 
H2O2 + carnitine vs H2O2 – carnitine) 
Deletion strains with above WT H2O2 
sensitivity (expression fold change: H2O2 + 
carnitine vs H2O2 – carnitine) 
Deletion mutants of overrepresented transcription factors 
Δaft2 (-1.48); Δcad1 (-1.08) Δaft1 (1.07); Δsok2 (-1.32);                 
Δrpn4 (-1.21) 
 Strains deleted for genes with up-regulated transcripts (fold-change) 
Δuip4 (2.01); Δalp1 (2.01); Δjlp1 (2.03); 
Δgut2 (2.09); Δgdb1 (2.19); Δhpf1 (1.97); 
Δlee1 (2.27); Δcos111 (2.33); 
Δtkl2 (3.44); Δgnd2 (3.77); 
Δsps100 (3.18); Δgph1 (1.97); 
Δcox23 (1.94); Δald3 (1.86); 
Δgsy1 (1.80); Δhes1 (1.43); Δadr1 (1.49); 
Δmig2 (1.85); Δras1 (1.86); 
Δykr075c (2.56); Δydl218w(2.02) 
Δykl187c (2.33); Δyfl052w (2.71) 
Δrtn2 (1.93) 
Δubr2 (2.01); Δsip18 (2.14); Δptr2 (2.25); 
Δhbt1 (2.43); Δmth1 (2.52); Δput4 (2.61); 
Δtsa2 (1.05); Δpai3 (1.97); Δnca3 (1.94); 
Δyor1 (1.81);  Δybr285w (2.03); 
Δypl113c (2.50); Δyol131w (2.25); 
Δcyc3 (1.99) 
 
Using a fold cut-off value of 1.8, 40 genes were found to be upregulated and also 40 
downregulated when comparing the peroxide treated cultures supplemented with 
carnitine to the unsupplemented, peroxide treated set. Comparing the carnitine treated 
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to untreated sets revealed only 5 genes up and 12 genes downregulated. Deletion 
mutants representing all of the identified, non-essential, genes upregulated by the 
presence of carnitine during peroxide stress were spotted in serial dilutions on plates 
containing 0.75 mM and 1.6 mM H2O2 and also on a duplicate set which contained 
carnitine (added to 1000 mgL-1). Also included in the set of mutants were strains 
bearing deletions of AFT1, AFT2, CAD1, RPN4 and SOK2, which were identified as 
overrepresented transcription factors within the set of upregulated genes using the 
yeast transcription factor database, Yeastract (http://www.yeastract.com/). In addition, 
strains bearing deletions of HES1 and TSA2, were included, since both genes were 
upregulated by the presence of carnitine in non-stressed conditions. The plates were 
incubated at 30°C for three days and inspected for growth. As indicated in Table 4.3, 14 
out of the 38 upregulated genes that were screened were sensitive to H2O2 present in 
the media. Out of the 5 overrepresented transcription factors, Δaft1, Δsok2, Δrpn4 also 
tested sensitive to peroxide. However, only in one case, Δcyc3, could a decrease in 
responsiveness to carnitine supplementation be observed. 
4.3.5. CARNITINE PROTECTION REQUIRES THE CYTOCHROME C HEME LYASE, 
Cyc3p 
 
Deletion of the cytochrome c heme lyase CYC3, leads to increased sensitivity 
compared to the wild type control on plates containing H2O2 (Figure 4.4 A). In addition, 
when compared to all other strains, the deletion of CYC3 results in a notable decrease 
in the strains responsiveness to carnitine treatment. Cyc3p, a conserved eukaryotic 
protein, is required for the maturation of the two yeast cytochrome c’s, Cyc1p and 
Cyc7p, through the attachment of prosthetic heme groups (Tong and Margoliash, 1998; 
Dumont et al, 1991; Schwartz and Cox, 2002). Deletion of Cyc3p results in a strain 
lacking mature cytochrome c. Interestingly, CYC3 expression is induced by carnitine 
and not H2O2, whereas the expression of CYC1 and to a lesser degree CYC7 is induced 
by the presence by H2O2 (Table 4.4).  
Table 4.4. Expression fold changes of CYC genes. Shaded blocks are used to highlight 
upregulation. The respective p-values are indicated in brackets 
Gene 
Name 
Expression fold change 
Wt vs. wt +H2O2 H2O2 vs. H2O2 + carnitine
CYC3 -1.06 (p = 0.42) 1.99 (p = 0.084) 
CYC1 2.92 (p = 0.0012) -1.08 (p = 0.016) 
CYC7 1.25 (p = 0.26) -1.11 (p = 0.033) 
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Figure 4.4. (A) deletion of the cytochrome c heme lyase, CYC3, renders the yeast strain more sensitive 
to H2O2 treatment compared to wild type and less responsive to growth enhancement by carnitine 
addition as compared to deletion of SOD2 and also all other gene deletions screened. (B) the effect of 
CYC3 deletion is comparable to a strain with no cytochrome c (Δcyc1Δcyc7) for carnitine’s protection in 
the presence of H2O2. (C) CYC3 and both cytochrome c encoding genes are enhancing carnitine’s toxicity 
in combination with DTT. 
 
To assess if the observed phenotype is due to the lack of functional cytochrome c, or 
a separate function of Cyc3p, a Δcyc3 strain was compared to a strain with both 
cytochrome c encoding genes, CYC1 and CYC7, deleted. The strains were spotted on 
plates containing H2O2 and also DTT, with and without carnitine supplementation. The 
double mutant’s sensitivity to the stress inducing agents and responsiveness to 
carnitine supplementation was in all cases comparable to that of the Δcyc3 strain 
(Figure 4.4 B). Both strains exhibit increased sensitivity towards H2O2 in comparison 
with the wild type strain and a decreased responsiveness to carnitine. Furthermore, 
both the Δcyc3 and the Δcyc1Δcyc7 double mutant grow slightly better than the wild 
type when exposed to 16 mM DTT (Figure 4.4 C). This difference is enhanced on plates 
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with DTT and carnitine. The absence of functional cytochrome c therefore suppresses 
both carnitine-related stress phenotypes, the improvement in the presence of H2O2 and 
the detrimental impact in the presence of thiol-modifying agents. Expressing CYC3 from 
the multi-copy plasmid, YEpLac195, resulted in complementation of the Δcyc3 strain 
with regards to sensitivity to oxidants and carnitine responsiveness. However, no effect 
was observed when the same construct was expressed in the wild type strain or the 
Δsod2, Δtrx2 or Δyap1 strains (data not shown). 
4.4. DISCUSSION 
 
A beneficial role for carnitine has been indicated in various human disease states 
associated with oxidative damage and mitochondrial decay (Calabrese et al, 2009). The 
molecular mechanisms behind these observations, however, remain poorly defined. In 
addition, a role for carnitine in protection against oxidative stress in yeast has recently 
been indicated (Franken et al, 2009). This study presents an analysis of the effect of L-
carnitine supplementation in oxidative stress conditions and aims to establish the yeast, 
Saccharomyces cerevisiae, as a model system for further studies in this field. 
Carnitine specifically protected yeast cells from the damaging effects of the ROS 
generating oxidants H2O2 and menadione. Interestingly, the effects of both oxidants on 
global gene expression were shown to be largely identical (Gasch et al, 2000). No or 
little effect was observed in the case of CHP and only a marginal difference in the case 
of LoaOOH induced stress, which suggests a specific and not general function for 
carnitine in oxidative stress protection. 
Intriguingly, carnitine supplementation in combination with the thiol oxidant diamide 
or the thiol reducing agent DTT resulted in an enhanced toxicity. It is noteworthy that in 
a yeast deletion library screen of the compounds used in this study it was reported that 
deletion of genes involved in mitochondrial function resulted in sensitivity towards H2O2 
and the same mutants caused resistance to diamide. As far as we are aware, this is the 
first report suggesting a detrimental or toxic effect of carnitine. This finding may be of 
significant importance when considering that DTT as well as carnitine have been 
proposed as therapeutic agents for the treatment of Alzheimer’s and other 
neurodegenerative diseases (Thal et al, 1996; Marcum et al, 2005; Offen et al, 1996). 
Co-administration of these two compounds could have unexpected effects. 
For both the protective and detrimental effects observed in carnitine supplemented 
conditions a linear correlation to carnitine concentration was observed. In all cases a 
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carnitine related effect was observed from concentrations of 100 mgL-1 (0.5 mM) 
upwards, in solid media. In liquid media, cells that were ptregrown at concentrations of 1 
mg/l of carnitine displayed significantly better survival than cells grown in the absence of 
carnitine, indicating that carnitine excerts protective affects at concentrations found in 
natural systems. The requirement for higher carnitine levels on solid media can possibly 
be accounted for by limited carnitine uptake) by the carnitine carrier Agp2 which is 
subject to glucose repression. Carnitine uptake in these conditions was reported to be 
only ~ 5% of carnitine uptake under non-repressed conditions (Van Roermund et al, 
1999; Stella et al, 2005). In the same studies it was also shown that carnitine added at 
higher concentrations (0.5 mM) could compensate for deletion of Agp2p, which may 
account for the concentration dependence of the carnitine phenotypes on solid glucose 
media. It seems therefore likely that carnitine is required at higher concentrations in 
solid media to provide a sufficient localized carnitine concentration around the growing 
colonies. 
A protective effect for carnitine against the generation of intracellular ROS has been 
extensively described in mammalian systems (Binienda et al, 2006; Savitha et al, 2005; 
Sachan et al, 2005). Using the ROS sensitive probe DCFH-DA we show that carnitine 
indeed protects against ROS formation in S. cerevisiae. Such findings have in some 
cases been explained by a possible antioxidant activity of carnitine (Calo et al, 2006), 
while other studies have indicated no such activity (Rhemrev et al, 2000). Our data 
confirm that carnitine has no free radical scavenging activity when used in the ABTS 
decolouration assay. The 1,1-diphenyl-2-picryl-hydrazyl (DPPH) free radical scavenging 
assay that was used in a previous study to indicate carnitine’s free radical scavenging 
capacity has been indicated to be a less chemically sound and valid measurement than 
the ABTS scavenging assay used in this study (Gulcin 2006; Huang et al, 2005). When 
using carnitine in yeast based system to screen for antioxidant potential, the molecule 
exhibited phenotypes strikingly similar to the phenotypes previously reported for known 
antioxidants. In summary, carnitine performs similar to an antioxidant in a biological 
context, but is not an antioxidant itself. This suggests the effect of carnitine to be 
mediated by genetic factors, similar to the antioxidant selenium (Rayman et al, 2000). 
The data show that carnitine requires the central regulators YAP1 or SKN7 as well as 
genes central to metabolism of the cellular antioxidant glutathione, namely GSH1 and 
GLR1 to protect against oxidative stress. This reflects the central role of these factors in 
oxidative stress protections and further strengthens the assumption that the effect of 
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carnitine is not due to a chemical activity of the compound itself. The presence of 
carnitine was able to enhance growth of strains that did not produce the enzymes 
Sod2p, Tsa1p, and Trx2p, which function in an antioxidant capacity downstream of 
regulators such as Yap1p. 
The effect of carnitine supplementation on global gene expression of peroxide 
stressed cultures was evaluated and several genes were found to be differentially 
expressed, confirming carnitine’s involvement in the regulation of gene expression. To 
establish if any of the genes upregulated above a 1.8 fold cut-off is required for 
carnitine-dependent protection, we evaluated representative deletion strains of the 
identified genes on H2O2 and DTT containing plates for responsiveness to carnitine. Of 
all strains tested, only deletion of the cytochrome c heme lyase, CYC3, led to a notable 
reduction in response to carnitine. This was found to be the case for both H2O2 and 
DTT. In addition, the effect of CYC3 deletion is similar to deletion of both cytochrome 
c’s, CYC1 and CYC7, indicating the effect to be caused by the absence of cytochrome c 
in the Δcyc3 strain. Since deletion of CYC3 leads to a reduced responsiveness to 
carnitine and multi-copy expression has no discernable effect it can be concluded that 
CYC3 is required for growth enhancement by carnitine, but not exclusively involved in 
the effect of carnitine. Interestingly, both CYC1 and CYC7 are upregulated by H2O2 
stress, but CYC3 expression is only induced once carnitine is added to the media. If the 
function of CYC3 is rate limiting under these conditions, its increased expression would 
explain its contribution to the protection of carnitine. In general, the integrity of the 
electron transport chain is required for resistance to H2O2. Increased cytochrome c 
content by enhancing expression of CYC3 or CYC1 and CYC7 can specifically be of 
benefit during oxidative stress conditions by (i) playing a role in the regulation of 
apoptosis caused by oxidative damage (Eisenberg et al, 2007), (ii) a suggested 
antioxidant function of cytochrome c itself (Forman and Azzi, 1997; Skulachev, 1998) 
and (iii) its role in the respiratory chain helping to keep H2O2 and superoxide at a lower 
physiological level (Zhao et al, 2003). 
Previous data have established a positive effect of carnitine on mitochondrial 
metabolism. This has been suggested to be caused by the stimulatory effect of the 
carnitine shuttle on mitochondrial functions (Hagen et al, 1998; Zhu et al, 2008). The 
results of this study present the first report that carnitine may act more specifically 
through other genetic systems, specifically by inducing the expression of CYC3, which 
directly impacts on mitochondrial function and also on resistance to oxidative stresses. 
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Future work will focus on the further elucidation of the role played by CYC3 in this 
context and also the identification of upstream factors involved in the regulation of the 
effects carnitine has on cellular physiology. 
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5.1. INTRODUCTION 
 
In eukaryotes the primary function of L-carnitine is as a shuttling molecule, transferring 
the intermediates of energy metabolism between intracellular compartments (Bremer, 
1983). Carnitine has been shown to have therapeutic potential, due to its stimulatory 
action on mitochondrial metabolism and also by balancing limited and 
compartmentalized pools of CoA and Acyl-CoA. Aside from carnitine’s central role in 
energy metabolism, several studies have reported beneficial effects associated with 
carnitine supplementation at concentrations above physiological levels that appear to be 
regulated by genetic factors. For instance, carnitine’s beneficial effect in 
neurodegenerative conditions, such as Alzheimer’s disease, have recently been 
proposed to be mediated by the transcriptional induction of factors such as heat shock 
proteins and HO-1 that are associated with cellular stress protection (Calabrese et al, 
2006). Furthermore, carnitine has been shown to have regulatory consequences on the 
induction of apoptosis by directly interacting with the Fas receptor system, inhibition of 
caspases 3, 7 and 8 and also inhibiting the mitochondrial permeability transition (Moretti 
et al, 1998; Mutomba et al, 2000; Pastorino et al, 1993). The mechanism by which these 
effects are achieved remains to be defined. 
Recently, carnitine has been shown to have a protective effect on yeast cultures 
during oxidative and organic acid stresses (Franken et al, 2008). The effect of carnitine 
supplementation was further investigated in chapter 4 of this thesis and shown to 
require the presence of the major factors, Yap1p and Skn7p, involved in oxidative stress 
protection. Furthermore, in an initial microarray based screen of genes upregulated by 
carnitine supplementation in cultures exposed to H2O2, a role for the cytochrome c 
heme lyase, Cyc3p, and the two yeast cytochrome c’s, Cyc1p and Cyc7p, was 
described in the mediation of carnitine related effects during redox related stresses. 
Although the involvement of cytochrome c could indicate mediation of apoptotic 
processes, this hypothesis still needs to be substantiated. 
This work presents a detailed analysis of the effect of carnitine supplementation on 
genome wide transcription. Microarray analysis was performed on growing cultures of 
wild type (BY4742) cells, with and without carnitine supplementation, and also similar 
cultures exposed to oxidative stress induced by the addition of H2O2. The results of the 
data generated by DNA microarrays were analyzed by assessing enrichment of 
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functional classification within sets of differentially expressed genes and also by cluster 
analysis of the data derived from the microarray analysis. In addition, possible links to 
apoptotic pathways were investigated by projecting the expression data onto known 
interaction pathways. The result of this analysis lays the foundation for further studies 
on carnitine’s role in redox related stresses. 
5.2. MATERIALS AND METHODS 
5.2.1. MICROARRAY ANALYSIS 
 
Cultures of the wild type strain BY4742 were grown overnight in SCD containing tubes 
to serve as pre-cultures. Two flasks containing 50 ml of freshly prepared SCD media 
and also two containing SCD with carnitine (1000 mgL-1) was inoculated to an O.D.600 ~ 
0.1 and grown to mid-log phase (O.D.600 0.4 -.0.5). A duplicate set was also inoculated 
and exposed to 0.4 mM H2O2 for 30 min before harvesting and isolation of total RNA. 
RNA was isolated as previously described (Schmitt et al, 1990). The quality of total 
RNA, cDNA, cRNA and fragmented cRNA were confirmed using the Agilent Bioanalyzer 
2100. Probe preparation and hybridization to Affymetrix Genechip® microarrays were 
performed according to Affymetrix instructions, starting with 6 μg of total RNA. Results 
for each condition were derived from 2 independent culture replicates. Gene chips were 
scanned using GeneChip® Scanner 3000. Acquisition of array images and were 
performed using Affymetrix GeneChip® Operating Software (GCOS) version 1.4. Before 
determination of induction or repression of each gene spot intensities were normalized 
using GC-RMA (Wu and Irazarry, 2004). The fold induction or repression was calculated 
as the ratio between carnitine treated and non-treated cultures for both stresses and 
non-stressed conditions. Genes that changed at least 1.5 fold were considered for 
further analysis. The data discussed in this study have been deposited in NCBI's Gene 
Expression Omnibus (Edgar et al, 2002) and are accessible through GEO Series 
accession number GSE16346  (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= 
GSE16346). Statistical analysis of functional groups was performed by using FUNSPEC 
(Robinson et al, 2002). Cluster analysis was performed using Cluster v 2.12 and 
visualized using Treeview v 1.6 (Eisen et al, 1998). Clusters were analyzed for 
enrichment of functional groups using FUNSPEC (Robinson et al, 2002). Centroid 
linkage hierarchical clustering was performed according to recommendations of the 
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Cluster v 2.12 software manual, except for using log-untransformed data (since the 
array data was not generated using a two-dye system). 
5.3. RESULTS AND DISCUSSION 
5.3.1. EFFECT OF NORMALIZATION METHOD CHOICE 
 
In the initial analysis of the microarray data described in chapter 4, the expression 
values was calculated using the Affymetrix GeneChip® Operating Software (GCOS) 
version 1.4, which calculates expression based on a weighed median (Affymetrix: 
Microarray Suite User Guide http://www.affymetrix.com/support/technical/manuals.affx). 
The outcome of this analysis presented difficulties in the interpretation of data for 
signals of a lower intensity, which constitute the majority of genes affected by carnitine 
supplementation. Although the data could be used to generate the screenable set of 
genes described in chapter 4, the variances in expression values, especially below 2 
fold differential expressions, prevents the generation of a large enough set of genes 
which can be used for analysis such as clustering or enrichment of functional 
categories. Therefore, the generated arrays were re-normalized using GC-RMA for 
further analysis (Wu and Irazarry, 2004). This method is founded on a model-based 
algorithm, which incorporates the expression of multiple microarrays to calculate the 
expression of a specific gene, compared to the use of one microarray for normalization 
in GCOS. The use of such a model based algorithm can be expected to generate more 
reproducible results, since probe response patterns are fitted over multiple arrays, 
which detects and excludes abnormally behaving probes. The outcome of this 
normalization method generally provided less variance in expression values and results 
in the generation of larger usable gene sets that are significantly induced or repressed. 
In addition, the use of GC-RMA for normalization enabled the use of a lower fold 
expression cut-off value at 1.5. 
5.3.2. DIFFERENTIAL GENE EXPRESSION EFFECTED BY CARNITINE 
SUPPLEMENTATION IN YEAST 
 
To establish the effect of carnitine supplementation on genome wide transcription, 
microarray analysis was performed on cultures of the wild type strain BY4742 that were 
grown in minimal media to mid-log phase and also a separate culture set that was 
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grown in similar media supplemented with carnitine (1000 mgL-1). In addition, a set of 
similarly treated yeast cultures (with and without carnitine supplementation) was 
exposed to 4 mM H2O2 to induce oxidative stress. The data from this experiment was 
used to asses the effect of carnitine on global gene transcription in conditions of 
oxidative stress. Enrichments of functional categories for genes which are up and 
downregulated, when comparing wild-type cultures to carnitine supplemented cultures 
are presented in Table 5.1. Table 5.2 lists enriched categories when H2O2 treated 
cultures with and without carnitine are compared. To distinguish between the effect of 
carnitine and the effect of H2O2 addition, the genes that were found to be differentially 
expressed by the presence of carnitine in conditions of oxidative stress were aligned 
and clustered in comparison with the expression values for the same genes under 
normal growing conditions (wt) and carnitine supplemented conditions (wt + C) (Figure 
5.1 and Table 5.3). 
Carnitine supplementation resulted in the induction of 41 genes and the repression 
of 86 transcripts ( 1.5 fold). Genes included in the functional categories of dipeptide 
transport (GO:0042938; p-value, 0.0001124) and regulation of DNA metabolism 
(GO:0051052; p-value, 3.543e-05) were represented among the genes induced by 
carnitine. Also included in the set of upregulated genes are cell wall associated genes 
(GO:0009277; p-value, 7.001e-06), which contains a group of cell wall mannoproteins of 
the Srp1p/Tip1p family (DAN1, TIR2, TIR3, TIR4) that have been shown to be induced 
by cellular stresses (Kowalski et al, 1995; Cohen et al, 2001). The genes that were 
downregulated by carnitine supplementation group into two main categories, one of 
which is a group associated with metal homeostasis including the functional groupings 
of iron ion binding (GO:0005506; p-value, 0.0001011), iron ion transport (GO:0006811; 
p-value, 1.853e-05) and copper ion transport ([GO:0015677; p-value, 1.805e-06). A 
second group of functionally enriched genes are associated with the metabolism of 
reserve energy carbohydrates and complex sugars and include the functional 
classifications of metabolism of energy reserves (e.g. glycogen and trehalose) (MIPS: 
02.19; p-value, 6.874e-06), sugar, glycoside, polyol and carboxylate metabolism (MIPS: 
01.05.02.07; p-value, 0.0006086) and maltose metabolism (GO:0000023; p-value, 
0.0004312). Furthermore, the downregulated gene set also contains the functional 
categories of phosphate transport (GO:0005315; p-value, 0.0002397) and membrane 
fusion (GO:0006944, p-value, 0.0008668). 
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Table 5.1. Functions overrepresented for wild type vs wild type + carnitine. 
Classification p Genes Sourcea 
Upregulated 
 
Catabolism of nitrogenous 
compounds 
 
Regulation of DNA metabolic 
process 
 
Dipeptide transport 
 
 
Fungal-type cell wall 
 
0.0003718 
 
 
3.543e-05 
 
 
0.0001124 
 
 
7.001e-06 
 
DAL7 DAL3 
 
 
NSE4 RAD55 PSY3 
 
 
DAL5 PTR2 
 
 
FIT1 TIR3 DAN1 YGP1 HPF1 TIR4 TIR2 
 
1 
 
 
3 
 
 
3 
 
 
3 
Downregulated 
 
Metabolism of energy reserves 
(e.g. glycogen, trehalose) 
 
Sugar, glucoside, polyol and 
carboxylate catabolism 
 
Heavy metal ion transport 
(Cu+, Fe3+, etc.) 
 
Phosphate transport 
 
Iron ion binding 
 
Iron ion transport 
 
Copper ion import 
 
Carbohydrate metabolic 
process 
 
Ion transport 
 
Maltose metabolic process 
 
Membrane fusion 
 
 
6.874e-06 
 
 
0.0006086 
 
 
0.0001728 
 
 
0.0003264 
 
0.0001011 
 
4.111e-06 
 
1.805e-06 
 
9.222e-06 
 
 
1.853e-05 
 
0.0004312 
 
0.0008668 
 
 
MAL32 GLC3 GIP2 GSY1 YGR287C YIL172C PGM2 ATH1 
 
 
GAL7 MAL32 XKS1 YGR287C YIL172C PGM2 ATH1 
 
 
FRE2 FRE1 PHO84 FET4 CTR1 
 
 
PHO89 PIC2 PHO84 
 
GAL7 CYC7 AIM17 ARN2 FRE2 FRE1 FET4 ENB1 FRE3 FIT2 PDH1 
 
ARN2 FRE2 FRE1 FET4 ENB1 FRE3 FIT2 
 
FRE2 FRE1 FET4 CTR1 
 
GAL7 MAL32 GLC3 XKS1 YGR287C YIL172C PGM2 YNR034W-A 
MDH2 YPL014W ATH1 
 
HSP30 ARN2 SPL2 FRE2 FRE1 FET4 ENB1 FRE3 FIT2 CTR1 
 
MAL32 YGR287C MAL11 YIL172C 
 
SPL2 PHO84 CTR1 
 
1 
 
 
1 
 
 
1 
 
 
2 
 
3 
 
 
3 
 
3 
 
3 
 
 
3 
 
3 
 
3 
 
aSource refers to classification source: 1, MIPS functional classification; 2, GO molecular function; 3, GO biological process. 
Classifications with p< 0.005 are shown. 
 
Genes in cluster A (Figure 5.2; Table 5.3) were also enriched in the functional 
category of iron homeostasis (GO:0006879; p-value, 0.001509). Genes in this cluster 
were generally induced by H2O2, whereas carnitine addition lowered expression in both 
wt and also H2O2 treated cultures. Iron homeostasis plays a central role in oxidative and 
specifically H2O2 induced stresses, since transition metals such as Fe2+ catalyze the 
formation of highly reactive hydroxyl radicals via the Fenton reaction (Halliwel and 
Aruoma, 1991; Perrone et al, 2008). Included in this group of genes is the transcription 
factor AFT2 (which regulates genes involved in iron homeostasis and oxidative stress), 
ISU1 (which performs a scaffolding function during assembly of iron-sulfur clusters and 
interacts physically and functionally with yeast frataxin, Yfh1p), MMT1 (involved in 
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mitochondrial iron accumulation), NFU1 (required for the maturation of Fe/S clusters). 
Interestingly, carnitine has previously been shown to protect yeast cells against 
exposure to high iron concentrations (Stella et al, 2005). It would certainly be of interest 
to further investigate the impact of carnitine on cellular iron homeostasis. 
Additional groupings in this cluster (A), which share similar expression patterns, 
includes the cellular responses to toxins (GO:0009636; p-value, 7.132e-08) and reactive 
oxygen species (GO:0000302; p-value, 0.0002457 ) and also genes involved in 
autophagy (GO:0006914; p-value, 0.000387). Furthermore, two genes from the y-AP1 
family, YAP7 and YAP4/CIN5, which regulate transcription in response to environmental 
stresses, are included in cluster A. 
Under conditions of oxidative stress carnitine supplementation increased the 
expression of 290 gene products and resulted in decreased expression of 303 genes ( 
1.5 fold). An interesting scenario presents itself in the categories of genes induced by 
carnitine under oxidative stress, in the sense that a prominent feature of this group 
involves enrichment of functional categories involved in carbon and carbohydrate and 
reserve energy metabolism [regulation of c-compound and carbohydrate metabolism 
(MIPS: 01.05.25, p-value, 0.0001137), carbohydrate transport (GO:0008643; p-value, 
6.002e-06), carbohydrate metabolic process (GO:0005975; p-value, 2.419e-05) and 
glycogen catabolism (GO:0005980; p-value, 8.388e-05)]. This is interestingly 
reminiscent of the categories regulated by carnitine in the absence of an oxidative 
stress signal, except that genes involved in glycogen synthesis and accumulation were 
downregulated in wt cultures, whereas glycogen catabolic genes were upregulated 
during oxidative stress by the presence of carnitine. A group of genes involved in 
glycogen metabolism is also represented in cluster B, which contains genes that are 
upregulated by carnitine, mostly in an oxidative stress dependent manner. Included in 
this set of genes are GPH1 (required for the mobilization of glycogen and expression 
regulated by stress-response elements and by the HOG MAP kinase pathway), GIP2 
and GAC1. The latter two genes are also included in the categories enriched from 
genes induced by carnitine under oxidative stress and form part of the protein 
phophatase I (PPI) complex (GO:0000164; p-value, 0.0001149), which includes REG2, 
encoding a protein involved in glucose repression, GIP2 and PIG1, which are both 
involved the regulation of glycogen metabolism and also GAC1, which is the PPI 
regulatory subunit that mediates glycogen metabolism and also the induction of genes 
involved in the response to heat shock. 
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Table 5.2. Functions overrepresented for wild type treated with H2O2 without carnitine vs. with carnitine. 
Classification p Genes Sourcea 
Upregulated 
 
Regulation of C-compound 
and carbohydrate metabolism 
 
Carbohydrate transport 
 
Carbohydrate metabolic 
process 
 
Transmembrane transport 
 
Glycogen catabolic process 
 
Proline catabolic process 
 
 
Protein phosphatase type 1 
complex 
 
RNA polymerase I 
transcription factor complex  
 
 
0.0001137 
 
 
6.002e-06 
 
2.419e-05 
 
 
3.158e-05 
 
8.288e-05 
 
0.0003246 
 
 
0.0001149 
 
 
0.000785 
 
 
 
REG2 MAL33 ADY2 SNF3 GAL3 MTH1 GIP2 MIG1 MIG2 RPI1 PIG1 
CAT8 ATO2 RAS1 GAC1 SWI1 
 
MAL31 SNF3 HXT7 MIG2 MAL11 HXT4 HXT5 YKR075C HXT2 HXT11 
 
MAL33 GAL3 MIG1 AMS1 MIG2 GUT1 HXT4 YHR210C SGA1 RPI1 
GUT2 XYL2 PGM2 CAT8 YNR071C HPF1 GPH1 GDB1  
 
MAL31 SNF3 HXT7 MAL11 HXT4 HXT5 HXT2 HXT11 
 
SGA1 GPH1 GDB1 
 
PUT3 PUT1 PUT4 
 
 
REG2 GIP2 PIG1 GAC1 
 
 
RRN7 RRN3 RRN11 
 
 
1 
 
 
 
2 
 
2 
 
 
2 
 
2 
 
2 
 
 
4 
 
 
4 
 
Downregulated 
 
biosynthesis of arginine 
 
mating 
 
 
purine nucleotide anabolism 
 
metabolism of nonprotein 
amino acids 
 
iron-sulfur cluster binding 
 
catalytic activity 
 
 
 
 
 
aromatic compound metabolic 
process 
 
 
amino acid biosynthetic 
process 
 
organic acid metabolic process 
 
sexual reproduction 
 
response to toxin 
 
 
propionate metabolic process 
 
 
1.89e-08 
 
5.866e-06 
 
 
5.66e-05 
 
4.102e-05 
 
 
0.0001424 
 
0.0001136 
 
 
 
 
 
3.01e-11 
 
 
 
1.29e-08 
 
 
3.037e-07 
 
3.71e-07 
 
4.33e-05 
 
 
0.0001363 
 
 
ARG5,6 ARG4 ARG3 CPA2 ECM40 ARG1 ARG8 ORT1 
 
FIG1 FUS1 KAR4 HO SPR3 PRM2 PRM10 SAG1 BFA1 PRM6 KAR5 
SCW10 AGA1 PRM3 
 
ADE1 HIS7 HIS4 ADE5,7 ADE6 ADE17 ADE12 ADE2 
 
YAT2 ARG5,6 ARG3 ECM40 ARG8 
 
 
GLT1 ACO2 ECM17 NFU1 ISA1 ACO1 ISU1 PDH1 
 
ADE1 ACH1 GAL7 MET8 PYC2 HIS7 HIS4 YCR102C GPM2 GLT1 
ALT2 SUR2 ARO10 PHM8 ARG5,6 STR3 ADE5,7 ADE6 SER2 SPO11 
ARG4 DOG1 LYS1 INO1 URA8 CPA2 ECM17 MAE1 URA1 YLL056C 
SHM2 YLR460C ECM40 ADE17 GAS3 SCW10 BIO3 GPD2 ARG8 
LEU9 ADE2 YPL033C 
 
PYC2 GCV1 ARG5,6 MET13 LYS1 ARG3 CPA2 ECM17 DRE2 
ECM40 SNO1 GCV2 NRK1 ARG1 GPD2 ADE2 ORT1 SSU1 
 
 
MET8 HIS7 HIS4 GLT1 HOM3 HIS1 ARG5,6 STR3 SER2 ARG4 LYS1 
ARG3 CPA2 ECM17 MET1 ECM40 ARG1 ARG8 LEU9 ORT1 MET16 
 
PYC2 ARG5,6 YJR111C ECM17 MET1 CTF13 ARG1 ORT1 
 
FIG1 FUS1 KAR4 PCL2 GIC2 PRM6 FUS2 PRM1 AGA1 
 
YCR102C YDR132C ATF2 RTA1 YKL070W YLL056C YLR108C 
YLR346C YLR460C YNL260C YOL163W RSB1 MET16 
 
ACO1 PDR12 CIT3 PDH1 
 
 
1 
 
1 
 
 
1 
 
1 
 
 
2 
 
2 
 
 
 
 
 
2 
 
 
2 
 
 
2 
 
 
2 
 
2 
 
 
2 
aSource refers to classification source: 1, MIPS functional classification; 2, GO molecular function; 3, GO biological process; 4, GO 
cellular component. Classifications with p< 0.005 are shown. 
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Figure 5.1. Clustered display of data from all genes differentially expressed (using a 1.5 fold cut-off) 
by carnitine addition under conditions of oxidative stress that is aligned with wild type cultures and 
wild type cultures supplemented with carnitine. Each gene is represented by a single coloured line, 
with red colouring indicating up and green downregulation, and each condition is represented by a 
single column. Five separate clusters are indicated by bars (A-E), the enriched classes for the genes 
in each cluster is presented in Table 5.3. 
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Table 5.3. Functions overrepresented in clusters A-E. 
Cluster Classification P Genes Sourcea 
 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
D 
 
 
 
 
 
 
 
 
 
 
 
 
 
E 
 
 
 
 
 
 
 
 
 
 
 
 
Response to toxin 
 
 
 
Response to ROS 
 
Autophagy 
 
 
 
Cellular iron ion homeostasis 
 
Water transport 
 
Glycogen metabolic process 
 
Fatty acid metabolic process 
 
Metabolic process 
 
 
Metal ion binding 
 
 
DNA binding 
 
 
Aromatic compound metabolism 
 
 
Amino acid biosynthetic process 
 
 
Glycine metabolic process 
 
Purine nucleotide biosynthesis 
 
 
Cell cycle 
 
 
Ribosome biogenesis 
 
 
 
RNA modification 
 
rRNA metabolic process 
 
 
Transcription from RNA 
polymerase I promoter 
 
 
7.132e-08 
 
 
 
0.0002457 
 
0.000387 
 
 
 
0.001509 
 
0.0002671 
 
0.000974 
 
0.003371 
 
0.003652 
 
 
0.0002795 
 
 
0.006955 
 
 
8.744e-10 
 
 
6.518e-06 
 
 
1.501e-05 
 
2.423e-05 
 
 
0.0004786 
 
 
2.108e-05 
 
 
 
7.992e-05 
 
0.0001021 
 
 
0.006239 
 
 
 
YCR102C YDR132C RTA1 YKL070W YLL056C 
YLR108C YLR346C YLR460C YNL260C YOL163W 
 
 
CTA1 CTT1 
 
FES1 YDR132C CTH1 ARO10 STR3 VEL1 PEF1 
YKL070W YLR108C APJ1 YNR068C ATG29 
 
 
CTH1 NFU1 MMT1 ISU1 AFT2 
 
AQY2 AQY1 
 
GIP2 GAC1 GPH1 
 
POX1 MGA2 CRC1 
 
TKL2 YDL144C GAL3 YDR018C POX1 GND2 
LAS21 XYL2 YIM1 ABZ1 
 
RPO21 GIS1 MRP1 PUT3 MUB1 RGM1 CAT8 
FAP1 MGS1 LEE1 
 
RPO21 GIS1 PLM2 PUT3 MUB1 RGM1 CAT8 
MGS1 
 
PYC2 GCV1 ARG5,6 MET13 CPA2 ECM17 GCV2 
NRK1 ARG1 ADE2 SSU1 
 
HIS7 GLT1 HIS1 ARG5,6 SER2 CPA2 ECM17 
ARG1 ARG8 LEU9 
 
GCV1 SHM2 GCV2 
 
ADE1 ADE5,7 ADE6 ADE17 ADE12 ADE2 
 
 
ALK2 MCD1 PDS1 ALK1 CDC20 SCM4 DBF2 BFA1 
BUD4 CLB4 HOF1 IQG1 CLN2 CLB2 
 
MAK16 YBL081W FUR4 GFD2 ATF2 RRN7 
SAP185 ALB1 TOR1 YEH1 RRS1 YPL068C RSA1 
 
 
FUR4 GFD2 HO MRS2 YPL068C RSA1 
 
YBL081W FUR4 GFD2 ATF2 RRN7 YEH1 YPL068C 
RSA1  
 
FUR4 RRN7 MOT3 
 
 
 
2 
 
 
 
3 
 
3 
 
 
 
 
3 
 
3 
 
3 
 
3 
 
 
3 
 
 
2 
 
 
 
2 
 
 
3 
 
 
3 
 
3 
 
 
3 
 
 
3 
 
 
 
3 
 
3 
 
 
3 
 
 
aSource refers to classification source: 1, MIPS functional classification; 2, GO molecular function; 3, GO biological process; 4, 
GO cellular component. Classifications with p< 0.005 are shown. 
 
Genes involved in the utilization of proline (GO:0006562; p-value0.0003246) are 
also upregulated under carnitine supplemented conditions during oxidative stress. The 
three genes in this grouping are PUT4, an integral membrane proline transporter, PUT1, 
which catalyzes the initial step in proline catabolism and PUT3, a 
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transcriptionalregulator of genes involved in proline degradation. Proline is degraded by 
this pathway to glutamate, which can either feed into the TCA cycle as -ketogluterate 
or act as a precursor for the biosynthesis of the cellular antioxidant glutathione (Takagi, 
2008).  
Proline, along with glycerol and glycogen, is considered to play an integral role in 
cellular stress protection. Interestingly the genes encoding the enzymes required for the 
degradation of glycerol, GUT1 and GUT2, are also upregulated by carnitine during 
oxidative stress. These enzymes form part of the glycerol-3-phosphate dehydrogenase 
shuttle, which presents an alternative means, aside from the electron transport chain, 
for the oxidation of glycolytic NADH without the production of O2- (Larsson et al, 1998). 
GPD2, which also forms part of this shuttle, is downregulated by the presence of 
carnitine during oxidative stress (Table 5.2). 
The genes involved in glycerol degradation are represented in the functional category 
of carbohydrate metabolic process (GO:0005975; p-value, 2.419e-05), which includes 
the central transcriptional regulators of carbon metabolism, MIG1, MIG2 and CAT8 and 
also RPI1, a putative transcriptional regulator which, when overexpressed, suppresses 
the heat shock sensitivity of RAS2 overexpression (Kim and Powers, 1991). CAT8 is 
also represented in cluster C, made up of genes induced by carnitine in wild-type and 
H2O2 treated cultures. This cluster contains several genes coding for metal dependent 
DNA binding factors, which include PUT3, RPO21 (largest subunit, B220, of RNA 
polymerase II), GIS1 (transcription factor involved in the expression of genes during 
nutrient limitation), MUB1 (required for ubiquitylation and degradation of Rpn4p, which 
stimulates expression of proteasome genes in response to various stress signals), 
FAP1 (confers rapamycin resistance by competing with rapamycin for Fpr1p binding), 
PLM2 (induced in response to DNA damaging agents and deletion of telomerase) and 
the zinc-finger protein LEE1. Several of these factors are induced by cellular stresses or 
involved in the regulation of carbon metabolism along with the cellular stress response 
and present attractive targets for further investigation. 
Genes enriched for in cluster B under the category metabolic process (GO:0008152; 
p-value, 0.003652) contain three genes associated with the pentose phosphate pathway 
(TKL2, GND2, XYL2). Genes involved in the pentose phosphate pathway have been 
shown to be required for resistance to the superoxide generating agent, menadione 
(Thorpe et al, 2004). Interestingly, cluster B also contains the cytochrome c heme lyase, 
Cyc3p, which has been shown to be required for carnitine’s protective function against 
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H2O2 (Chapter 4). Two genes required for cytochrome c oxidase function (COX20 and 
COX23) that are also part of this cluster, are also upregulated by carnitine in an 
oxidative stress specific manner. The enhanced expression of these three proteins 
could be expected to have an impact on the terminal end of the electron transport chain 
that reduces O2- formed by oxidative phosphorylation (Herrero et al, 2008). 
The set of genes downregulated by carnitine supplementation during oxidative 
stress include several functional categories associated with amino acid and purine 
biosynthesis, namely arginine biosynthesis (MIPS: 01.01.03.05.01; p-value, 1.89e-08), 
purine nucleotide metabolism (MIPS:01.03.01.03; p-value, 3.305e-05), aromatic 
compound metabolic process (GO:0006725; p-value, 3.016e-11) and amino acid 
biosynthetic process (GO:0008652; p-value, 1.29e-08). These genes are mostly 
grouped in cluster D along with genes involved in cell cycle regulation (GO:0007049; p-
value, 0.0004786) and organic acid metabolism (GO:0006082; p-value, 0.0001181). 
The expression patterns of genes within this cluster are characteristically downregulated 
upon exposure to H2O2 and see a further slight decrease in transcription in the presence 
of carnitine. The overall pattern, however, suggests the observed expression decrease 
to be as a result of the impact of H2O2 on the cell, which would expectedly lead to cell 
cycle arrest and also reduction in energy consuming biosynthesis pathways in order to 
direct more cellular energy towards stress related defences. 
Genes involved in mating and sexual reproduction (GO:0019953; p-value, 3.71e-07) 
were also enriched among transcripts downregulated by carnitine during oxidative 
stress (Table 5.2). This category includes several genes regulated by the pheromone 
responsive MAPK pathway (FUS1, KAR4, SPR3, PRM2, PRM10, PRM6, SCW10, 
PRM3). This signaling network has been shown to have an impact on the regulation of 
apoptosis and in combination with the high osmolarity glycerol (HOG) pathway 
regulates gene expression of genes in response to environmental stresses, including 
exposure to various oxidants (Zhang et al, 2006; Stavela et al, 2004). 
The expression of a group of iron-sulfer cluster binding proteins is also 
downregulated by carnitine (Table 5.2). This groups includes both mitochondrial 
aconitases (ACO1 and ACO2), which is required for the tricarboxylic acid (TCA) cycle 
and also independently required for mitochondrial genome maintenance (Chen et al, 
2005). Aconitases catalyze the interconversion of citrate and isocitrate, and aconitase 
activities are affected by iron levels, oxidative stress and by the status of the Fe–S 
cluster biogenesis apparatus (for review see Tong and Rouault, 2007). Additional 
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mitochondrial iron metabolism genes represented in this group includes NFU1 (involved 
in iron metabolism in mitochondria), ISA1 (involved in biogenesis of the iron-sulfur 
(Fe/S) cluster of Fe/S proteins) and ISU1 (performs a scaffolding function during 
assembly of iron-sulfur clusters, interacts physically and functionally with yeast frataxin, 
Yfh1p). 
Cluster E was enriched specifically for genes that are involved in ribosomal and 
RNA regulation, which includes the categories of ribosome biogenesis (GO:0042254; p-
value, 2.108e-0), RNA modification(GO:0009451; p-value, 7.992e-05), rRNA metabolic 
process (GO:0016072; p-value, 0.0001021) and transcription from RNA polymerase I 
promoter (GO:0006360; p-value, 0.006239). Genes in this cluster are upregulated by 
carnitine addition in both wild type and peroxide treated cultures, while H2O2 exposure 
downregulated expression compared to wild type. Genes of specific interest within 
these enriched categories are the TOR1 kinase, which functions as a subunit of 
TORC1, a complex that controls growth in response to nutrients by regulating 
translation, transcription, ribosome biogenesis, nutrient transport and autophagy 
(Wullschleger et al, 2006). The regulatory effects of the TORC1 complex have also 
been indicated to influence life-span by regulating mitochondrial metabolism (Scheike 
and Finkel, 2007). TORC1 complex mediated regulation has been shown to require the 
activity of the Sch9p protein kinase (Urban et al, 2007). Interestingly, transcription of 
SCH9 is also upregulated by carnitine supplementation and follows a similar expression 
pattern to that of TOR1 (data not shown). Furthermore, the two transcription factors 
AFT2 and MOT3 also group in cluster E. AFT2, has been previously discussed for its 
role in the regulation of iron homeostasis. The Mot3p transcription factor is involved in 
repression of a subset of hypoxic genes by Rox1p, as well as of several DAN/TIR genes 
during aerobic growth and repression of ergosterol biosynthetic genes (Grishin et al, 
1998; Sertil et al, 2003).  
Enhanced expression of TOR1 and SCH9 is, however, generally associated with a 
decrease in stress resistance and an increase in apoptosis and both chronological 
(CLS) replicative life-span (RLS). Furthermore, deletion of RAS1, which is also 
upregulated by carnitine, results in an extension of RLS, while slightly decreasing CLS. 
In the case of TOR1, this has been shown to be caused by the inhibition of the 
transcription factors MSN2 and MSN4, which are required for the activation of the 
general stress. Deletion of SCH9, has been shown to result in chronological life-span 
extension independent of MSN2/MSN4, but requires the activation of the RIM15 kinase 
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for activation of stress response genes (reviewed in Kaeberlein et al, 2007). The 
increased expression of these kinases could account for some of the differential 
expression patterns observed for carnitine supplementation, such as the increase in 
reserve carbohydrate metabolism, the effects on carbon metabolism, the increase in 
ribosomal biogeneis and the decrease in autophagy.  
This could provide an interesting explanation for the observed effect of carnitine in 
combination with various redox stress inducing agents (Chapter 5). Since, carnitine was 
shown to only protect specifically against H2O2 and menadione induced oxidative 
stresses and not exert general protection aganist oxidative stressors, it seems likely that 
the effect of carnitine is not due to an activation of general oxidative stress responses, 
but could be accounted for by the effect of carnitine on iron homeostasis and 
mitochondrial metabolism (which should aleviate the effects of H2O2 and superoxide 
generation by menadione) and possbly also activation of pentose phosphate 
assoctiated genes (which would specifically be required for menadione resistance). 
Exposure of cells to thiol modifying agents (DTT and diamide), would be expected to 
disrupt iron homeostasis by targeting iron-sulfur cluster proteins. The inhibition of 
general stress associated pathways associated with enhanced TOR1 and SCH9 
expression, would in such a scenario leave the cell with diminished defenses against 
the stresses caused by these compounds. A further investigation of the interplay 
between the three kinases and also the requirement of iron homeostasis and 
mitochondrial metabolism in carnitine associated phenotypes, would not only enhance 
understanding of carnitine’s effect on cellular physiology, but also further the 
understanding of the functioning of the regulation of stress metabolism in general. 
5.3.3. USING PATHWAY PROJECTIONS TO IDENTIFY CO-ORDINATELY 
REGULATED TRANSCRIPTS 
 
In a different approach to address the possible involvement of putatively carnitine 
specific regulated factors, all the genes that are co-ordinately over or under expressed 
by carnitine supplementation in both wild type and H2O2 treated cultures were identified 
(Figure 5.2). This resulted in the recognition of 41 induced and 20 transcripts that were 
co-ordinately downregulated. Only three transcription factors are included within the 61 
differentially expressed genes, namely YOX1, GAT2 and MGA1. Extracting all genes 
that are potentially up or down regulated (above or below a 1.5 fold change by carnitine 
in the presence of H2O2) by these three transcription factors yields the interaction  
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Figure 5.2. Genes that are co-ordinately over or under expressed (using a 1.5 fold cut-of) by 
carnitine supplementation in both wild type peroxide treated yeast cultures. Red colouring indicates 
induction and blue indicates transcriptional repression. 
 
Figure 5.3. The three transcription factors that are co-ordinately regulated by carnitine 
supplementation to wild type and H2O2 treated yeast cultures and their associated genes. Red 
colouring indicates induction and blue indicates transcriptional repression. 
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network represented in Figure 5.3. It is strikingly visible that any one of the three 
transcription factors directly or inderectly regulates the activity of the other two. 
Furthermore, out of the 155 genes that are affected by YOX1, GAT2 and MGA1, 29 
transcription factors are represented that include a large amount of the transcription 
factors that are regulated by carnitine, with or without oxidative stress. This includes the 
following factors: RTG3, GIS1, INO2, SWI5, MET32, YAP6, PLM2, MIG2, MGA1, XBP1, 
FKH1, SIP4, IME1, PUT3, PHD1, IFH1, YOX1, ARG80, MCM1, MOT3, GAT2, CAT8, 
FKH2, YAP7, CIN5, MSA1, SFG1, AFT2 and ROX1. This is suggestive of a central role 
for these three transcription factor in the regulation of carnitine associated effects under 
condiions of oxidative stress. 
5.3.4. USING PATHWAY PROJECTIONS TO INVESTIGATE POSSIBLE LINKS TO 
APOPTOTIC PATHWAYS 
 
 
Figure 5.4. Apoptosis related genes are indicated along with regulatory factors. Red colouring 
indicates induction and blue indicates transcriptional repression. 
 
Exposing yeast cultures to H2O2 has been indicated to result in cell death by inducing 
apoptosis (Madeo et al, 1999). Furthermore, carnitine administration has been shown to 
regulate apoptotic processes in higher eukaryotic organisms (Moretti et al, 1998; 
Mutomba et al, 2000; Pastorino et al, 1993). In addition, carnitine has been indicated to 
enhance growth of cultures exposed to H2O2 and also drastically diminishes ROS 
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formation, which serves as a primary trigger for apoptotic induction of H2O2 treated 
cultures (Franken et al, 2008; Chapter 4). For these reasons, this work aimed to 
investigate the effect of carnitine supplementation in yeast cultures on the expression of 
apoptosis associated genes after exposure to peroxide stress. As a data mining 
approach, pathway projections were used in order to establish potential connections to 
apoptosis related factors. Apart from establishing links between factors that are 
differentially expressed by carnitine supplementation, this approach adds biological 
significance to lesser expressed transcripts, by placement within the context of 
significantly expressed regulators. 
An extensive search of the Saccharomyces genome database (SGD; 
http://www.yeastgenome.org/) resulted in the identification of 50 genes that are 
associated with apoptotic phenotypes. Projecting these genes onto the yeast 
transcription factor network and filtering out all genes that are not differentially 
expressed (using a fold cut-of of 1.5 for values obtained from H2O2 treated vs H2O2 
treated, carnitine supplemented microarray experiments) extracted a total of 22 
transcription factors that could potentially be associated with apoptosis (Figure 5.2). For 
the purpose of this discussion expression changes are indicated as fold change values 
in brackets, where positive values are upregulated and negative downregulated. 
BIR1 (Baculovirus inhibitor-of-apoptosis repeat containing protein), has been 
indicated to inhibit apoptosis when overexpressed and deletion results in an increase of 
apoptosis (Li et al, 200). Expression of BIR1 is upregulated by carnitine during oxidative 
stress (1.25) and is connected to the transcription factor MGA1 (5.26; similar to heat 
shock transcription factors), which is regulated by KOG1 (-1.24; a subunit of the TORC1 
complex). RAD53 encodes a protein kinase, required for cell-cycle arrest in response to 
DNA damage that has been implicated in the regulation of apoptosis since a reduction 
of RAD53 function was shown to increase the occurrence of apoptosis Walter et al, 
2006). RAD53 expression has a 1.25 fold increase in response to carnitine, which is 
likely to be due to its regulation by the transcriptional activator MAL33 (1.95). The metal 
ion binding protein IZH2 encodes a plasma membrane protein involved in zinc 
metabolism and osmotin-induced apoptosis. A ∆izh2 null mutant displays an absence of 
apoptosis (Morton et al, 2007). The expression of this gene sees a fold increase of 1.4 
in response to carnitine supplementation and is associated with the transcriptional 
activator MGA2 (1.62). The YNK1, nucleotide diphosphate kinase, has been suggested 
to function in a signalling capacity in various species and effects the processes of 
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development, cell differentiation, proliferation, cell motility, tumor metastasis, and 
apoptosis (Amutha and Pain, 2003). The expression of YNK1 is slightly induced (1.1) by 
carnitine and is linked to the transcription factor encoding gene RTG3 (-1.5) that forms a 
complex with Rtg1p, to activate the retrograde (RTG) and TOR pathways (Crespo et al, 
2002). DCP2 encodes the catalytic subunit of the Dcp1p-Dcp2p decapping enzyme 
complex, which removes the 5' cap structure from mRNAs prior to their degradation and 
is also slightly downregulated by carnitine (-1.1). The decrease of DCP2 could possibly 
be accounted for by the reduction in SIP4 expression (-1.9). TOR1 and CAT8 was also 
isolated in this projection, the possible contributions of these factors have been 
described in section 5.3.2 of this chapter. The caspase-like cysteine protease encoding 
gene, ESP1 (Ciosk et al, 1998), is slightly upregulated (1.1) in the tripartite cluster 
regulated by the effects of the transcription factors MIG1 (1.87) and FKH1 (-1.8). The 
ESP1 null mutant is inviable. 
In addition, a central cluster of genes involved in the regulation of apoptosis that is 
co-regulated by the activities of several shared transcription factors. Significant, among 
this group of genes is the cyclin CLN3, which is upregulated by 2.1 fold by the presence 
of carnitine. CLN3 is transcriptionally controlled by the factors KAR4 (-1.5), SWI5 (-4.7), 
XBP1 (2.1), YOX1 (2.2), MCM1 (-2.1) and PHD1 (2.3). CLN3 deletion has been shown 
to result in an increase in apoptosis (Weinberger et al, 2007). PHD1 and YOX1, along 
with the factors YAP6 (1.5), YAP7 (-1.7) and IHF1 (1.8), also co-regulates the 
expression of IZH1 (1.45) which encodes a protein involved in zinc metabolism of which 
a null mutation results in the absence of apoptosis (Morton et al, 2007). YOX1 regulates 
the transcription of DHH1 (1.0), SSA4 (1.0) and SSA3 (1.4) together with GIS1 (1.7). 
SSA3 and SSA4 encode chaperone proteins that comprise the S. cerevisiae SSA 
subfamily of cytosolic HSP70 proteins (Werner-Washburne et al, 1987). However, the 
expression of only SSA3 is significantly increased within this group. SSA3 encodes an 
ATPase involved in protein folding and the response to stress and has been shown to 
protect S. cerevisiae cells that express human alpha-synuclein, the protein that forms 
amyloid fibres in Parkinson disease, from apoptosis (Flower et al, 2005). Deletion of 
DHH1, which encodes a cytoplasmic DExD/H-box helicase that stimulates mRNA 
decapping, has been shown to result in an increase in apoptosis (Mazzoni et al, 2003). 
GIS1, in combination with MOT3 (1.96), regulates the expression of CYC1, encoding 
one of the two yeast cyrochrome c’s, which is only slightly induced (1.16). NDI1 (1.23), 
which encodes a NADH:ubiquinone oxidoreductase that transfers electrons from NADH 
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to ubiquinone in the respiratory chain, is induced by the activities of MCM1 (-2.0) and 
CIN5/YAP4 (-2.4). Deletion of NDI1 has been indicated to result in decreased apoptosis 
(Liang and Zhou, 2007). CIN5/YAP4, which is an transcription factor of the yAP-1 
family, additionally regulates the expression of the genes NUC1 (1.0; major 
mitochondrial nuclease of which overexpression increases apoptosis, while deletion 
reduces apoptotic death) and COX12 (1.0; subunit of cytochrome c oxidase, null mutant 
decreases apoptosis) (Liang and Zhou, 2007; Buttner et al, 2007). 
Seeing that 22 of the differentially expressed transcription factors regulate genes 
involved in apoptotis processes, the involvement of programmed cell death in the 
observed phenotypes associated with carnitine supplemented cultures under peroxide 
stress needs to be considered. It is, however, possible that these processes are 
indirectly affected by the removal of the stress (such as ROS) that would result in 
apoptotic pathway induction. Further phenotypic analysis of the effect of carnitine on 
programmed cell death is required to answer these questions. The identified factors 
present an atrractive starting point for further investigation. 
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ABSTRACT 
 
L-carnitine plays an essential role in eukaryotic energy metabolism by mediating the 
transfer of activated acyl residues between organellar compartments. In eukaryotes, 
including the fungus Neurospora crassa, L-carnitine is biosynthesized through the 
stepwise hydroxylation and dehydrogenation of the precursor trimethyllysine. It has, 
however, been shown that the yeast Saccharomyces cerevisiae is unable to neo-
synthesize carnitine and is entirely dependent on extracellular supplementation. This 
study describes the cloning and characterization of all four of the carnitine biosynthesis 
genes from N. crassa and the reconstruction of the pathway in S. cerevisiae. In addition 
the free lysine methyltransferase from N. crassa, which converts lysine to trimethyllysine 
through sequential methylation was also cloned and heterologously expressed in yeast. 
A preliminary analysis of the engineered strains capacity to produce L-carnitine 
indicates that a strain bearing the reconstructed carnitine biosynthesis pathway is able 
to convert trimethyllysine to L-carnitine.  
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6.1. INTRODUCTION 
 
L-Carnitine functions as a shuttling molecule, which facilitates the transfer of activated 
acyl residues across the membranes of peroxisomes and mitochondria to enable further 
metabolism. This function is supported by the activities of various carnitine acyl-
transferases and transporters, which are collectively referred to as the carnitine shuttle 
(reviewed in Ramsey et al, 2004). The importance of this compound in energy 
metabolism became evident in early studies which attributed various diseases to a 
dysfunction in the carnitine metabolism (reviewed in Longo et al, 2006). In mammalian 
systems, carnitine uptake accounts for about 75% of the systemic requirement, the 
remaining 25% being provided through endogenous biosynthesis (Tein et al, 1996). 
Higher eukaryotes are able to neosynthesize their own carnitine by means of a four step 
biosynthesis pathway, which facilitates the enzymatic hydroxylation and 
dehydrogenation of the pathway’s precursor, trimethyllysine. Mutations in carnitine 
biosynthesis genes can be effectively treated through dietary carnitine supplementation. 
Furthermore, supplementation of either carnitine or acetylcarnitine has been shown to 
be of therapeutic benefit in several diseases associated with mitochondrial function 
(Calabrese et al, 2005). 
Since the initial description of the eukaryotic carnitine biosynthesis pathway in 
Neurospora crassa, the conserved enzymatic activities and most of the genes involved 
have been extensively characterised in various higher eukaryotes (reviewed in Vaz and 
Wanders, 2002; Figure 6.1). The first step, the hydroxylation of trimethyllysine to 
hydroxyl-trimethyllysine, is catalyzed by the activity of the enzyme trimethyllysine 
hydroxylase (TMLH), which has been cloned from humans and also from N. crassa 
(Vaz et al, 2001; Swiegers et al, 2002). This product is aldolytically cleaved by hydroxy-
trimethyllysine aldolase (HTMLA) to form the next intermediate, 
trimethylaminobutyraldehyde. This enzyme has not been cloned from any organism but 
early studies in rats speculated this activity to be that of a serine hydroxyl 
methyltransferase (Henderson et al, 1982; Stein and Englard, 1981). 
Trimethylaminobutyraldehyde is further dehydrogenated by the enzyme 
trimethylaminobutyraldehyde dehydrogenase (TMABA-DH), leading to the formation of 
the last intermediate, -butyrobetaïne. The gene encoding this dehydrogenase has been 
successfully isolated and characterized in studies on humans and rats (Vaz et al, 2000; 
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Kikonyogo and Pietruszko, 1996; Lin et al, 1996; Kurys et al, 1993; Chern and 
Pietruszko, 1995). The final hydroxylation step in this pathway is catalyzed by -
butyrobetaїne hydroxylase (BBH) to form L-carnitine. The human gene encoding BBH 
has previously been cloned (Vaz et al, 1998). In addition to the central pathway for 
carnitine biosynthesis, N. crassa has been shown to perform stepwise methylations of 
free lysine in order to form the precursor trimethyllysine (Borum and Broquist, 1977). In 
higher eukaryotic organisms this compound is mainly sourced from trimethyllysine pools 
formed as a byproduct of protein degradation (La Badie et al, 1976; Dunn et al, 1984).  
K
TMLH
Free Lysine
Carnitine
HTML TML
TML
TMABA
TMABA-DH
Butyrobetaine BBH
TMLH
N. crassa
HTMLA
Figure 6.1. Schematic representation of the eukaryotic carnitine biosynthesis pathway. 
In the brewer’s yeast, Saccharomyces cerevisiae, two separate metabolic routes 
exist in order to channel activated acyl residues to the mitochondrial TCA cycle. Apart 
from the carnitine shuttle, an alternate pathway, referred to as the glyoxylate-cycle, 
combines two acetyl-CoA units in order to form succinate, which can freely enter the 
mitochondria for further metabolism (Van Roermund et al, 1995). When this metabolic 
“bypass” is blocked through deletion of the citrate synthase encoding CIT2 gene, the 
first enzyme in the glyoxylate cycle, yeast cells are completely dependent on the 
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carnitine shuttle and on the presence of carnitine in the environment for growth on non-
fermentable carbon sources (Swiegers et al, 2001). These results indicate that S. 
cerevisiae, unlike most eukaryotes, is unable to neo-synthesize its own carnitine and is 
solely dependent on carnitine uptake from the extra-cellular environment. 
The beneficial attributes of L-carnitine as a dietary supplement and therapeutic agent, 
along with the wide range of genetic tools available for the introduction and 
heterologous expression of genes in the model organism S. cerevisiae presents an area 
of genetic research with a variety of possible industrial applications. This study 
describes the cloning, characterization and expression of the four genes from the N. 
crassa carnitine biosynthesis pathway in S. cerevisiae. Furthermore, the gene coding 
for the free lysine methyltransferase was also cloned from the same organism. All five 
genes from N. crassa were heterologously co-expressed in a laboratory strain of S. 
cerevisiae, thereby reconstituting the pathway in yeast. The constructed strains were 
used in a preliminary plate based assay for carnitine production. The results indicated 
that a yeast strain bearing all four of the central carnitine biosynthesis enzymes is able 
to synthesize carnitine from trimethyllysine. The assay system used here, however, 
does not allow ascertaining whether the free lysine methyl transferase is actively 
expressed in S. cerevisiae. 
6.2. MATERIALS AND METHODS 
 
6.2.1. MICROBIAL STRAINS AND MEDIA 
Escherichia coli carrying plasmids were grown in Luria Bertani (LB) broth with 10 mgL-1 
ampicillin. Yeast strains were grown in YPD (1% yeast extract, 2% bactopeptone, 2% 
glucose), synthetic glucose medium (6.7 gL-1 yeast nitrogen base without amino acids, 
2% glucose, amino acids as required) and synthetic ethanol medium (6.7 gL-1 yeast 
nitrogen base without amino acids, 3% ethanol and amino acids as required). The N. 
crassa wild type strains, 74-OR-1VA (Fungal Genetic Stock Centre) and PPRI3338 
(National Collection of Fungi, Agricultural Research Council, Pretoria, South Africa), 
were grown in potato dextrose media (Sigma) and on Vogel’s N medium. Growth and 
media conditions for N. crassa have been previously described (Davis and deSerres 
1970; Davis, 2000). 
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5.2.2 RNA EXTRACTION AND cDNA SYNTHESIS FROM Neurospora crassa 
Mycelia from growing plate cultures of N. crassa were inoculated into 5 ml starter 
cultures of Vogel’s N medium containing 1.5% sucrose. After 2 days growth at 28°C 
enough biomass was formed for transfer to larger volumes of fresh media. The sphere 
of fungal mass was removed from the media and slices of similar thickness were 
transferred to flask containing 100 ml of Vogel’s N medium with glucose, as carbon 
source and grown at 28°C for two days. The spheres of growing fungus were removed 
from the media and allowed to drain on Whattman paper. The drained fungal mass was 
flash frozen in liquid nitrogen and grinded with a mortar and pestle to a uniform powder 
to be kept at -80°C for RNA extractions when required. RNA extraction was performed 
as previously described (Siebert et al, 1993). cDNA was synthesized using the 
SuperScript® III  system from Invitrogen. 
Table 6.1. Primers used in this study. Introduced restriction sites are italicized. 
Primer Sequence 
NC-TMLH-F 5’-gatcgaattcATGAGACCGCAACGGGTAGGGGCA-3’ 
Cbs-1 revII_EcoRI 5’-gcccgaattcCTTAACCAGTAACCCTCGGAAGAACC-3’ 
NcSHMT-F 5’-gatcgaattcATGTCGAGCTTCCAGAGCACAG-3’ 
NcSHMT-R 5’-gatcgtcgacCTAAGACGACTGGTCCCAAGGG-3’ 
NCU03415-F 5’-tatagaattcATGTCTTCCAACGTCTTTGTTG–3’ 
NCU03415-R 5’–tatagtcgacCTAGTTGAGCTTGATAGCAACAGAC-3’ 
NcBBH-F 5’-gatcagatctATGAAAGTCGACAAGGAAGCCGGCAA-3’ 
NcBBH-R 5’-gatcagatctTTATGCGTTCCAGTTCACCGTGCCCAA-3’ 
NCU03826_rev 5’- GTCGGCATATG TTAGACGTTGGTCAACTTG-3’ 
NCU03826_fw 5’- GTAGAATTCCATGGCCTTCGGAAAGCTTTAC-3’ 
6.2.3. CLONING OF CARNITINE BIOSYNTHESIS GENES FROM N. crassa 
All primers used in the cloning of the carnitine biosynthesis genes are listed in Table 
6.1. Clones and constructs are listed in Table 6.2. The gene encoding for the N. crassa 
trimethyllysine dehydroxylase (NcTMLH) was amplified from N crassa cDNA using the 
primer set NC-TMLH-F (5’-gatcgaattc ATG AGA CCG CAA CGG GTA GGG GCA-3’) 
and Cbs-1 revII_EcoRI (5’-gcccgaattc CTT AAC CAG TAA CCC TCG GAA GAA CC-3’).  
The resulting 1416 bp fragment was cloned into the pGEM-TEasy cloning vector 
purchased from Promega. For integration and expression in yeast this fragment was 
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subcloned into the PGK1 promoter/terminator cassette of the yeast integration vector 
pRS-305 using the EcoRI sites (indicated in italics in the primer sequence) introduced 
through PCR at the 5’ and 3’ ends of the fragment. The construct was linearized using 
BstEII, for integration into the LEU2 locus, and transformed into the FY23 and also in 
combination with the other biosynthesis constructs. 
For the cloning of the mitochondrial serine hydroxyl methyltransferase (NcSHMT), 
cDNA from N. crassa was used as template together with the primer NcSHMT-F (5’-
gatcgaattc ATG TCG AGC TTC CAG AGC ACA G-3’) binding at the ATG and NcSHMT-
R (5’-gatcgtcgac CTA AGA CGA CTG GTC CCA AGG G-3’) binding at the STOP codon 
of the open reading frame. The amplified fragment was cloned into pGEM-Teasy. A 
1584 bp fragment was excised from this construct using the 5’ EcoRI and 3’ BglII sites 
introduced through PCR and cloned into the PGK1 promoter/terminator cassette of the 
centromeric vector YCpLac22-PGKpt. 
The following primers were used for the amplification of the N. crassa 
trimethylaminobutyraldehyde dehydrogenase (NcTMABA-DH) from N. crassa cDNA; 
NCU03415-F (5’- tatagaattc ATG TCT TCC AAC GTC TTT GTT G – 3’), binding at the 
ATG and NCU03415-R (5’ – tatagtcgac CTA GTT GAG CTT GAT AGC AAC AGA C - 
3’), binding at the STOP codon of the coding region. The amplified fragment was cloned 
into the pGEM-Teasy vector. A fragment of 1493 bp was excised using the introduced 
EcoRI and BglII sites and subcloned using the same restriction sites into the PGK1 
promoter/terminator expression cassette of the pCEL13 integration vector. For 
integration, the construct was linearized using an NcoI site that digests inside the URA3 
marker of pCEL13 and used in yeast transformations of the FY23 wild type strain and 
also in combination with the other carnitine biosynthesis constructs. 
For the cloning of the N. crassa butyrobetaïne hydroxylase (NcBBH), a 2016 bp 
fragment was cloned from N. crassa genomic DNA, extracted from strain PPRI 3338, 
using the primers NcBBH-F (5’-gatcagatct ATG AAA GTC GAC AAG GAA GCC GGC 
AA-3’) and NcBBH-R (5’-gatcagatct TTA TGC GTT CCA GTT CAC CGT GCC CAA-3’) 
with introduced 5’ and 3’ BglII restriction sites (indicated in italics). The fragment was 
cloned into the cloning vector pGEM-Teasy, from where it was subcloned into the BglII 
site of the integration vector pSP-PGK1pt. The cloned fragment is under the regulation 
of the PGK1 promoter and terminator. The construct was linearized using EcoNI, for 
integration into the ILV2 locus, using sulfometron methyl for selection (Casey et al, 
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1988). The linearized integration cassette was subsequently transformed into the FY23 
wild type strain and also in combination with the other carnitine biosynthesis constructs. 
The gene sequence coding for the free lysine methyltransferase (NcFLMT), N. 
crassa ORF NCU03826, was amplified using the primer set NCU03826_rev and 
NCU03826_fw and cloned into pGEM-Teasy. The fragment containing the free lysine 
methyltransferase ORF was excised using the introduced 5’ EcoRI and 3’ NdeI 
restriction sites and cloned into the PGK1 expression cassette of pDMPL. The cassette 
containing the PGK1 promoter, FLMT open reading frame and PGK1 terminator was 
excised using the BbrPI and NheI restriction sites and cloned into pPOF using the same 
restriction sites. The plasmid was linearized using SmaI for transformation into the 
POF1 locus and the KanMX marker (geneticin resistance) present on the cassette was 
used for selection. The FLMT integration construct was transformed into the FY23 wild 
type strain and also into the FY23 strain containing all four carnitine biosynthesis genes. 
The generated strains are listed in Table 6.3. All clones were sequenced using the ABI-
Prism sequencer to confirm the integrity of PCR amplifications. Integration of constructs 
was confirmed using a combination of primers that binds the integrated cassette and 
also the genomic DNA adjacent to the sites of integration for PCR amplifications. 
 
Table 6.2. Clones and constructs 
Plasmids Relevant genotype Sources and references 
YCpLac22-PGK1pt CEN4 TRP1 PGK1p-PGK1t This laboratory 
YCpLac22-PGK1pt-HTMLA CEN4 TRP1 PGK1p-HTMLA-PGK1t This study 
pRS305 CEN6 LEU2 PGK1p-PGK1t Sikorski and Hieter,1989 
pRS305-TMLH CEN6 LEU2 PGK1p-TMLH -PGK1t This study 
pSP-PGK1pt SMR PGK1p-PGK1t Sunbio 
pSP-PGK1pt-BBH SMR PGK1p-BBH-PGK1t This study 
pCEL13 2µ URA3 PGK1p-PGK1t Moses et al, 2005 
pCEL13-TMABA-DH 2µ URA3 TMABA-DH This study 
pGEM-Teasy  Promega. 
pDMPL PGK1p-PGK1t SunBio 
pDMPL-FLMT PGK1p-FLMT-PGK1t SunBio 
pPOF- KanMX4 SunBio 
pPOF-FLMT KanMX4 PGK1p-FLMT-PGK1t This study 
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6.2.4 CARNITINE PRODUCTION SCREEN USING A Δcit2 YEAST STRAIN 
The screen for carnitine production is based on the carnitine-dependent phenotype of 
the cit2 deletion strain. A liquid culture of cit2 was grown up overnight in SCD media, 
without carnitine. The cultures were harvested and after thorough washing, plated as a 
mat on a synthetic agar medium containing a non-fermentable carbon source, ethanol, 
and no carnitine. Growing yeast colonies that biosynthesise carnitine produce a zone of 
growth due to the complementation of the cit2 mutant by carnitine made available from 
the producing strain. 
Table 6.3. Yeast strains used in this study 
Yeast strains Relevant genotype Sources and references 
FY23 MATa leu2 trp1 ura3 Winston et al. 1995 
FY23 BBH MATa leu2 trp1 ura3 BBH This study 
F23 TMLH BBH MATa leu2 trp1 ura3 TMLH BBH This study 
FY23 TMLH HTMLA BBH MATa leu2 trp1 ura3 TMLH HTMLHA 
BBH 
This study 
FY23 TMLH TMABA-DH BBH MATa leu2 trp1 ura3 TMLH TMABA-DH 
BBH 
This study 
FY23 TMLH HTMLA      
TMABA-DH BBH 
MATa leu2 trp1 ura3 TMLH HTMLA 
TMABA-DH BBH 
This study 
FY23 CB MATa leu2 trp1 ura3 FLMT TMLH 
HTMLA TMABA-DH BBH 
This study 
6.3. RESULTS 
6.3.1. CLONING AND CHARACTERISATION OF THE N. crassa FREE LYSINE 
METHYLTRANSFERASE (NcFLMT) 
 
The cloning and expression of the N. crassa free lysine methyltransferase (N. crassa 
ORF NCU03826) in E. coli was previously described in an international patent 
application (application No. WO 2007/007987 A1). Primers for the amplification of N. 
crassa ORF NCU03826 (EMBL accession No. Q7S7R7) were designed according to 
the sequence submitted in the application. The predicted sequence of the gene 
encodes and ORF of 1059 bp. The coding region includes 5’ and 3’ UTR’s of 33 and 
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249 bp respectively. The amplified ORF size was 651 bp coding for a predicted protein 
217 aa with a molecular weight of 24,2 kDa. The predicted protein shares sequence 
similarity to eukaryotic transcription elongation factors. Except for one basepair change, 
which would lead to an amino acid change from proline to leucine at amino acid 150, 
the sequence was exactly similar to the sequence found on the N. crassa genome 
database for the ORF NCU03826. 
                 1                                               50 
   NcTMLH    (1) MRPQVVGAILRSRAVVSRQPLSRTHIFAAVTVAKSSSPAQNSRRTFSSSF 
humanTMLH    (1) -----MWYHRLSHLHSRLQDLLKGGVIYPALPQPNFKSLLPLAVHWHHTA 
  ratTMLH    (1) ---------------------MKRGDIAHGLRLSGFKSLFPFSLHWCHTA 
Consensus    (1)      M     S      Q LLK GIIA AL    FKSL P ALHW HTA 
                 51                                             100 
   NcTMLH   (51) RRLYEPKAEITAEGLELSPPQAVTGGKRTVLPNFWLRDNCRCTKCVNQDT 
humanTMLH   (46) SKSLTCAWQQHEDHFELKYANTVMR-----FDYVWLRDHCRSASCYNSKT 
  ratTMLH   (30) SKSVNCTWHQHEDHLELQYASTVMR-----FDYVWLRDHCRSASCYNSKT 
Consensus   (51) SKSL C W QHEDHLEL YANTVMR     FDYVWLRDHCRSASCYNSKT 
                 101                                            150 
   NcTMLH  (101) LQRNFNTFAIPSDIHPTKVEATKENVTVQWSDNHTSTYPWPFLSFYLTSN 
humanTMLH   (91) HQRSLDTASVDLCIKPKTIRLDETTLFFTWPDGHVTKYDLNWLVKNSYEG 
  ratTMLH   (75) HQRSLDTASVDLCIKPKTIRLDESTLFFTWPDGHVTRYDLDWLVKNSYEG 
Consensus  (101) HQRSLDTASVDLCIKPKTIRLDESTLFFTWPDGHVTKYDL WLVKNSYEG 
                 151                                            200 
   NcTMLH  (151) ARGHENDQISLWGSEAG--SRPPTVSFPRVMASDQGVADLTAMIKEFGFC 
humanTMLH  (141) QKQKVIQPRILWNAEIYQQAQVPSVDCQSFLETNEGLKKFLQNFLLYGIA 
  ratTMLH  (125) QKQEVIQPRVLWNAKLYQDAQLPSVDFQGFLETKEGLKKFLQNFLLYGIA 
Consensus  (151) QKQ VIQPRILWNAEIYQ AQLPSVDFQ FLET EGLKKFLQNFLLYGIA 
                 201                                            250 
   NcTMLH  (199) FVKDTPHDDPDVTRQLLERIAFIRVTHYGGFYDFTPDLAMADTAYTNLAL 
humanTMLH  (191) FVENVP-PTQEHTEKLAERISLIRETIYGRMWYFTSDFSRGDTAYTKLAL 
  ratTMLH  (175) FVENVP-PTQEHTEKLARRVSLIRETIYGRMWYFTSDFSRGDTAYTKLAL 
Consensus  (201) FVENVP PTQEHTEKLAERISLIRETIYGRMWYFTSDFSRGDTAYTKLAL 
                 251                                            300 
   NcTMLH  (249) PAHTDTTYFTDPAGLQAFHLLEHKAAPSRPPPPPPPPPPPSEEKEAAGSA 
humanTMLH  (240) DRHTDTTYFQEPCGIQVFHCLKHEGT------------------------ 
  ratTMLH  (224) DRHTDTTYFQEPCGIQVFHCLKHEGT------------------------ 
Consensus  (251) DRHTDTTYFQEPCGIQVFHCLKHEGT                         
                 301                                            350 
   NcTMLH  (299) AGEAAAAAEGGKSLLVDGFNAARILKEEDPRAYEILSSVRLPWHASGNEG 
humanTMLH  (266) ---------GGRTLLVDGFYAAEQVLQKAPEEFELLSKVPLKHEYIEDVG 
  ratTMLH  (250) ---------GGRTLLVDGFYAAQQVLQRAPEEFDLLSQVPLKHEYIENVG 
Consensus  (301)          GGRTLLVDGFYAA QVLQKAPEEFELLS VPLKHEYIENVG 
                 351                                            400 
   NcTMLH  (349) -ITIAPDKLYPVLELNEDTGELHRVRWNNDDRGVVPFGEKYSPSEWYEAA 
humanTMLH  (307) ECHNHMIGIGPVLNIYPWNKELYLIRYNNYDRAVINTVPYDVVHRWYTAH 
  ratTMLH  (291) QCHNHMIGVGPILNIYPWNKELYLIRYNNYDRAVINTVPYDVVRRWYAAH 
Consensus  (351)  CHNHMIGIGPVLNIYPWNKELYLIRYNNYDRAVINTVPYDVV RWY AH 
                 401                                            450 
   NcTMLH  (398) RKWDGILRRKSSELWVQLEPGKPLIFDNWRVLHGRSAFSGIRRICGGYIN 
humanTMLH  (357) RTLTIELRRPENEFWVKLKPGRVLFIDNWRVLHGRECFTGYRQLCGCYLT 
  ratTMLH  (341) RTLTTELRRPENELWVKLKPGKVLFIDNWRVLHGRESFTGYRQLCGCYLT 
Consensus  (401) RTLT ELRRPENELWVKLKPGKVLFIDNWRVLHGREAFTGYRQLCGCYLT 
                 451                   475 
   NcTMLH  (448) RDDFISRWRNTNYPRSEVLPRVTG- 
humanTMLH  (407) RDDVLNTARLLGLQ----------- 
  ratTMLH  (391) RDDVLNTARILGLHA---------- 
Consensus  (451) RDDVLNTARILGL             
Figure 6.2. Alignment of the amino acid sequences from the isolated N.crassa trimethyllysine 
hydroxylase (NcTMLH) to the previously cloned enzymes from rat and human. 
6.3.2. CLONING AND CHARACTERISATION OF THE N. crassa TRIMETHYLLYSINE 
HYDROXYLASE (NcTMLH) 
The N crassa gene, encoding a trimethyllysine hydroxylase (TMLH; NCU03802; NCBI 
accession No. XP_961191) was previously cloned in our laboratory (Swiegers et al, 
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2002). The predicted sequence contains 6 exons and codes for a 1978 bp gene, with a 
resulting protein product of 528 amino acids. Furthermore, a 3’ untranslated region of 
229 bp is present which was confirmed by Swiegers et al (2002). For the purposes of 
this work it was decided to re-isolate this gene from cDNA with a primer set that 
amplifies the coding region without the UTR. A fragment of 1416 bp, coding for a 
predicted protein product of 472 amino acids with a molecular weight of 52.7 kDa 
(EMBL accesion No. AJ421151) was amplified. The cloned TMLH gene from N. crassa 
shares significant similarity to the gene sequences that have been previously isolated 
from rat and human and also to the sequence of -butyrobetaïne hydroxylase (Swiegers 
et al, 2002; Figure 6.2.). 
                 1                                               50 
   NcSHMT    (1) MSTYSLSETHKAMLEHSLVESDPQVAEIMKKEVQRQRESIILIASENVTS 
  ScSHMT2    (1) -MPYTLSDAHHKLITSHLVDTDPEVDSIIKDEIERQKHSIDLIASENFTS 
  ratSHMT    (1) -------------------------------------------------- 
Consensus    (1)    YSLSD H  LI   LVDSDP V  IIK EI RQK SI LIASEN TS 
                 51                                             100 
   NcSHMT   (51) RAVFDALGSPMSNKYSEGLPGARYYGGNQHIDEIEVLCQNRALEAFHLDP 
  ScSHMT2   (50) TSVFDALGTPLSNKYSEGYPGARYYGGNEHIDRMEILCQQRALKAFHVTP 
  ratSHMT    (1) -------------------------------------------------- 
Consensus   (51)  AVFDALGSPLSNKYSEG PGARYYGGN HID IEILCQNRAL AFHL P 
                 101                                            150 
   NcSHMT  (101) KQWGVNVQCLSGSPANLQVYQAIMPVHGRLMGLDLPHGGHLSHGYQTPQR 
  ScSHMT2  (100) DKWGVNVQTLSGSPANLQVYQAIMKPHERLMGLYLPDGGHLSHGYATENR 
  ratSHMT    (1) ---------------------------PSENGDSLPLFGPLLLGGLCPAR 
Consensus  (101)   WGVNVQ LSGSPANLQVYQAIM  H RLMGL LP GGHLSHGY TPNR 
                 151                                            200 
   NcSHMT  (151) K---ISAVSTYFETMPYRVNIDTGLIDYDTLEKNAQLFRPKVLVAGTSAY 
  ScSHMT2  (150) K---ISAVSTYFESFPYRVNPETGIIDYDTLEKNAILYRPKVLVAGTSAY 
  ratSHMT   (24) RSAGLAGLRTLLGGLSLLVYPDTGYINYDQLEENASLFHPKLIIAGTSCY 
Consensus  (151) K   ISAVSTYFESLPYRVNPDTGIIDYDTLEKNA LFRPKVLVAGTSAY 
                 201                                            250 
   NcSHMT  (198) CRLIDYERMRKIADSVGAYLVVDMAHISGLIASEVIPSPFLYADVVTTTT 
  ScSHMT2  (197) CRLIDYKRMREIADKCGAYLMVDMAHISGLIAAGVIPSPFEYADIVTTTT 
  ratSHMT   (74) SRNLDYARLRKIADDNGAYLMADMAHISGLVAAGVVPSPFEHCHVVTTTT 
Consensus  (201) CRLIDY RMRKIAD  GAYLMVDMAHISGLIAAGVIPSPFEYADVVTTTT 
                 251                                            300 
   NcSHMT  (248) HKSLRGPRGAMIFFRRGVRSVDAKTGKETLYDLEDKINFSVFPGHQGGPH 
  ScSHMT2  (247) HKSLRGPRGAMIFFRRGVRSINPKTGKEVLYDLENPINFSVFPGHQGGPH 
  ratSHMT  (124) HKTLRGCRAGMIFYRKGVRSVDPKTGEETYYELESLINSAVFPGLQGGPH 
Consensus  (251) HKSLRGPRGAMIFFRRGVRSVDPKTGKETLYDLE  INFSVFPGHQGGPH 
                 301                                            350 
   NcSHMT  (298) NHTITALAVALKQAASPEFKEYQQKVVANAKALEKKLKELGYKLVSDGTD 
  ScSHMT2  (297) NHTIAALATALKQAATPEFKEYQTQVLKNAKALESEFKNLGYRLVSNGTD 
  ratSHMT  (174) NHAIAGVAVALKQAMTTEFKIYQLQVLANCRALSDALTELGYKIVTGGSD 
Consensus  (301) NHTIAALAVALKQAATPEFKEYQ QVLANAKALE  LKELGYKLVS GTD 
                 351                                            400 
   NcSHMT  (348) SHMVLVDLRPIGVDGARVEFLLEQINITCNKNAVPGDKSALTPGGLRIGT 
  ScSHMT2  (347) SHMVLVSLREKGVDGARVEYICEKINIALNKNSIPGDKSALVPGGVRIGA 
  ratSHMT  (224) NHLILMDLRPKGTDGGRAEKVLEACSIACNKNTCPGDKSALRPSGLRLGT 
Consensus  (351) SHMVLVDLRPKGVDGARVEFILE INIACNKNSIPGDKSAL PGGLRIGT 
                 401                                            450 
   NcSHMT  (398) PAMTSRGFGEADFEKVAVFVDEAVKLCKEIQASLPKEANKQKDFKAKIAT 
  ScSHMT2  (397) PAMTTRGMGEEDFHRIVQYINKAVEFAQQVQQSLPKDACRLKDFKAKVDE 
  ratSHMT  (274) PALTSRGLLEEDFQKIAHFIHRGIELTLQIQSHMTMRAT-LKEFKEKLTG 
Consensus  (401) PAMTSRGLGEEDF KIA FI KAVEL  QIQASLPKDA KLKDFKAKI   
                 451                              486 
   NcSHMT  (448) SDIPR--INELKQEIAAWSNTFPLPVEGWRYDAGL- 
  ScSHMT2  (447) GSDVLN---TWKKEIYDWAGEYPLAV---------- 
  ratSHMT  (323) DEKFQSAVAALREEVENFASNFSLPGLPDF------ 
Consensus  (451)  D     I  LK EI  WA  FPLPV           
Figure 6.3. Alignment of the cloned serine hydroxymethyltransferase (SHMT) from N. crassa to the 
rat serine hydroxy-methyltransferase gene and also the S. cerevisiae Shm2p. 
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6.3.3. CLONING AND CHARACTERISATION OF THE N. crassa HYDROXY 
TRIMETHYLLYSINE ALDOLASE (NcSHMT) 
A previous study reported the isolation of a serine hydroxymethyltransferase (SHMT) 
from rat liver that was able to catalyze the conversion of hydroxytrimethyllysine to 
trimethylaminobutyraldehyde, the second step of carnitine biosynthesis (Henderson et 
al 1980; 1982). A search of the Neurospora genome database 
(http://www.broad.mit.edu/annotation/genome/neurospora/Home.html) identified two 
SHMT’s in the fungal genome, one coding for a cytosolic and the other a mitochondrial 
enzyme. It was decided to clone the cytosolic isoform (NCU02274; EMBL accession No. 
P34898), since the rest of the carnitine biosynthesis activities are located in the cytosol. 
The predicted locus from the Neurospora genome database consists of an open reading 
frame spanning 2248 bp, containing 3 exons and leads to a processed product of 2097 
bp. The gene also contains 5’ and 3’ UTRs of 99 and 558 bp respectively. The primer 
set designed for the isolation of SHMT amplifies the central region, excluding both 
UTRs, and resulted in an amplicon of 1443bp. The sequence of the cloned SHMT does 
not differ from the predicted sequence of the Neurospora Genome Database. The 
predicted protein product contains 481 amino acids and has a molecular weight of ~ 53 
kDA. The N. crassa SHMT shares 73% homology to the rat SHMT gene (EMBL 
accession No. BC099219) and 80% homology to that of S. cerevisiae Shm2p (Figure 
6.3.). 
6.3.4. CLONING AND CHARACTERISATION OF THE N. crassa 
TRIMETHYLAMINOBUTYRALDEHYDE DEHYDROGENASE (NcTMABA-DH) 
A gene family of aldehyde dehydrogenases was identified using the sequence of the 
human and rat trimethylaminobutyraldehyde dehydrogenases in a BLAST analysis of 
the N. crassa genome. Of these enzymes the enzyme under the accession number 
NCU03415 (EMBL accession No. Q8X0L4) had the closest similarity (~60%) to the 
previously identified rat and human copies. The predicted genomic sequence contains 3 
exons coding for a primary transcript of 1853bp with 5’ and 3’ UTRs of 139 and 211 bp 
respectively. This would lead to a predicted peptide consisting of 495 amino acids with a 
molecular mass of ~ 54 kDa. 
A fragment of 1488 bp was amplified from cDNA using primers homologous to the 5’ 
and 3’ regions of the gene NCU03415, which excludes the respective UTRs. The 
sequence of the cloned fragment is 100% similar to that of the N. crassa gene 
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NCU03415, as indicated in the N crassa genome database. The cloned NcTMABA-DH 
shares 60% similarity to that of the previously cloned ALDH9 gene from rat, which has 
been indicated to function as a trimethyl-aminbutyraldehyde dehydrogenase (Lin et al, 
1996; Figure 6.4.). Furthermore, this gene also has significant homology to the four 
aldehyde dehydrogenase enzymes present in the S288c genetic background, namely 
Ald4p (67%), Ald2p (66%), Ald5p (65%), and Ald3p (64%). 
                   1                                               50 
 NcTMABA-DH    (1) MEVELTAPNGKKWMQPLGLFINNEFVKSANEQKLISINPTTEEEICSVYA 
ratTMABA-DH    (1) -----MSTGTFVVSQPLNYRGGARVEPVDASGTEKAFEPATGREIATFKC 
  Consensus    (1)       A       QPL                  A  P T  EI S    
                   51                                             100 
 NcTMABA-DH   (51) ATAEDVDAAVSAARKAFRHESWKSLSGTERGALMRKLADLVAENAEILAT 
ratTMABA-DH   (46) SGEKEVNLAVENAKAAFKIWSKK--SGLERCQVLLEAARIIKERRDEIAI 
  Consensus   (51) A   DV  AV  AK AFK  S K  SG ER  LL   A II E  D IA  
                   101                                            150 
 NcTMABA-DH  (101) IECLDNGKPYQTALNENVPEVINVLRYYAGYADKNFGQVIDVGPAKFAYT 
ratTMABA-DH   (94) METINNGK-SIFEARLDVDTSWQCLEYYAGLAASMAGEHIQLPGGSFGYT 
  Consensus  (101) IE I NGK         V    N L YYAG A    G  I L  A FAYT 
                   151                                            200 
 NcTMABA-DH  (151) VKEPLGVCGQIIPWNYPLDMAAWKLGPALCCGNTVVLKLAEQTPLSVLYL 
ratTMABA-DH  (143) RREPLGVCLGIGAWNYPFQIACWKSAPALACGNAMIFKPSPFTPVSALLL 
  Consensus  (151)  KEPLGVC  I  WNYP  IA WK APAL CGN MI K A  TPLS L L 
                   201                                            250 
 NcTMABA-DH  (201) AKLIKEAGFPPGVINIINGHGREAGAALVQHPQVDKIAFTGSTTTGKEIM 
ratTMABA-DH  (193) AEIYTKAGAPNGLFNVVQG-GAATGQFLCQHRDVAKVSFTGSVPTGMKIM 
  Consensus  (201) A I   AG P GL NIING G   G  L QH  V KIAFTGS  TG  IM 
                   251                                            300 
 NcTMABA-DH  (251) KMASYTMKNITLETGGKSPLIVFEDADLELAATWSHIGIMSNQGQICTAT 
ratTMABA-DH  (242) EMAAKGIKPITLELGGKSPLIIFSDCNMKNAVKGALLANFLTQGQVCCNG 
  Consensus  (251)  MAA  IK ITLE GGKSPLIIF D  L  A   A IA    QGQIC    
                   301                                            350 
 NcTMABA-DH  (301) SRILVHEKIYDEFVEKFKAKVQEVSVLGDPFEESTFHGPQVTKAQYERVL 
ratTMABA-DH  (292) TRVFVQKEIADAFTKEVVRQTQRIKIG-DPLLEDTRMGPLINAPHLERVL 
  Consensus  (301) SRI V   I D F        Q I I  DP  E T  GP I     ERVL 
                   351                                            400 
 NcTMABA-DH  (351) GYINVGKEEGATVMMGGE----PAPQNGKGFFVAPTVFTNVKPTMKIFRE 
ratTMABA-DH  (341) GFVRSAKEQGATVLCGGEPYAPEDPKLKHGYYMTPCILTNCTDDMTCVKE 
  Consensus  (351) GFI  AKE GATVL GGE      P    GFFM P I TN    M   KE 
                   401                                            450 
 NcTMABA-DH  (397) EIFGPCVAITTFKTEEEALTLANDSMYGLGAALFTKDLTRAHRVAREIEA 
ratTMABA-DH  (391) EIFGPVMSILTFETEAEVLERANDTTFGLAAGVFTRDIQRAHRVAAELQA 
  Consensus  (401) EIFGP MAI TF TE E L  ANDS FGLAAALFTKDI RAHRVA EI A 
                   451                                            500 
 NcTMABA-DH  (447) GMVWVNSSNDSDFRIPFGGVKQSGIGRELGEAGLAPYCNVKSIHVNLAA- 
ratTMABA-DH  (441) GTCYINNYNVSPVELPFGGYKKSGFGRENGRVTIEYYSQLKTVCVEMGDV 
  Consensus  (451) G  WIN  N S   IPFGG K SG GRE G   I  Y NLKSI V LA   
                   501 
 NcTMABA-DH  (496) ------- 
ratTMABA-DH  (491) ESPFENQ 
  Consensus  (501)         
Figure 6.4. Alignment of the cloned N. crassa trimethylaminobutyraldehyde dehydrogenase 
(NcTMABA-DH) to the previously identified rat gene ALDH9. 
6.3.5 CLONING AND CHARACTERISATION OF THE N. crassa -BUTYROBETAÏNE 
HYDROXYLASE (NcBBH) 
Genes coding for -butyrobetaïne hydroxylase have been cloned from human (Vaz et al, 
1998). The sequences of these genes were used to BLAST the Neurospora genome 
database for homologous sequences and led to the identification of one locus 
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(NCU06891; EMBL accession No. Q7S3G2) with significant homology to that of the 
human and rat enzymes. The predicted sequence contained 5 exons and codes for an  
                 1                                               50 
humanBBHp    (1) -------------------------------------------------- 
   NcBBHp    (1) MKVDKEAGKETDKIGVNKSDKKAGRKANEETDKLAEAQREFDIQLSRLRN 
  ratBBHp    (1) -------------------------------------------------- 
Consensus    (1)                                                    
                 51                                             100 
humanBBHp    (1) -------------------------------------------------- 
   NcBBHp   (51) DLAQLKKSNNKLRKDKGALRLDIVNMKKAFNGVPPTAAVQRDGQLLELYK 
  ratBBHp    (1) -------------------------------------------------- 
Consensus   (51)                                                    
                 101                                            150 
humanBBHp    (1) ---------MACTIQKAEALDGAHLMQILWYDEE----ESLYPAVWLRDN 
   NcBBHp  (101) KIAKEAREFKAGTPQSVEVVDGQQQLVITFAQPDGTTKQVAMSLHWLRDT 
  ratBBHp    (1) ---------MHCAILKAEAVDGARLMQIFWHDGA----ESLYPAVWLRDN 
Consensus  (101)          MACTIQKAEAVDGA LMQI WHD D    ESLYPAVWLRDN 
                 151                                            200 
humanBBHp   (38) CPCSDCYLDSAKARKLLVEALDVNIGIKGLIFDRKK----------VYIT 
   NcBBHp  (151) CKCPHCVNPDSGQKNFSSTSLPETLEVQSAEVNAADGSVTIVWANDTVST 
  ratBBHp   (38) CQCSDCYLHSAKARKLLLEALDVNIRMDDLTFDQKK----------VYIT 
Consensus  (151) C CSDCYL SAKARKLLLEALDVNI I  L FD KK          VYIT 
                 201                                            250 
humanBBHp   (78) WPDEHYSEFQADWLKKRCFSKQARAKLQRELFFPECQYWGSELQLPTLD- 
   NcBBHp  (201) NATSEATTHTSTYDASDIFTWQLPYDLAGNLLPVERTLWDRSKLQAHIDS 
  ratBBHp   (78) WPNGHYSEFEANWLKKRCFSQEARAGLQGELFLPECQYWGSELQLPTLN- 
Consensus  (201) WP  HYSEF A WLKKRCFS QARA LQGELF PECQYWGSELQLPTLD  
                 251                                            300 
humanBBHp  (127) ------FEDVLRYDEHAYKWLSTLKKVGIVRLTGASDK----PGEVSKLG 
   NcBBHp  (251) GDLRVSYNDWLTSDAAFWKAFESLARFGILFVHSIPSDRALVESQVEKIA 
  ratBBHp  (127) ------FEDVLNDDDHAYKWLSSLKKVGIVRLTGAADK----RGEIIKLG 
Consensus  (251)       FEDVL  DDHAYKWLSSLKKVGIVRLTGAADK     GEV KLG 
                 301                                            350 
humanBBHp  (167) KRMGFLYLTFYGHTWQVQDKIDANNVAYTTGKLSFHTDYPALHHPPGVQL 
   NcBBHp  (301) NRIGILMHTFYGFTWDVRSKPRAENVAYTNVFLGLHQDLMYIDPPPRLQL 
  ratBBHp  (167) KRIGFLYLTFYGHTWQVQDKIDANNVAYTTGKLSFHTDYPALHHPPGVQL 
Consensus  (301) KRIGFLYLTFYGHTWQVQDKIDANNVAYTTGKLSFHTDYPALHHPPGVQL 
                 351                                            400 
humanBBHp  (217) LHCIKQTVTGGDSEIVDGFNVCQKLKKNNPQAFQILS---STFVDFTDIG 
   NcBBHp  (351) LHCISNSFQGGESLFSDGARAAYSLELNNPLAFDQLRGNRSPQFHYHRNG 
  ratBBHp  (217) LHCIKQTVTGGDSEIVDGFNVCQKLKEKNPQAFSILS---STFVDFTDIG 
Consensus  (351) LHCIKQTVTGGDSEIVDGFNVCQKLK NNPQAF ILS   STFVDFTDIG 
                 401                                            450 
humanBBHp  (264) VDYCDFSVQSKHKIIELDDKGQVVRINFN--------------------- 
   NcBBHp  (401) NDYHMGRNTFRYAGRTGEGKGFLSRIHWAPPFQAPFSRQTGATATNVLGN 
  ratBBHp  (264) VDYCDFSVQSKHKIIELDDKGQVVRINFN--------------------- 
Consensus  (401) VDYCDFSVQSKHKIIELDDKGQVVRINFN                      
                 451                                            500 
humanBBHp  (293) ------------NATRDTIFDVPVERVQPFYAALKEFVDLMNSKESKFTF 
   NcBBHp  (451) RVIQDGGGGAYAENEHAVVVEEKGKNMTKWVPAAKEFEREISAEENMFEL 
  ratBBHp  (293) ------------NATRDTVFDVPIERVQPFYAALKEFVDLMNSKEYKYTF 
Consensus  (451)             NATRDTVFDVPIERVQPFYAALKEFVDLMNSKE KFTF 
                 501                                            550 
humanBBHp  (331) KMNPGDVITFDNWRLLHGRR---SYEAGTEISRHLEGAYADWDVVMSRLR 
   NcBBHp  (501) KMKEGECVIFDNWRVLHGRREFQTEGQAEGAERWLKGTYISHQVYKAMED 
  ratBBHp  (331) KMNPGDVITFDNWRLLHGRR---SYEAGTEISRHLEGAYADWDVVMSRLR 
Consensus  (501) KMNPGDVITFDNWRLLHGRR   SYEAGTEISRHLEGAYADWDVVMSRLR 
                 551                                            600 
humanBBHp  (378) ILRQRVENGN---------------------------------------- 
   NcBBHp  (551) KLQWKLAQKEGGIPLAIGVAEAHGLGWKERGQLPKKEAPKQETTAPVQPK 
  ratBBHp  (378) ILRQRVMNGN---------------------------------------- 
Consensus  (551) ILRQRV NGN                                         
                 601                                            650 
humanBBHp  (388) -------------------------------------------------- 
   NcBBHp  (601) EEAPKVEEAPKVEETPKVEEAPKVEEAPKVEEAPKVEEAPKVEEAVKPEE 
  ratBBHp  (388) -------------------------------------------------- 
Consensus  (601)                                                    
                 651               671 
humanBBHp  (388) --------------------- 
   NcBBHp  (651) AQNEGPSRQPKEQLGTVNWNA 
  ratBBHp  (388) --------------------- 
Consensus  (651)                       
Figure 6.5. Alignment of the cloned fragment of the N. crassa γ-butyrobetaïne hydroxylase (NcBBH; 
NCU06891) to the similar genes cloned from human and rat. 
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mRNA product of 3786 bp, with the resulting protein predicted to contain 1262 amino 
acids. This is considerably larger than the rat and human copies which both consist of 
387 amino acids. Furthermore, only the last exon of the predicted ORF is homologous 
to the mammalian enzymes. Several attempts were made to amplify the full predicted 
fragment from N. crassa cDNA; however, the only primer set that could be used 
successfully amplified the region encoded by the last exon. The size of the amplified 
product was 2016 bp, which would lead to a predicted protein of 672 amino acids and a 
molecular weight of 75.2 kDa. Regions from the central part of the predicted amino acid 
sequence from the N. crassa BBH (excluding 111 aa on the N-terminal and 110 aa on 
the C-terminal) share similarity with the human and rat genes (Figure 6.5.). The C-
terminal domain contains a six-fold repeat of the sequence “PKVEE”. 
6.3.6 CARNITINE PRODUCTION BY TRANSGENIC S. cerevisiae STRAINS 
 
To asses the ability of the generated strains to produce carnitine, strains were 
inoculated onto plates containing ethanol as carbon source (SCE) and covered with a 
mat of FY23Δcit2 cells. Since the Δcit2 strain cannot grow on non-fermentable carbon 
sources, such as ethanol, without exogenous supplementation of carnitine, the 
production of carnitine by a nearby colony allows growth to occur leading to the 
formation of a halo of growing Δcit2 cells around the colony. This provides for a 
straightforward means of screening for strains able to produce carnitine. Similar 
amounts of the engineered yeast strains containing the various carnitine biosynthesis 
genes were inoculated on the described plates, and also plates supplemented with the 
precursors -butyrobetaïne (20 mgL-1), trimethyllysine (20 mgL-1) and also with lysine 
and methionine (added to final concentrations of 200 and 500 mg L-1 of each amino 
acid). The plates were incubated at 30 °C for 8 days and monitored for halo formation. 
As can be expected, no growth of Δcit2 cells was visible on the unsupplemented SCE 
plate which served as a control (Figure 6.6.). Supplementation with -butyrobetaïne 
resulted in a halo of Δcit2 growth around all strains which contained the integrated 
NcBBH gene, confirming the functional expression thereof in yeast. SCE plates 
supplemented with trimethyllysine resulted in halo formation in the yeast strain which 
contain all four carnitine biosynthesis genes, FY23 TMLH HTMLA TMABA-DH BBH and 
also FY23 CB, which contains all four genes and also the N. crassa free lysine 
methyltransferase. Interestingly, a yeast strain expressing only BBH, TMLH and 
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HTMLA, excluding TMABA-DH also produced carnitine resulting in visible growth of 
Δcit2. Supplementation with lysine and methionine, in order to assess the functionality 
of the cloned free lysine methyltransferase did not lead to halo formation. 
 
Figure 6.6. Engineered S. cerevisiae strains producing carnitine lead to the formation of a halo of 
growth around the spotted colony, as a result of the complementation of the carnitine dependent 
Δcit2 strain. SCE plates were supplemented with either -butyrobetaïne (-BB; 20 mgL-1), 
trimethyllysine (TML; 20 mgL-1) or lysine and methionine (500 mgL-1). Unsupplemented (SCE) plates 
were used as control. 
6.4. DISCUSSION 
 
In the fungus N. crassa, as in higher eukaryotes, carnitine is synthesized via four 
sequential enzymatic conversions of the precursor trimethyllysine. The precursor 
trimethyllysine either originates from the release of trimethylated lysine residues 
liberated after protein degradation or is produced, as is uniquely the case in N. crassa, 
by the sequential enzymatic methylation of free lysine. This conversion of lysine to 
trimethyllysine is catalyzed by the N. crassa free lysine methyltransferase (FLMT).  
The four central carnitine biosynthesis genes were successfully cloned from cDNA 
extracted from growing cultures of N. crassa and heterologously expressed in the 
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laboratory yeast strain FY23. The generated strains were assessed for carnitine 
production in a plate based screen. This analysis allows only for the preliminary 
detection of carnitine production and does not provide quantitative insight into levels of 
carnitine produced. The data indicate that the gene encoding a -butyrobetaïne 
hydroxylase is functionally expressed in S. cerevisiae and is able to convert -
butyrobetaïne to L-carnitine in all transformed strains. The sequential integration of the 
remaining three biosynthesis genes as well as of the free lysine methyl transferase did 
not have negative impact on BBH functionality. Furthermore, a strain expressing all four 
genes from the N. crassa carnitine biosynthesis was able to convert supplemented 
trimethyllysine to L-carnitine. This is the first report of a genetically engineered strain of 
S. cerevisiae that is able to neo-synthesize L-carnitine. It should be noted that in the 
assay system that was used, no carnitine production was observed without 
trimehtyllysine supplementation in a strain bearing all four biosynthesis genes. This 
indicates that the physiological concentration of trimethyllysine in yeast is likely to be 
insufficient for the effective production of carnitine by the carnitine biosynthesis 
pathway. Interestingly, the presence of the gene encoding TMABA-DH was not required 
for this conversion to take place. This could indicate that one of the native yeast 
aldehyde dehydrogenases is able to perform the conversion from 
trimethylaminobuteraldehyde to -butyrobetaïne. This would be a reasonable 
explanation, since the native S. cerevisiae aldehyde dehydrogenases do share 
significant similarity with the gene cloned from N. crassa. From the plate assays used in 
this study, it is clear that the amount of trimethyllysine that is naturally derived from 
protein degradation in S. cerevisiae is insufficient to lead to halo formation, since this 
phenomenon is only observed when TML is added to the media. The addition of the 
gene encoding the N. crassa free lysine methyltransferase did not result in halo 
formation, even when lysine and methionine were added to the medium. While this 
observation certainly suggests that this first step in the pathway is limiting carnitine 
production in this strain, the lack of sensitivity of this preliminary assay does not allow 
drawing further conclusions regarding the functionality of the expressed gene. It is 
possible that there is insufficient S-adenosyl methionine to perform the sequential 
methylations of the supplemented lysine. However, S. cerevisiae is known to 
accumulate large quantities of SAM upon methionine supplementation (Gawel et al, 
1962). A second possibility is that L-carnitine is produced at amounts that are not 
sufficient to ensure growth of the plated matt of Δcit2 cells. Clearly, a more quantitative 
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and sensitive measurement of carnitine production is required. Current efforts are 
focused on standardizing a LC-MS based analytical technique for the measurement of 
L-carnitine and all the intermediates of the carnitine biosynthesis pathway. 
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7.1. CONCLUDING REMARKS 
 
The role of carnitine and of the carnitine shuttle in the transfer of activated acyl 
groups between intracellular compartments has been clearly defined. In the yeast, 
Saccharomyces cerevisiae, the enzymes involved have previously been isolated in 
genetic screens using the carnitine dependen phenotype of a Δcit2 strain, which is 
relies on the function of the carnitine shuttle to sustain growth on non-fermentable 
carbon sources (such as ethanol, acetate and glycerol) and fatty acids. From studies in 
mammalian systems its has, however, become increasingly clear that the modulatory 
effect of the shuttle has a far reaching impact on the regulation of metabolic 
homeostasis and that shuttle independent activities of carnitine do exist (reviewed in 
Chapter 2). With this as background, the major aim of this study was to shed light on the 
fundamental question of what the function of carnitine and also the three CATs are 
within the framework of a eukaryotic cell.  
In yeast, three separate carnitine acetyl-transferases (CATs) have been identified 
and shown to be required for the integrity of the carnitine shuttle (Swiegers et al, 2001). 
The work done in this study indicates that each of these enzymes are located in 
separate cellular compartments and have specific functions within the shuttle and that, 
at least for Cat2p, shuttle independent functions do exist. Although the exact roles of 
these enzymes in the context of the shuttle and yeast metabolism in general remains to 
be defined, this does give a clear indication of the tight regulation that is required to 
maintain the function of the carnitine shuttle.  
Considering that yeast is able to metabolize non-fermentable carbon sources in the 
cytosol to generate acetyl-CoA, the presence of cytoslic CAT activity would be required 
to enable the trafficking of acetyl groups to the mitochondria. This does not, however, 
explain the requirement of two CATs (Yat1p and Yat2p) that would be able to catalyze 
the cytosolic reaction. In addition, enzymatic carnitine-acetyltransferase assays 
previously done in this laboratory, using both a spectrophotometric method and also an 
ES-MS based method was unable to detect CAT activity for either Yat1p or Yat2p and 
indicated Cat2p to be responsible for at least 95 % of total CAT activity in cultures 
grown on all non-fermentable carbon sources and fatty acids (data not shown). These 
assays did however not address the possible effect of carnitine on the regulation of CAT 
activity. In fact, there is no data, transcriptional or post-translational, available on 
regulation of these enzymes in general and future studies on these aspects will greatly 
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add to the understanding of their specific functions. Furthermore, data describing the 
effect of the three yeast CATs on the regulation of carbon metabolism is required to 
gain a holistic understanding of the roles of the enzymes and the influence of the 
carnitine shuttle in general. 
Recently, an interesting report from studies on the Candida albicans CATs indicated 
that complementation of the S. cerevisiae CAT mutants results in intriguing differences 
and similarities between the two species. CTN2 (homologous to CAT2) was found to not 
to be functional in S. cerevisiae, whereas, CTN3 (homologous to YAT2) was able to 
complement deletion of YAT2 in combination with CIT2. On the other hand, CTN1 
(homologous to YAT1) was able to restore growth in both a Δcit2Δyat1 and also a 
Δcit2Δyat2 strain (Zhou and Lorenz, 2008). It would be of interest to investigate the role 
of specific regions/domains of the C. albicans CTN1 protein in the complementation of 
both YAT1 and YAT2. This could shed light on the specific and also distinct roles of 
Yat1p and Yat2p. Future studies on the S. cerevisiae CATs would also be greatly aided 
by the identification of interacting protein partners. This would advance the 
understanding of the enzymes function within the context of the carnitine shuttle and 
also the shuttle independent functions, such as described for CAT2 with regards to 
oxidative stress. 
The work done in Chapter 3 also led to the initial description of a role for carnitine, 
independent of the carnitine shuttle, in the protection against oxidative cellular stresses 
(Franken et al, 2008). Although, several clinical studies have based conclusions on the 
assumption that carnitine is an antioxidant, the results of this study indicates that even 
though carnitine behaves similar to known antioxidants within a biological context, the 
molecule itself does not possess free radical scavenging activity (Chapter 4). 
Furthermore, the data also indicate carnitine to have toxic effects in combination with 
thiol modifying agents. This is the first report of a detrimental outcome associated with 
carnitine supplementation. These findings should certainly be taken into account when 
considering potential therapeutic applications.  
It is interesting to note that supplementation of carnitine protects growing cells 
against H2O2 insult, but does not protect against a sudden oxidative shock, induced 
under non-growing conditions. This signifies that the effect of carnitine present in the 
media is not due to an enhanced state of cellular protection, such as reported from 
studies in neuronal systems, but rather a consequence of either stimulating growth or 
delaying cell death (Calabrese et al, 2006). It seems unlikely that carnitine would be 
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able to enhance growth of yeast cultures, since no such an effect has been observed in 
any media condition that has been tested to date. Furthermore, the dual function 
(protective and detrimental) of carnitine is reminiscent of the divergent outcomes 
observed for carnitine supplementation in apoptosis, when comparing healthy to 
cancerous cells (Wenzel et al, 2005; Ferrara et al, 2005). In addition, the function of 
cytochrome c is required for both phenotypic outcomes. These observations in 
combination with global gene expression analysis of carnitine treated cultures indicate a 
possible role for carnitine in delaying the onset of programmed cell death. Future work 
should establish whether the phenotype of apoptosis is affected by carnitine 
supplementation.  In addition, it would be of importance to investigate processes, such 
as ageing, that are affected by the build-up of reactive oxygen species. 
The most intriguing question that arises from this work is how a molecule that 
functions in a specific and tightly regulated metabolic niche would have specific and 
evolutionary conserved impacts on cellular stresses. It would be of great interest to 
identify the upstream regulators of the effect of carnitine under these conditions. 
Promising targets identified from the microarray analysis (Chapter 5) are the conserved 
kinases Tor1p and Sch9p and also regulators of iron homeostasis, such as Aft2p. 
Furthermore, this also raises the question of what generates the signal that results in 
these specific outcomes. Since the protective effect of carnitine is independent of 
shuttle activity, carnitine itself does appear to be directly involved as an effector. It 
would be interesting to screen the yeast proteome, using bioinformatics based methods, 
for proteins containing sites resembling the carnitine binding site present in CATs. A 
ligand-binding protein array study could also be considered with the same goal in mind. 
The second part of the work presented in this thesis formed part of an applied study 
that focused on the creation of yeast strains that are able to neo-synthesize L-carnitine, 
by heterologously expressing the four genes involved in carnitine biosynthesis from 
Neurospora crassa (Chapter 6). The data indicates that carnitine production is indeed 
achieved by the engineered strains expressing the genes involved in this pathway. 
Quantitative data on the amounts of carnitine and the intermediates of the pathway will 
answer questions regarding the functionality of the N. crassa free lysine 
methyltransferase and also give insight to the metabolic flux through the engineered 
system. This should allow the implementation of strategies aimed at maximizing 
carnitine production. The eventual aim of this project envisions the establishment of 
carnitine producing industrial yeast strains that could be used in a variety of potential 
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commercial applications, such as fermented products and single cell proteins with 
enhanced carnitine content. The main obstacle in this project will likely be to obtain 
sufficient amounts of synthesized carnitine in order to have a benefit in specific 
products. An additional consideration that stems out of the work presented is the 
possibility that carnitine producing strains could be more resistant to the stresses 
encountered in industrial applications, such as wine making. This would indeed be an 
avenue worthwhile exploring. 
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